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Christopher J. Contreras 
GLYCOGEN METABOLISM IN LAFORA DISEASE 
 
 Glycogen, a branched polymer of glucose, serves as an osmotically 
neutral means of storing glucose. Covalent phosphate is a trace component of 
mammalian glycogen and has been a point of interest with respect to Lafora 
disease, a fatal form of juvenile myoclonus epilepsy. Mutations in either the 
EPM2A or EPM2B genes, which encode laforin and malin respectively, account 
for ~90% of disease cases. A characteristic of Lafora disease is the formation of 
Lafora bodies, which are mainly composed of an excess amount of abnormal 
glycogen that is poorly branched and insoluble. Laforin-/- and malin-/- knockout 
mice share several characteristics of the human disease, formation of Lafora 
bodies in various tissues, increased glycogen phosphorylation and development 
of neurological symptoms. The source of phosphate in glycogen has been an 
area of interest and here we provide evidence that glycogen synthase is capable 
of incorporating phosphate into glycogen. Mice lacking the glycogen targeting 
subunit PTG of the PP1 protein phosphatase have decreased glycogen stores in 
a number of tissues. When crossed with mice lacking either laforin or malin, the 
double knockout mice no longer over-accumulate glycogen, Lafora body 
formation is almost absent and the neurological disorders are normalized. 
Another question has been whether the abnormal glycogen in the Lafora disease 
mouse models can be metabolized. Using exercise to provoke glycogen 
degradation, we show that in laforin-/- and malin-/- mice the insoluble, abnormal 
 vii
glycogen appears to be metabolically inactive. These studies suggest that a 
therapeutic approach to Lafora disease may be to reduce the overall glycogen 
levels in cells so that insoluble, metabolically inert pools of the polysaccharide do 
not accumulate.  
Peter J. Roach, Ph.D., Chair 
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INTRODUCTION 
 
1. Glycogen Structure 
Many organisms store excess glucose in the form of branched polymers, 
such as glycogen or amylopectin. Glycogen is mainly stored in the liver and 
skeletal muscles of mammals, which can be catabolized to individual glucose 
units to meet energy demands (4). Plants store glucose in the form of starch, 
which is composed of amylose, a long mainly unbranched glucose polymer, and 
amylopectin, a branched polymer of glucose. Amylopectin and glycogen are 
similar in that they are branched polymers of glucose. However, the branching 
patterns, topology and average chain length of each is different, which 
contributes to their distinct physical properties.  
 Glycogen is a highly branched polymer of glucose that is readily soluble in 
water and serves as an osmotically neutral means of storing glucose. Glucose 
residues are linked together via α-1,4 glycosidic linkages, which make up the 
polymer chains, and branch points are introduced by α-1,6 glycosidic linkages 
(Figure 1). Because of the heterogeneous structure and size of glycogen it is 
impossible to obtain a three dimensional structure by conventional structural 
techniques. However, chemical analysis of glycogen chain length and branching 
has led to a widely accepted model of its structure (5-7) (Figure 2). In this model, 
the average glucose chain length would be ~13 glucose residues long and would 
consist of inner B chains, which would be branched twice, and the outer 
unbranched A chains (Figure 2). On average, branch points occur about 1 in 
every 8-12 glucose residues, which is inconsistent with the average chain length 
of ~13 glucose residues long. However, if the outer unbranched A chains make 
up 50% of the total glucose then the average chain length and branching 
frequency are consistent with the model. Additionally, it has been calculated that 
a 13th tier added to glycogen would result in an impossible density of glucose. 
Therefore, the largest possible glycogen molecule would consist of  
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Figure 1. Glycosidic linkages. A) Glucose residues are linked together via 
α-1-,4- and α-1-6-glycosidic linkages, which make up the bulk of the 
polymerization of glycogen. B) Structure of glucose, numbers indicates the 
numerical nomenclature of the carbons, C1, C2, C3, C4, C5 and C6.  
Figure 2. Glycogen structure. A portion of a glycogen molecule is shown, 
indicating branching pattern and tiered structure. 
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12 tiers, have a molecular mass of ~107 kDa, a diameter of ~44 nm and contain 
about 55,000 glucose residues (5,8). Interestingly, electron microscopy analysis 
of skeletal muscle glycogen shows that glycogen granule size is normally 
distributed, the average size being ~25 nm and the maximum size being ~44 nm, 
consistent with the proposed model of glycogen (7,9). 
 Although glycogen is mainly composed of glucose it also contains trace 
amounts of phosphate and glucosamine (10,11). There has been more research 
on phosphate in glycogen due to its association with a juvenile form of 
myoclonus epilepsy known as Lafora disease. Recent studies have shown 
phosphate to be present in a range from 1 phosphate per 500 – 2000 glucose 
residues depending on the source of glycogen (12-14). Covalently bound 
phosphate was originally proposed to exist as a monoester at the C6-OH and as 
a phosphodiester which would link the C1 to the C6 of another glucose residue, 
effectively forming a novel type of branch point. (2,3). Nuclear magnetic 
resonance (NMR) analysis of phospho-oligosaccharides purified from glycogen 
has shown that phosphate is located at the C2, C3 and C6 positions of glucose 
residues but no evidence for a phosphodiester bond has been observed (14,15). 
Amylopectin, also a branched polymer of glucose, contains covalently bound 
phosphate monoesters at the C3 and C6 positions (14,16,17). Phosphate in 
starch is well known and plays a role in disrupting its semicrystaline structure to 
allow for proper breakdown and utilization (17). However, the role of phosphate 
in glycogen is not well understood but excess accumulation of phosphate in 
glycogen has been associated with Lafora disease (12-14,18,19).  
 The metabolism of glycogen is dynamic and involves multiple bouts of 
degradation and synthesis, which could result in the accumulation of 
modifications, such as phosphate, throughout its lifespan. The accumulation of 
modifications could potentially lead to an altered structure and negatively impact 
its metabolism. It has been proposed that the chemical modifications in glycogen 
might indicate the age of the molecule and serve as signal for its disposal (3). 
Interestingly, in normal aging tissue poorly branched insoluble glycogen-like 
material, polyglucosan, accumulates and forms deposits in the brain, known as 
 4
corpora amylacea (20) and in heart as cardiac colloid (21). These observations 
support the idea that chemical modifications may reflect the age of the molecule 
and the need to dispose abnormal glycogen in order to avoid adverse outcomes.  
 
2. Glycogen Metabolism 
 
2.1 Overview 
In mammals, the liver and skeletal muscle contain the major deposits of 
glycogen but other tissues such as heart, fat, kidney and brain are capable of 
storing glycogen. Although many of the processes involved in glycogen 
metabolism are similar in skeletal muscle and liver, there are significant 
differences that reflect metabolic flexibility along with tissue-specific enzyme 
isoform expression. Glucose, derived from ingested carbohydrates or from 
gluconeogenesis, is the major precursor for glycogen synthesis, utilized in a 
direct pathway, but gluconeogenic precursors, such as lactate or alanine can 
serve as precursors in an indirect pathway (22,23). The direct pathway begins 
with glucose entering cells through one or more of the glucose transporters 
(GLUTs) (24). Skeletal muscle takes up glucose from the bloodstream via the 
GLUT4 transporter, which is translocated to the plasma membrane in response 
to insulin signaling. In the liver and beta cells of the pancreas, GLUT2 is the 
major glucose transporter that allows glucose to be transported down a positive 
gradient between the blood stream and the tissue. Intracellular glucose is then 
converted to glucose-6-phosphate by hexokinase, in the muscle, and by 
glucokinase, in the liver. In times when nutrients intake is low, glucose that enters 
tissues is typically oxidized through glycolysis. However, when nutrients are 
plentiful excess glucose is converted to UDP-glucose through a series of 
enzymatic reactions (Figure 3). Following conversion to glucose-6-phosphate, 
glucose-1-phosphate is generated by phosphoglucomutase and converted to 
UDP-glucose by UDP-glucose pyrophosphorylase. UDP-glucose serves as a 
substrate for glycogen synthase, which transfers the glucose moiety to existing 
glycogen molecules or as substrate for glycogenin during de novo glycogen 
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synthesis. Bulk glycogen synthesis requires three key enzymes, glycogenin, 
glycogen synthase and the glycogen branching enzyme (Figure 3). 
Glycogenin serves as a primer for glycogen synthesis and self-
glucosylates to form an oligosaccharide primer chain (25-27). Branch points, α-
1,6-glycosidic linkages are introduced by the branching enzyme. Multiple rounds 
of elongation by glycogen synthase and branching result in the formation of 
glycogen molecules and provide an efficient and osmotically neutral means of 
storing glucose. The regulation of glycogenin and the branching enzyme are not 
well understood, but glycogen synthase, the rate-limiting enzyme in glycogen 
synthesis, is highly regulated and many of the regulatory mechanisms are well 
known.  
Glycogen degradation occurs by two distinct pathways. The first, known 
as phosphorolysis, occurs in the cytosol of cells and is mediated by the actions of 
glycogen phosphorylase, the rate-limiting enzyme, and the debranching enzyme 
(AGL). Phosphorolysis produces glucose-1-phosphate and free glucose is 
produced by AGL, which hydrolyzes α-1,6-glycosidic linkages and liberates a 
free glucose residue (28). In the liver, glycogen breakdown is stimulated by 
nutrient deprivation and by hormonal signaling, mainly glucagon, which results in 
the breakdown of glycogen to glucose for export into the blood stream. The 
breakdown of glycogen is initiated by conditions that elevate cAMP and Ca2+ 
levels, such as exercise (4). The second pathway for degradation occurs in the 
lysosome. Glycogen is transported to the lysosome, by mechanisms that are not 
well understood at this point, where it is directly hydrolyzed to glucose by the 
lysosomal α-glucosidase, also known as acid α-glucosidase (GAA) (29) (Figure 
3).  
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Figure 3. Glycogen metabolism. HK, hexokinase/glucokinase; PGM, 
phosphoglucomutase; UDPGPPase, UDP-glucose pyrophosphorylase; BE, 
branching enzyme; AGL, debranching enzyme; GAA, lysosomal -
glucosidase 
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 2.2 Glycogen Metabolism, Enzymes and Regulation 
  2.2.1 Glycogenin 
 In the early 1930’s the Cori’s observed that in vitro glycogen synthesis by 
phosphorylase occurred only in the presence of trace amounts of glycogen, 
suggesting that a ‘primer’ was necessary for polysaccharide synthesis (30). 
Krisman and Barengo later proposed that the initial primer for glycogen synthesis 
was a protein (26). This led to the discovery of a specialized self-glycosylating 
enzyme, glycogenin, that was found to be necessary for the initiation of glycogen 
synthesis (31,32). Glycogenin can be co-purified with glycogen synthase from 
rabbit muscle (27) and is found covalently bound to glycogen from muscle (33) 
and liver glycogen (34).  
Glycogenin is a member of the family 8 retaining glycosyltransferases 
(35,36), which serves as a primer for glycogen synthesis. Humans have two 
genes that encode glycogenin, GYG1 and GYG2 (37) whereas rodents only have 
a single gene (38,39). GYG1 is widely expressed while GYG2 is mainly 
expressed in the liver, heart and to a lesser extent pancreas of humans (37). 
Glycogenin from rabbit muscle is the most studied form of the enzyme, but the 
corresponding human enzyme is 90% identical in amino acid sequence (40). A 
crystal structure of glycogenin from rabbit muscle has been solved and shows 
that the enzyme functions as a dimer (41). 
 Glycogenin catalyzes two distinct reactions: the first involves 
glucosylation of Try194 through the formation of the α-C1-O-tyrosyl linkage, 
using UDP-glucose as the glucose donor, and the second is the subsequent 
addition of glucose residues, forming α-1,4-glycosidic linkages, which can be 
extended to a length of 10—20 glucose residues (33,42-44). For the initiation of 
bulk glycogen synthesis, glycogenin interacts directly with glycogen synthase 
through a conserved amino acid sequence in its C-terminus. Glycogen synthase 
is then able to associate with the glucosyl-primer and elongate the nascent 
polyglucose chain  
 There are no known modes of regulating glycogenin at this time. However, 
Roach and colleagues proposed that glycogenin could be regulated by glucose 
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(45). When overexpressing glycogenin in COS cells and in the presence of high 
glucose, they observed an increased molecular weight of glycogenin, suggesting 
that glucose might initiate glycogen synthesis by controlling the glucosylation 
state of glycogenin (46) (32).  
2.2.2 Branching Enzyme 
 Branch points are formed by the branching enzyme which excises an 
oligosaccharide from glycogen by hydrolyzing an α-1,4-glycosidic linkage and 
forming a new α-1,6-glycosidic linkage between the excised oligosaccharide and 
an existing chain within glycogen (47,48). The frequency of branching determines 
the topology and solubility properties of glycogen molecules and is what 
distinguishes glycogen from amylopectin. For example, glycogen has branch 
points every ~12 glucose residues and amylopectin has branch points every ~30 
glucose residues. In mammals, the glycogen branching enzyme is encoded by 
the GBE1 gene, which operates as a monomer and has a predicted Mr of 81.5 
KD (47). The glycogen branching enzyme contains a domain similar by sequence 
(residues 222-568) to α-amylase and a smaller region (residues 73-168) similar 
to polysaccharide-modifying enzymes that act on branched structures (49). The 
mechanism for the branching enzyme is a two step reaction that involves the 
catalytic amino acids Asp 357 and Glu 412 (50). The branching of glycogen is 
critical in maintaining its solubility and function. Defects in the branching enzyme 
lead to formation of poorly branched and insoluble glycogen-like material known 
as polyglucosan and is associated with glycogen storage disease type IV. 
However, not much is known about its regulation.  
  2.2.3 Glycogen Synthase and Regulation 
Glycogen synthase is the rate-limiting enzyme in glycogen synthesis and 
is highly regulated. Glycogen synthase is responsible for the formation of glucose 
polymer chains by forming the α-1,4-glycosidic linkages by transferring glucose 
residues from UDP-glucose to the non-reducing end of existing glycogen 
molecules or to the oligosaccharide attached to glycogenin. The enzyme is 
negatively regulated by phosphorylation and allosterically activated by glucose-6-
phosphate, which can completely restore the activity of the enzyme in the 
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phosphorylated state (28). In fact, glycogen synthase was the third enzyme 
discovered that is regulated by reversible phosphorylation (51). In vitro assays 
take advantage of the allosteric activation of glycogen synthase by glucose-6-
phosphate by assaying for its activity in the presence and absence of glucose-6-
phosphate, which gives an activity ratio that can be used as indication of its 
phosphorylation status (52).  
Glycogen synthase belongs to the family 3 retaining glycosyltranserases 
(GT3) and mammals have two isoforms of the enzyme encoded by GYS1 and 
GYS2, with GYS1 expressed in skeletal muscle and many other cells while 
GYS2 expression is restricted to the liver (28). GYS2 is 70% identical in 
sequence to the muscle isoform (53,54). The yeast, Saccharomyces cerevisiae, 
also contains two genes that encode for glycogen synthase, Gsy1 and Gsy2, with 
Gsy2p being the predominant protein isoform. It has ~50% sequence identity to 
the human enzyme (55). Based on sequence identity, the skeletal muscle 
isoform seems to be conserved between mammals, for example human and 
rabbit skeletal muscle glycogen synthases are 97% identical (56).  
Rabbit skeletal muscle glycogen synthase, which was initially the most 
studied enzyme, contains 9 serine phosphorylation sites, clustered at the N- and 
C- termini, that can be phosphorylated in vivo (57). The sites, 1a, 1b, 2, 2a, 3a, 
3b, 3c, 4 and 5 correspond respectively to amino acids 697, 710, 7, 10, 640, 644, 
648, 652, and 656. Yeast glycogen synthase also contains phosphorylation sites 
but lacks the phosphorylation sites at its N-terminus (58). Studies on glycogen 
synthase phosphorylation have led to the concept of hierarchal phosphorylation 
(59,60), where the phosphorylation of one site promotes the phosphorylation of a 
secondary site. Several protein kinases are capable of phosphorylating glycogen 
synthase in vitro: glycogen synthase kinase-3 (GSK3) (61,62), phosphorylase 
kinase (PhK) (63), cAMP dependent protein kinase (PKA) (64), protein kinase-
CK1 ( previously known as casein kinase 1) (CK1) (65,66), protein kinase-CK2 
(CK2) (67), AMP activated protein kinase (AMPK) (68), PAS kinase (69), 
DYRK1A (70) and p38 MAPK (71). An example of hierarchical phosphorylation 
comes from in vitro studies where site 2 can be phosphorylated by cyclic AMP-
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dependent kinase (64) and phosphorylase kinase (63), which then allows for the 
phosphorylation of site 2a by casein kinase 1 but only when site 2 is 
phosphorylated (65). Additionally, mutation of site 2 prevents phosphorylation of 
site 2a in COS cells, which is consistent with the idea of hierarchal 
phosphorylation (72). The skeletal muscle isoform of glycogen synthase, GYS1, 
contains 7 phosphorylation sties at its C- terminus while the liver isoform, GYS2, 
has 5 phosphorylation sites and is lacking the 1a and 1b sites found in GYS1. 
Phosphorylation of the 3a and 3b sites have been found to have the largest effect 
on enzyme activity (57). These regulatory sites can be phosphorylated by 
glycogen synthase kinase-3 (GSK3), in vitro, by the hierarchal and sequential 
phosphorylation of sites 4, 3c, 3b, and 3a (60,61,67). Phosphorylation of site 5 by 
casein kinase II results in a recognition motif –S-X-X-X-S(P) (where X can be any 
amino acid) for GSK3, which primes glycogen synthase for sequential 
phosphorylation of sites 4, 3c, 3b and 3a (62,67) . However, cell based 
experiments, where the GSK3 recognition sites were mutated from serine to 
alanine, have demonstrated that glycogen synthase can still be phosphorylated 
at sites 3a or 3b, suggesting that other kinases are able to phosphorylate 
glycogen synthase at those sites (73). A member of the dual-specificity tyrosine 
phosphorylated and regulated protein kinase, DYRK1A, was purified from rabbit 
skeletal muscle and shown to be a site 3a kinase (70). Additionally, a site 3a 
kinase, PAS kinase (69), was identified based on an ortholog in S. cervisiae  and 
found to be required for normal maintenance of glycogen stores (74).  
Dephosphorylation and activation of glycogen synthase is mediated by 
members of a family of glycogen-associated protein phosphatases (PP1Gs) that 
are composed of a catalytic subunit (PP1C) bound to a glycogen-targeting (G) 
subunit (75,76). Regulatory G subunits contain carbohydrate-binding domains, 
which localize them to glycogen and recruit the catalytic PP1C subunits, thus 
allowing the complex to dephosphorylate substrates, such as glycogen synthase 
(77). Biochemical and bioinformatics analysis have identified seven glycogen-
targeting subunits (75,76). Of the seven identified, three have been extensively 
studied. The RGL or GM subunit is mainly expressed in the skeletal muscle and 
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heart (78). Expression of the GL subunit is found mainly in the liver and its 
expression is induced by insulin (79,80). A more ubiquitously expressed subunit, 
the protein targeting to glycogen (PTG) or (R5) is expressed in several insulin-
sensitive tissues, such as skeletal muscle, liver and fat (80). Less is known about 
the other family members but they seem to have roles in glycogen metabolism 
and some are highly expressed in brain (81).  
There are crystal structures for two eukaryotic glycogen synthase 
enzymes, S cerevisiae (82) and Caenorhabditis elegans (83). The C. elegans 
glycogen synthase structure was solved in complex with 34 amino acids of the C-
terminus of human glycogenin, and is superimposable with the basal state of the 
yeast enzyme. Interestingly, structures of the yeast enzyme have been solved for 
the intermediate state and the glucose-6-phosphate activated state (82). The 
binding of glucose-6-phosphate to an arginine rich region of the C-terminus 
induces structural changes that allow for more efficient binding of substrates and 
catalysis. Recently, a crystal structure of a mutant yeast enzyme, which based on 
kinetic data mimics a phosphorylated state of the enzyme, has been solved and 
shows structural changes that occur when the enzyme is in an inhibited state 
(84). 
The dynamic process for activation and inactivation of glycogen synthase 
is necessary to maintain proper stores of glycogen and to release stored glucose 
in an appropriate manner. Excessive activation of glycogen synthase results in 
the aberrant structure and over accumulation of glycogen in mice that 
overexpress skeletal muscle glycogen synthase (85). Defects in glycogen 
synthase or lack of glycogen synthase leads to glycogen storage disease type 0 
(86-89). Additionally, Irimia et al demonstrated the importance of liver glycogen 
stores in maintaining whole body glucose homeostasis and that mice lacking liver 
glycogen synthase physiologically mimic glycogen storage disease type 0 (90).  
2.2.4 Glycogen Phosphorylase 
 Phosphorylase catalyzes the phosphorolysis of α-1,4-glycosidic linkages 
to generate glucose-1-phosphate and stalls four glucose residues from an α-1,6-
glycosidic linkage. In mammals, it is widely expressed and tissue specific 
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isoforms, liver, skeletal muscle, and brain, have been identified (91,92). The 
skeletal muscle and liver isoforms are thought to dominate in their specific 
tissues, but there is some evidence for expression of multiple isoforms in the 
same tissue (93). The liver isoform is ~83% identical to the skeletal muscle 
isoform (93). Like glycogen synthase, rabbit skeletal muscle glycogen 
phosphorylase has been extensively studied and shares a 97% amino acid 
identity with the human muscle ortholog (91,92,94). A three-dimensional 
structure of glycogen phosphorylase is known and much effort has been made to 
relate mechanistic catalysis and regulation to the structure of the enzyme (92,95-
97). Like glycogen synthase, glycogen phosphorylase is regulated by reversible 
phosphorylation and by allosteric ligands. The enzyme undergoes structural 
changes between the less active T state and a more active R state, which is 
dependent on its phosphorylation status and the binding of allosteric ligands 
(94,98). 
 Phosphorylation of glycogen phosphorylase, unlike glycogen synthase, 
occurs at a single site and activates the enzyme. In fact, phosphorylase was the 
first enzyme shown to be controlled by both covalent and allosteric modifications 
(99-101). Phosphorylase kinase is responsible for the phosphorylation of 
glycogen phosphorylase at Ser14 (102,103). Phosphorylase kinase is thought to 
be activated by two primary mechanisms, phosphorylation by cAMP-dependent 
protein kinase and by increased cellular Ca2+ levels (104,105). During exercise or 
epinephrine signaling intracellular Ca2+ and cAMP levels increase, which causes 
activation of cyclic AMP-dependent protein kinase and results in the 
phosphorylation of phosphorylase kinase thus allowing for activation of glycogen 
phosphorylase (104,106,107). The phosphorylated form of phosphorylase can be 
fully activated by binding of AMP. The binding affinity for AMP is increased when 
the enzyme is phosphorylated and occurs at a major allosteric binding site. The 
liver isoform shares similar properties with regards to regulation, but is not as 
readily activated by AMP (92). The ratio of the phosphorylase activity, in the 
presence or absence of AMP, is used as a kinetic index for its activity status 
(108). Dephosphorylation of skeletal muscle glycogen phosphorylase and 
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phosphorylase kinase is mediated by glycogen associated protein phosphatases 
containing a glycogen targeting subunit, such as RGL or PTG.  
2.2.5 Debranching Enzyme 
 Glycogen breakdown is accomplished by the coordinated actions of 
glycogen phosphorylase and the debranching enzyme (AGL), which is 
responsible for the hydrolysis of α-1,6-glycosidic linkages. The enzyme has two 
catalytic activities in two domains. The N-terminal domain has α-amylase-like 
activity, which hydrolyzes an α-1,4-glycosidic linkage and transfers a maltotriose 
unit from the four glucose residues left by phosphorylase, to the main chain of 
glucose residues via an α-1,4-glycosidic linkage. The remaining glucose at the 
branch point is hydrolyzed by the C-terminus of AGL, which contains a domain 
with amylo-1,6-glucosidase activity that hydrolyzes the α-1,6-glycosidic linkage to 
liberates a free glucose residue. Little is known about the regulation of AGL but 
defects in the enzyme lead to Type III glycogen storage disease or Cori’s disease, 
which is characterized by the formation of abnormal glycogen with short outer 
chains.  
 
3. Insulin Signaling and Glycogen Metabolism 
Insulin is the primary hormone responsible for driving glycogen synthesis 
in skeletal muscle (Figure 4). Impairments in insulin signaling or insulin secretion 
are associated with impaired glycogen metabolism, which occurs in the diabetic 
state (109). Besides glycogen synthesis, insulin promotes the uptake of glucose 
in insulin sensitive tissues, inhibits hepatic gluconeogenesis, promotes fat 
synthesis and protein synthesis. Insulin secretion, by the β-cells, occurs when 
blood glucose levels increase post-prandially, and once in the blood stream it 
binds to the insulin receptor found on the plasma membrane of insulin sensitive 
cells. The insulin receptor consists of two subunits, α and β, with the α subunit on 
the extracellular side of the plasma membrane. Binding of insulin to the α subunit 
causes a conformational change that activates a tyrosine kinase domain on the 
β-subunit, which autophosphorylates a series of its own tyrosine residues 
promoting the phosphorylation of insulin receptor substrates There are four 
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members of the insulin receptor substrate (IRS) family that are phosphorylated 
on tyrosine residues by the activated insulin receptor (110). In addition to IRS 
family members, Shc adapter proteins and SIRP family members are also 
phosphorylated. The phosphorylation of tyrosine residues on IRS-1 forms 
docking sites for proteins that contain SH2 (Src-homology-2) domains (111), 
such as the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K). 
Phosphorylation of IRS-1 promotes the activation of PI3K and the production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3) by phosphorylating 
phosphatidylinositol-4,5-bisphosphate. 
 
Figure 4. Regulation of glycogen metabolism. Schematic represents 
major signaling pathways that regulate glycogen metabolism. GSK3, 
glycogen synthase kinase 3; PIP2, phosphatidylinositol-4-5-bisphosphate; 
PIP3, phosphatidylinositol-3-4-5-bisphosphate; PI3-K phosphatidylinositol 
kinase; PP1, protein phosphatase 1. 
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 PIP3 binds to and activates the protein kinase PDK1, which in turn 
phosphorylates and activates the protein kinase Akt (112). Akt, a major signaling 
kinase, once activated, can phosphorylate glycogen synthase kinase-3 (GSK3), 
which is a negative regulator of glycogen synthase. Therefore, the 
phosphorylation of GSK-3 through insulin signaling prevents the phosphorylation 
of glycogen synthase and allows for increased activity of glycogen synthase. 
 Glycogen associated phosphatases also play a role in the hormonal 
control of glycogen synthase. In skeletal muscle, it had been proposed that 
insulin signaling involves a protein phosphatase 1 containing the glycogen 
binding subunit RGL (113) but these results were later shown to be incorrect (114). 
Studies in mice lacking the RGL subunit showed that glycogen synthase was still 
activated by insulin (115), suggesting that other mechanisms or phosphatases 
are involved in regulating glycogen synthase during insulin signaling. The protein 
targeting to glycogen, PTG has also been implicated in insulin control of 
glycogen synthase (116,117). 
  
4. Regulation of Glycogen Metabolism by Epinephrine and Glucagon 
 Epinephrine and glucagon promote glycogen degradation, with 
epinephrine mainly acting on the muscle and glucagon on the liver (Figure 4). 
Epinephrine binds to β-adrenergic receptors and induces a signaling cascade 
that activates adenyl cyclase, which converts ATP to cAMP. The production and 
increased concentration of cAMP activates protein kinase A (PKA) by binding to 
the regulatory subunit and releasing the catalytic subunit. PKA, once activated, 
can phosphorylate a large number of target proteins, one of which is 
phosphorylase kinase. In response to epinephrine signaling phosphorylase 
kinase is phosphorylated by PKA on its α and β subunits, which activates the 
enzyme and allows it to phosphorylate phosphorylase on Ser14 to activate it as 
described above. Glucagon and epinephrine signaling also inhibits glycogen 
synthesis through PKA dependent phosphorylation of glycogen synthase (118-
121). Epinephrine signaling has been associated with the PKA dependent 
phosphorylation of PP1 inhibitory protein, inhibitor 1 (122). In the liver glucagon 
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signaling increases cAMP and causes the activation of PKA, which in turn 
promotes the phosphorylation and activation of glycogen phosphorylase, inhibits 
glycogen synthesis by binding to GL and inhibits phosphatases that target 
glycogen synthase, effectively promoting glycogenolysis and inhibiting glycogen 
synthesis (123,124).  
 
5. Regulation of Glycogen Metabolism by Exercise 
 Glycogen serves as a major source of energy during muscle activity and is 
critical for prolonged exercise endurance (125,126). It is well established that the 
ability for muscle to perform is seriously compromised when glycogen stores are 
depleted even when other fuel sources are available (126). The most recognized 
theory for the association between impaired muscle contraction and reduced 
glycogen stores is that glycogen is an essential substrate, and its depletion 
results in a decreased rate of ATP regeneration (125). There has been a great 
deal of research into the exact mechanisms that regulate glycogen metabolism 
during exercise and much progress has been made, but the exact mechanism 
still remain elusive.  
Glycogen is catabolized during exercise and is utilized locally to meet 
energy demands in the skeletal muscle while breakdown in the liver results in the 
export of glucose to maintain blood glucose levels (Figure 5). Following a bout of 
exercise glycogen stores must be replenished, which involves the activation of 
glycogen synthase. Experimentally, and depending on the experimental 
conditions, it has been observed that glycogen synthase can either be activated 
or inactivated during exercise (127,128). 
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Figure 5. Regulation of Glycogen Metabolism by Exercise. Schematic 
represents pathways responsible for glycogen metabolism in response to 
exercise. AMPK, AMP activated kinase; GLUT-4, glucose transporter-4, PKA, 
protein kinase-A; Glucose-6P, glucose-6-phosphate; UDP-Glc, uridine 
diphosphate glucose; PP1G, protein phosphatase type 1 associated with 
glycogen; +, indicate allosteric activators. 
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 It has also been observed that glycogen synthase can be activated post 
exercise (127). Activation of glycogen synthase during exercise can be viewed as 
paradoxical since there is an overall net loss of glycogen during exercise. There 
are three possible explanations for the activation of glycogen synthase during 
exercise. One is that activation of glycogen synthase ‘primes’ the enzyme for 
rapid glycogen synthesis once muscle contraction has decreased. The second 
explanation would involve other factors besides phosphorylation to inhibit the 
enzyme to prevent ‘futile cycling’ of glycogen. The third reason for the activation 
of glycogen synthase during exercise would be to actually synthesize and utilize 
glycogen during exercise (129).  
 The exact mechanism for glycogen synthase regulation during exercise is 
not clear. However, there is a consensus that it differs from insulin-mediated 
regulation (127). Mice with muscle specific insulin-receptor knockout show that 
glycogen synthase can be activated by exercise (130). Mice with inactive 
mutation on GSK3 were generated to investigate the role GSK-3 plays in insulin 
and Wnt signaling by generating knockin mice where the Akt phosphorylation 
sites were mutated, GSK3α (Ser21) and GSK-3β (Ser9) were changed to alanine 
(131). The authors determined, in muscle, that GSK-3β is the major enzyme that 
regulates glycogen synthase in response to insulin signaling. However, muscle 
contraction induced activation of glycogen synthase remained normal suggesting 
that exercise activates glycogen synthase by a different mechanism, possibly 
through the GM/RGL-PP1 complex since activation of glycogen synthase by 
exercise or by in situ electrical stimulation is blocked in mice lacking the PP1 
glycogen targeting subunit RGL(132). However, how RGL is regulated is not known. 
Additionally, it has been observed that glycogen synthase can be phosphorylated 
by exercise at sites 2 and 2a (128). However, upon more prolonged exercise, 
sites 3a and 3b can be dephosphorylated, which would result in activation of the 
enzyme (133). Site 2, in vitro, serves as a substrate for a variety of kinases, 
some of which could be activated by muscle contraction (128)  One such kinase 
could be AMPK. A possible role for AMPK as a site 2 kinase has been 
investigated. AMPK is activated under exercise conditions (134) and when ATP 
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levels decrease (135). Additionally, AMPK is viewed as a cellular energy sensor. 
It has been proposed that AMPK bound to the outer chains in glycogen, via its 
CBM20 domain on the β-subunit, could be active and able to phosphorylate 
glycogen synthase (136,137). There seems to be a correlation between AMPK 
activation and decreases in glycogen content, particularly in muscle under 
exercise conditions (134). However, studies of Hampshire pigs (138) or humans 
with mutations in the PRKAG2 gene, that encodes the γ2 non-catalytic subunit of 
AMPK (139), where AMPK is more active, indicated an accumulation of glycogen 
in the skeletal muscle of the pigs and in the heart of the humans, suggesting the 
opposite, that AMPK is not a negative regulator of glycogen synthase. 
Although the regulation of glycogen synthase remains complex and not 
fully understood, the regulation of glycogen phosphorylase is well established. 
Breakdown of glycogen during exercise is mediated by glycogen phosphorylase, 
resulting in the phosphorolysis of α-1,4 glycosidic linkages and the release of 
glucose-1-phosphate. During exercise, ATP is consumed and AMP levels 
increase. Glycogen phosphorylase is allosterically activated by AMP, which 
would result in the degradation of glycogen. Additionally, during muscle 
contraction Ca2+ levels increase, which binds to the δ subunit (calmodulin) of 
phosphorylase kinase and participates in allosteric control by relieving 
autoinhibition of the γ subunit. Additionally, cAMP levels increase during exercise 
resulting in the phosphorylation and activation of phosphorylase kinase by PKA, 
which activates phosphorylase kinase. During exercise there is a paradoxical 
activation of glycogen synthase and the activation of glycogen phosphorylase 
that results in the decrease of glycogen levels, which is utilized to meet energy 
demand. Figure 5 shows an overview of glycogen metabolism and exercise 
 
6. Glycogen Storage Diseases 
 Glycogen storage diseases (GSDs) or glycogenoses are rare inherited 
disorders of glycogen metabolism that result in alterations of amounts and/or 
structure of glycogen (Figure 6). Mutations that affect either glycogen synthesis, 
degradation or enzymes whose products are involved with glycogen metabolism 
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result in GSDs and mainly affect the liver, skeletal muscle and heart although 
other tissues may also be affected. 
 
 6.1. Glycogen storage disease type 0 
 Glycogen storage disease type 0 is caused by mutations in the GYS2 
gene, the liver isoform of glycogen synthase. The mutations are autosomal 
recessive and result in fasting hypoglycemia that is present in infancy. Patients 
have postprandial hyperglycemia hyperlactatemia, hyperlipidimia along with high 
blood ketones, low alanine and lactate concentrations (88). Mice lacking the 
Gys2 gene have a similar phenotype to human patients, although not as severe, 
but they have a 95% reduction in liver glycogen content, develop mild 
hypoglycemia, have impaired insulin suppression of endogenous glucose 
production and have an elevated rate of gluconeogenesis (90). More recently 
mutations in the muscle isoform GYS1, have been reported in humans (86,87,89) 
(90). In humans, mutations in GSY1 result in cardiomyopathy and exercise 
intolerance (87), which is in contrast to the phenotype of mice lacking Gsy1 
which have no impaired ability to exercise  (140)  
 
 6.2. Glycogen Storage Disease Type I: von Gierke Disease 
 The most common of the GSDs is glycogen storage disease type I or von 
Gierke Disease, resulting from mutations in the G6PC and G6PT genes, which 
encode glucose-6-phophatase and glucose-6-phosphate translocase (G6PT) 
respectively, and characterized by the accumulation of glycogen and fat in the 
liver and kidneys. The disease results in hypoglycemic seizures, hepatomegaly, 
growth retardation and severe lactic acidosis (141). In the absence of glucose-6-
phosphatase, which hydrolyzes glucose-6-phosphate to glucose, glucose is not 
transported out of the liver to maintain blood glucose levels in the fasted state.  
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Figure 6.Glycogen Storage Diseases. Schematic of glycogen metabolism 
and some of the glycogen storage diseases (GSD), represented by Roman 
numerals. GAA, lysosomal enzyme, acid α-glucosidase; GBE, glycogen 
branching enzyme; UDP-glc, uridine diphosphate glucose; PLD, 
phosphorylase limit dextrin; AGL, glycogen debranching enzyme; G6PPase, 
glucose-6-phosphatase.  
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G6PT is involved in the terminal steps of gluconeogenesis and glycogenolysis 
where cytoplasmic glucose-6-phosphate is transported to the lumen of the 
endoplasmic reticulum by G6PT to be dephosphorylated by glucose-6-
phosphatase (142). Loss of G6PT results in the same phenotype as loss of 
glucose-6-phosphase (142). 
  
 6.3. Glycogen storage disease type II: Pompe Disease 
 Mutations in the lysosomal enzyme, acid α-glucosidase (GAA), result in 
the accumulation of glycogen in the lysosomes of heart and skeletal muscle and 
leads to GSDII. Patients with Pompe Disease mutations in the GAA gene 
develop cardiomegaly, cardiomyopathy, hypotonia, muscle weakness, failure to 
thrive, which is dependent on the severity of the mutations, and death can occur 
within the first year of life (143) (144). The acid-α-glucosidase enzyme is 
localized in the lysosome and is responsible for the lysosomal catabolism of 
glycogen. The enzyme does not participate in the cytosolic degradation of 
glycogen. Mice lacking the GAA gene have a similar phenotype to the human 
disease. However, the symptoms develop later in life and they do not die (145). 
Interestingly, mice lacking both GAA and GYS1 have a marked reduction in the 
heart and skeletal muscle glycogen levels, reduced lysosomal swelling and a 
complete reversal of the cardiomegaly (146).  
 
 6.4. Glycogen Storage Disease Tyep III: Cori Disease 
 Cori’s disease is caused by infantile autosomal mutations in the AGL/DBE 
gene that leads to defects in the glycogen debranching enzyme, AGL (147). 
Symptoms usually present themselves during infancy with hypoglycemia and 
failure to thrive. The disease is characterized by accumulation of glycogen with 
shorter branches in the liver, muscles and heart (147). 
 
 6.5. Glycogen Storage disease Type IV: Andersen Disease  
 Mutations in the GBE1 gene, which encodes the glycogen branching 
enzyme, results in one of the most severe of the GSDs, GSD IV or Andersen’s 
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disease (148). Patients have symptoms of hepatospleenomegaly, failure to thrive 
and cirrhosis of the liver (149). There are several subtypes of GSD IV that have 
been recognized, but the phenotype is a continuum that ranges from mild to 
severe (150). Since the glycogen branching enzyme is responsible for 
introducing branch points into glycogen, patients with Andersen disease develop 
poorly branched insoluble glycogen, also known as polyglucosan that 
accumulates in the muscle and liver.  
  
 6.6. Glycogen Storage Disease Type V: McArdle Disease 
 McArdle disease was identified as a glycogenolytic defect in the muscle 
due to the absence of muscle phosphorylase  (151,152) resulting from mutations 
in the PYGM gene, which encodes the muscle glycogen phosphorylase isoform. 
The disease is characterized by exercise intolerance and muscle cramps in 
childhood or adolescence. Patients may experience transient myoglobinuria after 
bouts of exercise, which is due to rhabdomyolysis. In some cases severe 
myoglobinuria may lead to acute renal failure (153). However, the disease is 
relatively benign and patients may report muscle weakness, myalgia, and lack of 
endurance during childhood or adolescence (154).  
 
 6.7. Glycogen Storage Disease Type VI: Hers Disease 
 Glycogen storage disease type VI is caused by mutations in the PYGL 
gene, which encodes the liver isoform of glycogen phosphorylase. The disease is 
characterized by hypoglycemia, hyperlipidemia, hyperketosis, hepatomegaly and 
growth retardation (155).  
 
 6.8. Glycogen Storage Disease Type VII: Tarui Disease 
 Tarui disease is caused by mutation in the PFKM gene, which encodes 
the muscle form of phosphofructokinase. Phosphofructokinase is a rate limiting 
enzyme in glycolysis that catalyzes the phosphorylation of fructose-6-phosphate 
and generates fructose-1,6-bisphosphate. Loss of function leads to the 
accumulation of glycolytic intermediates, such as glucose-6-phosphate. The build 
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up of glucose-6-phosphate can allosterically activate glycogen synthase and lead 
to an over-accumulation of glycogen (156).  
 
7. Lafora Disease 
Lafora Disease is a fatal juvenile form of progressive myoclonus epilepsy, 
with onset usually occurring in the teenage years followed by death within ten 
years after diagnosis (157,158). Gonzalo Lafora first described Lafora disease 
over a century ago, from an autopsy of a patient with teenage-onset myoclonus 
epilepsy with associated dementia (159). A hallmark and diagnosis marker of 
Lafora Disease is the presence of Lafora bodies, which were described by Lafora 
as a material that stained positive for starch in the ganglion cells, also known as 
amyloid bodies (Figure 7). Lafora bodies are mainly composed of polyglucosan, 
poorly branched insoluble glycogen-like carbohydrate found in the brain, skeletal 
muscle and heart. Their presence in the brain is considered to be causative of 
the disease (20,160-162). Patients present stimuli-sensitive grand mal, absences, 
visual and myoclonic seizures, which progress to dementia, cerebellar ataxia, 
psychosis, amaurosis and muscle wasting (163-167). Autosomal recessive 
mutations in either the EPM2A or EPM2B genes, which encode laforin and malin 
respectively, account for ~90% of Lafora Disease cases (168). 
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Figure 7. Lafora Body. Electron micrograph of a Lafora body in the center of 
an unidentified process. Single arrows represent filamentous material, double 
arrows represent amorphous material and triple arrows represent high electron 
density material (1). 
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 7.1. Laforin 
 Lafora Disease patients have either homozygous or compound 
heterozygous loss of function mutations in laforin (169). Laforin is conserved 
among vertebrates and in a small group of protists that are able to produce 
floridean starch, a carbohydrate that resembles amylopectin (170,171). 
Expression of laforin in mammals is ubiquitous with the highest levels of 
expression in the skeletal muscle, liver, kidney, heart and brain, which are also 
the tissues that develop Lafora bodies (172,173). Based on primary structure, 
laforin belongs to the dual specificity protein phosphatase (DSP) family and also 
contains a carbohydrate binding module (CBM20) within the same peptide (169), 
making laforin unique in that no other known protein phosphatases share these 
same features. To date there are 79 different mutations described in the EPM2A 
gene (The Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism 
database, http://project.tcag.cal/lafora/). The mutations are evenly distributed 
across the four exons of the gene and affect the ability of the enzyme to bind to 
polysaccharides or the dual specificity phosphatase activity.  
 Laforin is able to bind to branched polymers of glucose such as glycogen, 
amylopectin and polyglucosan, via its CBM20 (174-176). One of the disease 
mutants, W32G (177), is located in the CBM20 domain and affects carbohydrate 
binding. Although it retains a significant amount of phosphatase activity towards 
PNPP as a substrate it loses activity toward glycogen (12,174,178), suggesting 
that impaired glycogen binding by laforin may be sufficient to cause the disease. 
Additionally, levels of laforin have been correlated with the levels of glycogen in a 
series of mouse models where glycogen content has been altered by genetic 
manipulation (179).  
  A common hypothesis in Lafora research has been that polyglucosan 
formation results from an imbalance between the glycogen synthase and 
branching enzyme activities, the ‘imbalance hypothesis’. One example of an 
imbalance between glycogen branching and polymer synthesis is Andersen 
disease, which results from loss of function mutations in the glycogen branching 
enzyme (180). The impaired glycogen branching enzyme activity results in the 
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development and accumulation of polyglucosan (181). Tarui disease results in a 
build up of glucose-6-phosphate, due to defects in phosphofructokinase, which 
allosterically activates glycogen synthase and leads to the accumulation of 
abnormal glycogen (156). Additionally, overexpression of glycogen synthase in 
the skeletal muscle of mice leads to the accumulation of glycogen that was 
poorly branched and developed structures similar to Lafora bodies (85,145). As a 
result of the “imbalance hypothesis” many researchers have looked for a link 
between laforin and glycogen metabolizing enzymes. In fact, many have 
suggested that, besides glycogen, laforin can bind to several proteins involved in 
glycogen metabolism including glycogen synthase, GSK3, PTG, malin, the α2 
and β2 subunit of AMPK and the Alzheimer’s disease protein Tau (182-187). One 
mutation of laforin has been found that does not affect carbohydrate binding or 
phosphatase activity, instead it is said to affect its interaction with PTG (185). It 
has also been proposed that laforin could be responsible for regulating GSK3, 
which would affect glycogen synthase activity (186,188). In this proposal, laforin 
would dephosphorylate and activate GSK3, which would negatively regulate 
glycogen synthase. In Lafora disease, where laforin is defective, GSK3 would be 
less active and result in a more active glycogen synthase and allow for excess 
glycogen production. However, in mouse models of Lafora disease it was shown 
that the phosphorylation status of GSK3 remains unchanged (12,189), 
suggesting that GSK3 regulation of glycogen synthase is not affected by laforin 
or malin. Wang et al. also showed that there was no observable change in 
glycogen synthase or banching enzyme activity in mice over expressing a 
dominant-negative form of laforin (190). Additionally, skeletal muscle and brain 
tissue of mice lacking laforin or malin did not show altered glycogen synthase or 
the branching enzyme activity (12,189), arguing against the imbalance theory for 
Lafora body formation. 
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 7.2. Laforin, Malin and Autophagy 
 Autophagy is an intracellular process that delivers cell components to the 
lysosome. Autophagy plays a role in glycogen metabolism and defects in the 
GAA enzyme result in an inability for glycogen to be broken down in the 
lysosome where it accumulates, such as in Pompe disease. The mechanism for 
delivery of glycogen to the lysosome is not well understood but is believed to 
involve an autophagy-like process. Defects in autophagy also lead to 
neurodegeneration, behavioral changes and early death in mice (191), 
suggesting that it is an essential process for the function of the central nervous 
system. Autophagy is also thought to play a role in removing disease-associated 
cytoplasmic aggregate-prone proteins, which can be detected by anti-uibiquitin 
antibodies associated with Lafora bodies (192,193). Aguado et al. reported that 
laforin activates autophagy by acting upstream of the TCS (tuberous sclerosis 
complex) 2 (194). Loss of TCS2 leads to activation of mTOR (mammalian target 
of rapamycin), which causes activation of protein synthesis, cell growth and 
inhibits autophagy (195,196). Therefore, when laforin is disabled, autophagy 
would be inhibited via mTOR activation and lead to the disease phenotype. 
These results however are controversial. Indeed, patients with TCS2 mutations 
do not develop Lafora bodies. Additionally, there are no reports of TCS-like 
tumors in Lafora disease patient or in Lafora disease mouse models, suggesting 
that laforin may not be acting upstream of TCS2. Other studies have suggested 
that malin and not laforin affects autophagy (197). However unpublished work 
from our laboratory and work from the Guinovart laboratory (198) have shown 
that normalization of glycogen in malin knockout mice normalizes markers of 
autophagy arguing that defective autophagy is not pathogenic in Lafora Disease 
and may only be a consequence of the abnormal glycogen accumulation. 
  
 7.3. Laforin as a Glycogen Phosphatase 
 Glycogen contains trace amounts of covalently linked phosphate (see 
below). Amylopectin, a component of plant starch, also contains covalently linked 
phosphate, in fact much more phosphate than glycogen. The abnormal glycogen, 
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polyglucosan, which makes up Lafora bodies, is often described as having a 
structure more like amylopectin. In plants starch phosphate plays a critical role in 
the metabolism of starch. The plant enzyme starch excess 4 (SEX4) is 
responsible for hydrolyzing phosphate from starch and loss of SEX4 causes 
starch accumulations in Arabidopsis (170,199,200). Plants lacking SEX4 are 
unable to degrade starch during the night cycle and develop a starch excess 
phenotype, suggesting that phosphate removal is necessary for proper starch 
breakdown. Dixon and colleagues (184) demonstrated that laforin was able to 
dephosphorylate amylopectin. Tagliabracci et al. (13) later showed that, in vitro, 
laforin can also remove phosphate from rabbit skeletal muscle glycogen. When 
laforin is incubated with rabbit skeletal muscle glycogen, in vitro, ~25% of the 
phosphate can be removed by laforin. However, when glucosidase enzymes are 
added to the reaction, ~90% of the total phosphate can be released by laforin 
(13). This demonstrated that a majority of covalently bound phosphate is located 
in the inner tiers which can be accessed by laforin only after the outer tiers are 
degraded. Additionally, structural analysis of laforin demonstrates that the 
binding of carbohydrate is necessary for phosphatase activity (201).  
 The hypothesis that laforin functions as a physiological glycogen 
phosphatase has gained strength from analysis of highly purified glycogen from 
mice lacking the Epm2a gene. Mice lacking the Epm2a gene (will be designated 
as laforin-/-) accumulate glycogen, glycogen phosphate and develop Lafora 
bodies in an age dependent manner (13). Skeletal muscle glycogen phosphate 
levels in the laforin-/- mice were 4 – 6 times higher compared to wild-type 
littermates. Additionally, the skeletal muscle glycogen became less branched and 
decreased in solubility, consistent with the ability to form Lafora body. Glycogen 
from 12 – month old mice, when viewed by electron microscopy, had a larger 
diameter than wild type glycogen and appeared to be aggregated (12). 
Interestingly, when the glycogen purified from 12-month-old laforin-/- mice was 
treated with recombinant laforin it alleviated the aggregation of the glycogen and 
resulted in more of a rosette like appearance, much like the wild-type glycogen 
(12). How phosphate disrupts glycogen structure is still not known, but a 
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possibility is that it may disrupt hydrogen bonding that is associated with helical 
polyglucose (8,202). 
 
7.4. Malin 
 Malin is a putative E3-ubiquitin ligase encoded by the EPM2B gene. It is a 
395-amino acid protein with an N-terminal RING finger domain followed by 6 
NHL domains (203). To date there are some 75 disease-causing mutation, 
polymorphisms and deletions in the EPM2B gene (The Lafora Progressive 
Myoclonus Epilepsy Mutation and Polymorphism Database; 
http://projects.tcag.ca/lafora/). The RING finger domain is a characteristic of E3 
ubiquitin ligases (204). It has been reported, in cell culture experiments, that 
malin interacts with laforin and catalyzes its polyubiquitiylation, which results in 
its proteasomal degradation (187). Based on these observations, a defect in 
malin would cause an upregulation of laforin. This upregulation of laforin would 
be difficult to reconcile with the phenotype of the malin knockout mice as well 
with the development of Lafora disease in patients bearing malin mutations. 
 It has also been proposed that malin is responsible for regulating enzymes 
involved in glycogen metabolism. Mainly based on cell culture experiments, it has 
been reported that proteins such as glycogen synthase, PTG and AGL are malin 
substrates (205-208). Co-expression of malin and laforin, in cell culture, resulted 
in the ubiquitylation and proteosomal degradation of PTG (207,208). The authors 
of these studies proposed that laforin, bound to glycogen, would recruit malin 
resulting in PTG ubiquitinatylation. In this model, if malin were defective this 
would result in a build up of PTG, which would result in a more active form of 
glycogen synthase and excess glycogen synthesis, polyglucosan and Lafora 
body formation. Cheng et al (205) reported that the debranching enzyme AGL is 
a substrate for malin and that the ubiquitylation of AGL was independent of 
laforin. The authors proposed that a loss of function mutation in malin would 
prevent the proteosomal degradation of AGL and result in excessive AGL activity, 
removal of α-1,6-glycosidic linkages, which would lead to polyglucosan formation. 
However, glycogen degradation involves the coordinated actions of both AGL 
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and phosphorylase. Excessive AGL activity would only reduce branching 
frequency if phosphorylase were limiting. Furthermore, analysis of skeletal 
muscle from 3-month-old Epm2b knockout mice (which will be designated as 
mallin-/-) show no changes in the protein levels of glycogen synthase, AGL or 
PTG (189), suggesting that malin is not a major regulator of their protein levels. It 
has also been proposed that AMPK phosphorylates laforin, which would promote 
association with malin and degradation of laforin (183). However, analysis of 
skeletal muscle from WT exercised mice revealed that although AMPK was 
phosphorylated no changes in the levels of laforin were observed (189). 
There seems to be an increase in laforin levels in the malin-/- mice, 
particularly in the brain, and it is associated with enrichment in the insoluble 
fraction of extracts with depletion from the cytosol (189). This would be 
consistent with the idea that laforin is a malin substrate. However, increased 
levels of laforin have been observed in several mouse models that accumulate 
glycogen and viceversa, decreased in animal model where glycogen is 
decreased, indicating that laforin, like glycogen synthase, tracks with glycogen 
(178). Laforin has been shown to preferentially bind to starch over glycogen 
(175), suggesting that it might also prefer to bind to the polygucosan. In the 
malin-/- mice glycogen phosphate content is increased suggesting that a majority 
of the laforin may be inactive or that the insoluble glycogen and its associated 
phosphate and proteins may not be subject to normal metabolism. Therefore, we 
proposed that the abnormal glycogen accumulation in the malin knockout mice 
binds and sequesters laforin away from the metabolically active soluble glycogen 
pools (189). Furthermore work in our laboratory and by Duran et al (198) has 
shown that genetically decreasing glycogen by deficiency in PTG or glycogen 
synthase in either malin or laforin knockout mice, rescues the glycogen 
phenotype and normalizes the levels of glycogen synthase and/or laforin, arguing 
that these proteins are not malin substrates.  
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7.5. Lafora Disease and Glycogen 
There has been serious debate as to whether Lafora body formation is a 
cause or consequence of the disease, for example (209). However, there is 
growing evidence that accumulation of glycogen, and most likely abnormal 
glycogen, leads to Lafora body formation and the disease pathology. Besides 
elevated phosphate, abnormal glycogen found in mouse models of Lafora 
disease also has reduced branching, which contributes to its insolubility. The 
relationship between phosphorylation, branching and structure remains unknown.  
Our laboratory and others have also shown that suppressing or eliminating 
glycogen synthesis in mouse models of Lafora disease reduced Lafora body 
formation and restored neurological function (198,210-212). Furthermore, when 
PTG knocked mice were crossed with malin or laforin knockouts there was no 
longer an over-accumulation of glycogen, Lafora body formation is suppressed 
and neurological dysfunction is alleviated (210,211). Additionally, knockout of the 
GYS1 gene and either laforin or malin completely or partially eliminates brain 
glycogen, abolishes Lafora body formation along with restoring neurological 
function (198,212). Duran et al (213) have reported that over expression of an 
active form of glycogen synthase in neurons of mice resulted in neuronal loss, 
locomotion defects. Interestingly, in two different mouse models where glycogen 
accumulates in the brain, defects in autophagy, similar to those found in mouse 
models of Lafora disease, have been observed and is independent of malin 
function (198).  
Therefore, evidence is suggesting that Lafora disease may be dependent 
on the accumulation of glycogen and could be considered a glycogen storage 
disease. Mice lacking brain glycogen do not display any severe neurological 
defects. These observations offer a therapeutic approach for Lafora disease 
along with other glycogen storage diseases by targeting glycogen synthesis.  
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8. Glycogen Phosphate  
 
8.1. Preface 
Our understanding of the role of phosphate in glycogen and glycogen 
metabolism has advanced in recent years but its function, if any, remains 
something of a mystery. It has become clear that defects in glycogen phosphate 
metabolism are associated with Lafora disease (12-14,18,19,214). In the 1970’s 
it was established that starch, specifically amylopectin, contained covalent 
phosphate (215). However, because phosphate would often be a contaminant of 
purified biological components, due to its ubiquitous abundance, low phosphate 
content in early glycogen preparations was viewed as an indicator of its purity 
(216-218). Then in 1980, Fontana had the first convincing report that phosphate 
was stably bound to glycogen (11).  
 
8.2. Phosphate Abundance and Chemistry 
Phosphate is present in glycogen in low amounts ranging from 1 
phosphate per ~650 glucose residues to 1 in 2000 glucose residues, with the 
abundance of phosphate being dependent on the source (12-14). In mouse 
                    
 
Figure 8. Proposed location of phosphoesters in glycogen. Structure 
on the left represents the phosphodiester and the structure on the right 
represents a phoshomoester at the C6 location proposed by Lomako and 
colleagues (3) 
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models of Lafora disease, either laforin-/- or malin-/-, there is increased glycogen 
phosphate that is further increase with age (13,14,189). The location of the 
phosphate has been an area of interest for some time. Whelan and colleagues 
originally proposed that the phosphate existed as a phosphomonester that would 
be located at the C6 of glucose residues or as a glucose-1,6-phoshodiester (3) 
(Figure 8). The first report of phosphate location was in 2011 when Tagliabracci 
et al. reported that phospho-oligosaccharides, purified from enzymatically 
hydrolyzed rabbit skeletal muscle glycogen, had phosphate monoesters located 
at the C2 and C3 carbons of glucose residues (16). In 2013 Nitschke et al 
reported that NMR analysis of phospho-oligosaccharides showed phosphate at  
the C2, C3 and C6 carbon atoms of glucose residues and that the C6 
phosphomonoester was the predominant site of phosphorylation that could affect 
glycogen structure. 
 
 8.3. Introduction of Glycogen Phosphate 
 The incorporation of phosphate into glycogen is still not fully understood. 
There is evidence that glycogen synthase is capable of incorporating phosphate 
during glycogen synthesis (16,219). Lomako et al had earlier proposed that an 
uncharacterized enzyme, distinct from glycogen synthase, could be responsible 
for phosphate incorporation into glycogen (2) (Figure 9). They proposed that the 
enzyme, a glucose-1-P-transferase, would form the proposed C1-C6 
phosphodiester bond, forming a novel branch point, by transferring the β-
phosphate from UDP-glucose (2). This hypothesis was tested in our laboratory 
using skeletal muscle extracts of mice lacking the skeletal muscle isoform of 
glycogen synthase, which was incubated with radiolabeled [β-32P]UDP-glucose 
and no phosphate incorporation was observed, while wild type skeletal muscle 
extract did show the incorporation of phosphate (16). 
 These data suggested that glycogen synthase might be responsible for 
incorporating phosphate into glycogen. A second possible mechanism for 
phosphate incorporation would involve phosphorylation by a glycogen water 
dikinase, similar to enzymes found in plants. In plants, amylopectin is 
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phosphorylated at the C3 and C6 carbon atoms of glucose. The glucan water 
dikinase enzyme is responsible for transferring the β-phosphate from ATP to the 
glucan at the C6 position (220,221). Phosphorylation of the C6 position promotes 
the phosphorylation of the C3 site by a second enzyme, phosphoglucan water 
dikinase (PWD), which prefers substrates that have been previously 
phosphorylated at the C6 position (222,223). One might predict that a similar 
type of enzyme could exist in mammals. However, at this time neither 
bioinformatics nor biochemical analysis has found evidence for such enzymes.  
 
 
 
Figure 9. Glucose-1-posphate transferase. Proposed mechanism for 
phosphate introduction by Lomako and colleagues. (2).  
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Figure 10. Proposed mechanism for phosphate incorporation by 
glycogen synthase. The normal glycogen synthase reaction is shown on 
the left where glucose from UDP-glucose is added to the non-reducing end. 
The proposed mechanism for phosphate introduction would involve the 
formation of either glucose-1,3-cyclic phosphate (a) or a glucose-1,2-cyclic 
phosphate (b) in the active site of glycogen synthase, which would result in 
the incorporation of either a glucose-3-phosphate or a glucose-2-phosphate 
into glycogen.  
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Tagliabracci et al. proposed a mechanism for the incorporation of phosphate by 
glycogen synthase that would involve the a glucose 1,2- or 1,3-cyclic phosphate 
that would form in the active site of glycogen synthase, which would result in 
UMP leaving and the incorporation of a glucose-2 or glucose-3 phosphate into 
the growing glucose polymer (16) (Figure 10). Using purified glycogen synthase 
from rabbit skeletal muscle (224), yeast (82) and human (225) recombinant 
glycogen synthase the rate of phosphate incorporation was measured to be ~1 
phosphate per 10,000 glucose residues (16). However, the results and 
conclusions from Tagliabracci et al 2011 were challenged by Nitschke et al 2013. 
Nitschke et al. labeled glycogen with [β-32P]UDP-glucose in a similar manner to 
that described in Tagliabracci et al. 2011 and reported that the signal could be 
removed by gel filtration, and concluded that the 32P signal observed was due to 
[β-32P]-UDP produced during the glycogen synthase reaction, which was binding 
non-specifically to the glycogen (15).  
The mechanism for phosphate incorporation by glycogen synthase has 
not been confirmed, but there is some evidence that supports the mechanism 
proposed by Tagliabracci et al. (16). The formation of a glucose cyclic phosphate 
from UDP-glucose has been known since the mid 1900’s and was described by 
Paladini and Leloir (226). The glucose cyclic compound described was known as 
““fast ester,” due to its mobility on TLC, where it migrated ahead of UDP-glucose. 
The fast ester is formed from UDP-glucose in the presence of divalent metals 
under slightly alkaline condition, to yield the glucose-1,2-cyclic phosphate. The 
formation of glucose-1,2-cyclic phosphate and glucose-1,3-cyclic phosphate are 
known (227) and may account for the introduction of phosphate at the C2 or C3 
positions. Structural and enzymatic studies of glycogen synthase provide further 
support of the hypothesis proposed by Tagliabracci et al. (16,228). A crystal 
structure of glycogen synthase shows glucose-1,2-cyclic phosphate and UMP 
bound to the active site of the enzyme. Also, glycogen synthase, when incubated 
with UDP-glucose, produces the cyclic phosphate (228). These data suggest that 
glycogen synthase can incorporate phosphate at the C2 and possibly the C3 
locations but proving the proposed mechanism (Figure 10) (16) is challenging.  
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 There are still many unknowns regarding the source of phosphate in 
glycogen and what its role may be. For instance, how phosphate is incorporated 
at the C6 location remains unknown. Cyclic phosphates of glucose-6,3- or 
glucose 6,4-phosphates are known and can be chemically synthesized (227). 
Formation of glucose-1,6-cyclic phosphate from UDP-glucose would be sterically 
impossible. There is evidence that phosphate groups can migrate between 
hydroxyl groups on glucose residues, under alkaline or acidic conditions (229-
231). However, at this point there is no evidence for phosphate migration within 
glycogen. 
  
8.4 Phosphate and Glycogen Metabolism 
 Elevated levels of phosphate have been associated with the formation of 
Lafora bodies, which are mainly composed of insoluble glycogen like material 
known as polyglucosan (145,161,232). Mice lacking either the Epm2a or Epm2b 
genes have an age dependent accumulation of glycogen, glycogen phosphate 
and formation of Lafora bodies (12,13,19,189,214). The mechanism linking 
excess phosphate and its relationship between glycogen becoming poorly 
branched and insoluble is not well understood at this time. In plants, the 
phosphorylation of starch is critical for its degradation (17,233-235). Although 
starch and glycogen share some similarities the overall metabolism and functions 
between the two carbohydrates are distinctly different. Starch forms a semi-
crystalline structure with highly organized branching patterns and is mostly 
insoluble and inaccessible to enzymes (233,236,237). The incorporation of 
phosphate into starch is thought to disrupt the semi-crystalline structures, which 
makes it more soluble and accessible for enzymes. However, a similar role for 
glycogen degradation is unlikely because glycogen is typically soluble and the 
accumulation of phosphate in glycogen is associated with glycogen insolubility 
(12).   
 The metabolism of glycogen may be associated with its structure and 
solubility properties. Laforin-/- mice, at 3 months of age, have elevated levels of 
phosphate but do not have an excessive accumulation of glycogen and the 
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glycogen is only slightly less branched compared to wild type (12). As the laforin 
-/- mice age, up to 12 months of age, glycogen levels increase, glycogen 
phosphate levels further increase, branching decreases, solubility decreases and 
Lafora bodies are formed in many tissues (12,13). Using exhaustive exercise to 
metabolize glycogen, 3 month-old laforin -/- mice were able to utilize skeletal 
muscle glycogen to the same extent as the wild type animals (238). Immediately 
following exercise in both the wild type and laforin-/- mice there is a significant 
increase in phosphate levels (238). Glycogen phosphate content, as determined 
on a mmole of phosphate per mole of glucose, increases following a bout of 
exhaustive exercise. This is due the release of glucose from glycogen, which 
effectively increases the ratio of phosphate to glucose.  
Additionally, pervious reports demonstrated that laforin was capable of liberating  
~25% of the total phosphate from glycogen and that only after treating with 
amyloglucosidase, in order to degrade the outer tiers of glycogen and exposing 
the inner core, laforin was able to release the remaining phosphate (13). These 
data show that a majority of the phosphate is located within the inner tiers of 
glycogen and is inaccessible for removal by laforin. Therefore, the observation 
that glycogen phosphate increases after exercise in both wild type and the laforin 
-/- mice is in agreement (238) with previous observations (12). Furthermore, 
glycogen phosphate, as mole of phosphate per gram of tissue (total phosphate), 
can be used to determine if there is a loss of glycogen phosphate during a given 
experimental procedure, within the mouse tissue. Indeed, Irimia et al observed 
that total phosphate decreases in the wild type animals. However, when laforin is 
lacking there was no change in the total glycogen phosphate levels, and the 
authors concluded that laforin can remove phosphate from glycogen in vivo 
during exercise and possibly acts during glycogen degradation (238) 
Analysis of branching following exercise showed that the laforin -/- mice 
had a slower rate of branching remodeling, suggesting that the high levels of 
phosphate may affect branching (238). Irimia et al. concluded that the laforin -/- 
mice had a delay in the remodeling of their glycogen compared to wild type mice. 
This would suggest that perhaps the high amount of phosphate in the laforin -/- 
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mice, and most likely in Lafora disease patients, might inhibit the ability for 
branching to properly occur and with multiple rounds of degradation and 
synthesis would eventually lead to Lafora body formation.  
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METHODS 
 
1. Purification of Rabbit Skeletal Muscle Glycogen for Phosphate 
Determination 
Rabbit muscle glycogen was purified by either of two procedures, one 
involving treatment of muscle extracts with 10% TCA (Figure/v) at 4oC to remove 
protein prior to precipitation with ethanol (TCA Method) and the other involving 
direct KOH digestion of muscle (KOH Method). Two male New Zealand white 
rabbits, ~ 2 kg each, were sacrificed by lethal injection with pentobarbital 
(150mg/kg body weight) followed by exsanguination. Back and hind limb muscles 
were removed, ~ 75% of the harvested muscle was placed immediately under ice 
and used for glycogen purification by the TCA method. The remaining tissue was 
flash frozen in liquid N2 and stored at -80oC for glycogen purification by the KOH 
method. 
 
1.2. TCA Method.  
Immediately following exsanguination, skeletal muscle was harvested from 
rabbits, ~1.45 kg, cut into small pieces and then homogenized with three 
volumes of 4 mM EDTA in a large Waring blender, 60 seconds at low speed and 
30 sec at high speed. All steps, such as homogenizations, centrifugations and 
other steps were conducted at 4oC. The homogenate was centrifuged for 45 min 
at 7,000 x g. The supernatant was then passed through two layers of Miracloth to 
remove floating fat. The recovered supernatant (2.8 L) was transferred to a 4 L 
glass beaker placed in an ice bath and 100% (Figure/v) TCA was slowly added 
under constant stirring to a final concentration of 10% TCA. The suspension was 
then centrifuged for 30 min at 7,000 x g, the supernatant (2.7 L) transferred to a 4 
L glass beaker placed in a ice-salt bath and glycogen was precipitated by slowly 
adding 1 volume of -80oC 100% ethanol. After stirring in the ice-salt bath for an 
additional 20 min, the sample was centrifuged at 7,000 x g for 60 min, the 
supernatant was decanted and the precipitate dissolved in water using a motor 
driven pestle of a Dounce homogenizer. The solution (80 ml) was transferred to a 
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glass Corex tube and lipids were extracted with an equal volume of a 3:1 
chloroform:octanol solution followed by vigorous mixing and centrifuged at 6,000 
x g for 10 min to separate the aqueous and organic phases. The aqueous layer 
was collected and re-extracted with an equal volume of 3:1 chloroform:octanol. 
Ten ml of water was added to the organic phase of the first extraction, mixed and 
centrifuged. The process was repeated once more and all aqueous phases were 
combined, 90 ml total. Glycogen was then precipitated from the aqueous phase 
by slow addition under stirring of an equal volume of -20oC 100% ethanol and the 
suspension was kept overnight at -20oC. The precipitated glycogen was collected 
by centrifugation, 7,000 x g for 30 min, the pellet was re-dissolved with 45 ml of 1% 
SDS and then subjected to ultracentrifugation in a Ti45 rotor at 196,000 x g for 3 
hr at 4oC. After ultracentrifugation, the supernatant was decanted and 30 ml of 
water was added to the translucent glycogen pellet which was re-dissolved by 
rocking on a Nutator overnight at 4oC. The solution was then placed on ice for 1 
hr to precipitate any remaining SDS, which was removed by centrifugation at 
12,000 x g for 20 min. The glycogen in the supernatant (45 ml) was precipitated 
with two volumes of -20oC 100% ethanol and kept at -20oC for 2.5 hr followed by 
centrifugation at 15,300 x g for 30 min. The precipitated glycogen was washed 
with -20oC 100% ethanol, centrifuged at 15,300 x g and then dissolved in 30 ml 
of water. The glycogen solution was dialyzed using Spectra/Por (Spectrum) 16 
mm diameter with 12-14,000 MW cutoff dialysis tubing at 4oC against 4L of water, 
which was changed after 4.5 hr and allowed to dialyze overnight. The dialyzed 
glycogen solution was centrifuged at 23,000 x g for 20 min to remove insoluble 
material. Glycogen in the supernatant (53 ml) was then precipitated with two 
volumes of -20oC 100% ethanol with stirring and then kept at -20oC for 2 hr. After 
centrifugation at 23,000 x g for 20 min, the precipitated glycogen was washed 
with -20oC 100% ethanol and re-centrifuged. The pellet was kept at room 
temperature to evaporate all residual ethanol. After the glycogen was completely 
dried, it was pulverized using a ceramic mortar and pestle. From the 1.45 kg of 
muscle 4.0 g of glycogen was recovered and kept at -20oC until use. 
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1.2. KOH Method 
Liquid N2 flash frozen rabbit skeletal muscle (~105 g) stored at -80oC was 
rapidly broken into small pieces and added to 10-volumes of boiling 30% KOH 
and maintained in a 100oC water bath for 1 hr with mixing about every 10-15 min. 
The digested tissue was then placed on ice to cool and centrifuged at 10,000 x g 
for 10 min. All centrifugations were done at 4oC. The supernatant, 1 L, was 
filtered through 2 layers of Miracloth to remove floating fat, transferred to a 4 L 
glass beaker placed in a ice-salt bath and glycogen was precipitated by slowly 
adding two volumes of -80oC 100% ethanol with constant stirring in the presence 
of 10 mM LiCl and 0.02% Na2SO4 to aid precipitation. After an additional 5-10 
min stirring, the suspension was placed overnight at -20 oC. All subsequent 
ethanol precipitations included 6 mM LiCl. The precipitated glycogen was 
collected by centrifugation, 7,000 x g for 45 min, the pellet was re-dissolved in 30 
ml water and centrifuged at 10,000 x g for 25 min to remove insoluble material. 
The supernatant (36 ml) was precipitated by adding two volumes of -20oC 100% 
ethanol with the addition of LiCl and kept at -20oC for 2 hr. The sample was then 
heated in a boiling water bath for 3 min, which causes glycogen flocculation, then 
cooled on ice followed by centrifugation at 10,000 x g for 30 min. The pellet was 
re-dissolved in 20 ml of water and 13 ml of the solution was added to each of two 
glass Corex tubes. Ten volumes of 4:1 methanol:chloroform was added to each 
tube, vigorously mixed and incubated at 80oC for 5 min. The tubes were then 
cooled on ice and centrifuged at 5,500 x g for 30 min to pellet the glycogen. The 
pellets were dried in a Speed Vac for 10 min to remove residual solvents, re-
dissolved with ~25 ml of water, heated to aid solubilization and centrifuged at 
10,000 x g for 25 min to remove insoluble material. The supernatant was 
precipitated again with two volumes 100% ethanol and kept at -20oC overnight. 
After heating for 2 min in a boiling water bath and cooling on ice, the sample was 
centrifuged at 15,000 x g for 30 min. The glycogen pellet was dried in a Speed 
Vac for 5 min. The pellet was then re-dissolved with 20 ml of water and TCA was 
added under stirring to a final concentration of 10% (Figure/v) followed by 
centrifugation at 15,000 x g for 30 min. The glycogen in the supernatant, 27 ml, 
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was precipitated with ethanol and centrifuged at 15,000 x g for 30 min. The pellet 
was re-dissolved in 20 ml of water and filtered by passing through one layer of 
Miracloth that had been extensively washed with water. The filtered solution was 
then transferred to dialysis tubing, Spectra/Por, 16 mm diameter, 12-14,000 MW 
cutoff, and dialyzed against 4 L of water, which was changed after 2.5 hr and 
dialysis continued overnight at 4oC. After dialysis, the glycogen solution (19 ml) 
was precipitated with ethanol and the pellet was dried in a Speed Vac. The dried 
pellet was minced and weighed, yielding 0.48 g of glycogen.  
 
2. Preparation of Potato Amylopectin for Phosphate Analysis 
Potato amylopectin (Sigma-Aldrich #A8515), to be analyzed for phosphate 
content and as a positive control for the presence of glucose-6-P, was also 
subjected to the KOH purification procedure. Four aliquots of ~ 3 mg amylopectin 
were treated with 10 volumes of boiling 30% KOH as described for glycogen. 
After boiling, the samples were cooled on ice, precipitated with two volumes of -
20oC 100% ethanol and LiCl and Na2SO4 to final concentrations of 10 mM and 
0.02%, respectively and kept overnight at -20oC. The samples were then heated 
in a boiling water bath for 2 min, cooled on ice for 10 minutes and centrifuged at 
15,000 x g for 20 min at 4oC. The pellets were re-dissolved in 300 μl of water. 
The precipitation was repeated two more times with LiCl at a final concentration 
of 6 mM. After the last precipitation, the amylopectin pellets were dried in a 
Speed Vac, re-dissolved in 500 μl H2O and dialyzed in Spectra/Por tubing of 10 
mm diameter and 12-14,000 MW cutoff. The samples were dialyzed against 4 L 
of water overnight at 4oC. The dialysates were ethanol precipitated again. The 
pellets were dried in a Speed Vac to completely remove any residual liquid, 
weighed, dissolved in water at a final concentration of ~ 5 mg/ml and stored at -
20oC until use. Glucose equivalents were determined as in the Glycogen and 
Inorganic Phosphate Determination section. 
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3. Mouse Models of Lafora Disease 
Epm2a-/- (laforin-/-) mice were generated as previously described (239) 
and were backcrossed five times with C57BL/6 mice. From this generation, 
heterozygotes were crossed to generate the Epm2a+/+ (wild type, WT) and the 
laforin-/- mice (240). The Epm2b-/- (malin-/-) mice were generated as previously 
described (189). The PPP1R3C gene, which encodes the protein phosphatase 1 
(PP1) glycogen targeting subunit PTG, was deleted as previously described (241) 
to generate the PTG knockout (PTG-/-) mice. Crossing PTG-/- mice with either 
laforin-/- or malin-/- mice generated double knockout mice, PTG/laforin-/- (211) or 
PTG/malin-/-. All mice were kept in temperature and humidity controlled housing 
with a 12:12 light-dark cycle at the Indiana University School of Medicine 
Laboratory Animal Resource Center. Mice were fed standard chow (Harlan 
Tekland global diet 2018SX), and allowed food and water ad libitum. All studies 
were conducted in accordance with federal guidelines and were approved by the 
Institutional Animal Care and Use Committee of Indiana University School of 
Medicine.  
 
4. Mouse Skeletal Muscle Glycogen Purification for Phosphate 
Determination 
 Animals were sacrificed by cervical dislocation, were decapitated and the 
heads dropped directly in liquid nitrogen. Other tissues (skeletal muscle, liver and 
heart) were rapidly harvested and immersed in liquid nitrogen. Tissues were kept 
at -80oC until use. 
Flash frozen mouse skeletal muscle was pulverized under liquid nitrogen 
and a minimum of 500-600 mg of tissue was weighted in a 15 ml screw cap 
centrifuge tube (ENEMate, C-3313-15). Ten volumes of boiling hot 30% KOH 
were added to the tubes and heated in a 1000C water bath for 1 hour, with mixing 
about every 15 minutes, to hydrolyze the tissue. The digested tissue was then 
placed on ice for 10 minutes and centrifuged at 10,000 x g for 10 min. All 
centrifugations were done at 4oC. The supernatant was filtered through 2 layers 
of Miracloth to remove floating fat and transferred to a new 15 ml screw cap tube. 
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Glycogen was precipitated by adding two volumes of -20oC 100% ethanol, LiCl 
and Na2SO4, with a final concentration of 66% ethanol, 10 mM LiCl and 0.02% 
Na2SO4. The mixture was mixed by inverting and placed overnight at -20oC. The 
tubes were incubated in a boiling water bath for 2 minutes and then cooled on ice 
for 10 minutes. The precipitated glycogen was collected by centrifugation, 10,000 
x g for 30 min, the pellet was re-dissolved in 500 l water (occasionally heating 
to fully dissolve the pellet) and transferred to a 1.5 ml screw cap centrifuge tube. 
The sample was then centrifuged at 17,500 x g at 4oC for 20 minutes in a 
microcentrifuge to remove insoluble material. The supernatant was then 
transferred to a new 1.5 ml screw cap tube and 2 volumes of -20oC 100% 
ethanol and LiCl were added to precipitate the glycogen. All subsequent ethanol 
precipitations included 6 mM LiCl. The tubes were mixed by inverting and 
incubated at -20oC overnight. Samples were incubated in a boiling water bath for 
2 min, cooled on ice for 10 minutes and glycogen was collected by centrifugation, 
17,500 x g for 20 minutes at 4oC. The supernatant was removed and the 
glycogen pellet was dried in a Speed Vac for 10 minutes. The glycogen pellet 
was re-dissolved in 100 µl of water, and heated in a boiling water bath to aid in 
solubilization. Lipids were removed by adding ten volumes of 4:1 
methanol:chloroform solution to each tube, vigorously mixed and incubated at 
80oC for 5 min. The tubes were then cooled on ice and centrifuged at 17,500 x g 
for 20 min to pellet the glycogen. The pellets were dried in a Speed Vac for 10 
min to remove residual solvents, redissolved with 500 µl of water, heated to aid 
solubilization and centrifuged at 17,500 x g for 25 min to remove insoluble 
material. The supernatant, after transfer to a new tube, was precipitated again 
with two volumes 100% ethanol and kept at -20oC for a minimum of 1 hour. After 
heating for 2 min in a boiling water bath and cooling on ice, the sample was 
centrifuged at 17,500 x g for 20 min. The glycogen pellet was dried in a Speed 
Vac for 10 min. The glycogen pellets were then re-dissolved with 400 µl of water 
and 100 µl of 50% TCA was added to a final concentration of 10%, mixed well by 
vortexing and centrifuged at 17,500 x g for 20 min. The glycogen in the 
supernatant was precipitated with ethanol and centrifuged at 17,500 x g for 20 
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min. The pellet was redissolved in 500 µl of water, transferred to dialysis tubing, 
Spectra/Por, 10 mm diameter, 12-14,000 MW cutoff, and dialyzed against 4 L of 
water, overnight at 4oC. After dialysis, the glycogen solution was transferred to a 
new weighed 1.5 ml tube, precipitated with ethanol, the supernatant removed 
and the pellet was dried in a Speed Vac. The dried pellet and tube were weighed 
and the glycogen weight was determined. The glycogen was dissolved in MiliQ 
water for a final 5 mg/ml . The final glycogen concentration was determined using 
the method described in (115) (see Glycogen and Inorganic Phosphate 
Determination for details). 
 
5. Purified Glycogen and Inorganic Phosphate Determination 
  
 5.1 Glycogen Determination 
Glucose equivalents from purified mouse and rabbit skeletal muscle  
glycogen, and amylopectin were determined using the assay previously 
described in Suzuki et al. (115) by the method of Bergmeyer (242). 
Approximately 50-150 μg of polysaccharide, based on a 5 mg/ml solution, 
described above, was enzymatically digested with 300 μg/ml amyloglucosidase 
in 200 mM sodium acetate (NaOAc) pH 4.8 in a final volume of 50 μl at 40oC 
overnight. Glucose equivalents from the digest were determined using a coupled 
enzymatic reaction involving the formation of glucose-6-phosphate by 
hexokinase (Roche) followed by the reduction of NADP+ to NADPH by glucose-6-
phosphate dehydrogenase (G6PDH) (Roche). Briefly, the glycogen and 
amylopectin digest were typically diluted 1:2 and 10 µl of the digest was added to 
300 µl of the glucose assay buffer consisting of 0.3 M triethanolamine pH7.6, 4 
mM MgCl2, 0.9 mM NADP+,2 mM ATP and 2 µg/ml G6PDH. Background 
readings of the reaction were determined at 340 nm. Hexokinase was then 
added, 5 µl of 100 µg/ml in 3.2 M (NH4)2SO4, and incubated at room temperature 
in the dark for 30 minutes. After the hexokinase incubation, the absorbance at 
340 nm was again measured and using the extinction coefficient for NAPDH 
(6.22 mM-1), glucose equivalents were determined. The glucose equivalents were 
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used to normalize phosphate measurements from the same samples to give the 
mol phosphate/mol glucose ratio.  
  
 5.2 Total Phosphate Determination 
Polysaccharide phosphate content from mouse and rabbit skeletal muscle 
glycogen, and amylopectin was determined using the sensitive Malachite green 
assay as previously described (13,243). Briefly, ~200 μg of polysaccharide was 
taken in triplicate, one non-hydrolyzed and two hydrolyzed samples, from a 
solution of glycogen or amylopectin, placed in borosilicate glass tubes and dried 
in a Seed Vac. The polysaccharide was hydrolyzed by adding 40 μl of a 3:1 
solution of 60% HCLO4:10N H2SO4 and incubated at 190oC for 2 hours. After 
hydrolysis, 100 μl of water was added to the samples and mixed. The Malachite 
green solution (400 μl) was added to the samples and mixed. The solution was 
then transferred to a cuvette and the absorbance at 620 nm was measured using 
a spectrophotometer. Phosphate amounts were determined using a standard 
curve of KH2PO4, which was linear from 0-70 nmols. 
The Malachite green solution was prepared by dissolving 13.5 mg of 
Malachite green oxalate salt (Sigma) in 30 ml of H2O. After the Malachite green 
was completely dissolved, 10 ml of 4.2% ammonium molybdate in 4 N HCL was 
added, mixed and placed on a Nutator at 4oC for 1 hour. The solution was then 
filtered through a 0.22 μm syringe filter and Tween-20 was added for a final 
concentration of 0.01%. 
 
6. Measurement of Phosphate at the C6 Position in Glycogen 
 Dr. DePaoli-Roach developed a method for measuring glucose-6-
phosphate in hydrolysates of glycogen or amylopectin (14). The procedure was 
based on that described in Zhu et al. (244). Highly purified glycogen from mouse 
and rabbit skeletal muscle, and amylopectin, 0.5 mg of each, were hydrolyzed in 
75 µl of 1 N HCL for 3 hours in a boiling water bath. The reaction was neutralized 
by adding 37.5 µl of 2 N NaOH. For glycogen samples 10 µl of sample, in 
triplicate, were added to wells of a 96-well plate (Costar 3603, Corning) with a 
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clear bottom and black walls. Amylopectin samples were diluted 1:10 and 10 µl of 
sample was added to the 96-well plate in triplicate. The reaction mixture (90 µl) of 
50 mM triethanolamine, pH 7.6, 1 mM MgCl2, 100 M NADP+, 10µM high 
purity resazurin (Acros Organics #18990), and 0.2 units/ml Clostridium kluyveri 
diaphorase (Sigma #D2322), was added to each well. Samples were centrifuged 
at 2000 rpm for 45 seconds in a Fisher Marathon 8K centrifuge and then mixed 
at 700 rpm for 45 seconds in an Eppendorf Mixmate. Background fluorescence 
was measured using a FlexStation II plate reader (Molecular Devices) with 
excitation at 530 nm and emission at 590nm. The reaction was started by adding 
0.1 units/ml Leuconostoc mesenteroids glucose-6-phosphate dehydrogenase 
(Roche Applied Science #10165875001), centrifuged, mixed and incubated at 
room temperature for 30 minutes in the dark. Fluorescence was again measured 
and the background readings subtracted. Each assay included a set of standards 
which contained 0 – 150 pmols of glucose-6-phospahte. Due to the low amounts 
of glucose-6-phosphate relative to glucose in the hydrolysates, it was determined 
that a 4000-fold molar excess of glucose to glucose-6-phosphate did not interfere 
with the measurements of glucose-6-phosphate  (data not shown).  
 
7. Purification of Glycogen For Total Glycogen Content in Mouse Tissue 
 Total glycogen in skeletal muscle, liver and brain was determined by a 
protocol similar to that described in Suzuki et al. (115) using the method of 
Bergmeyer (242). Under liquid nitrogen, brain tissue was harvested by breaking 
open the skulls and transferred to a new tube. Flash frozen tissues were 
pulverized under liquid nitrogen and 30 – 50 mg of muscle, heart, brain or liver, 
were weighed in a 1.5 ml screw cap tube. The tissue was hydrolyzed by adding 
300 µl of boiling 30% KOH and incubating in a boiling water bath for 30 minutes, 
with mixing every 5-10 minutes. Samples were then cooled on ice for 10 minutes. 
Glycogen was precipitated by adding 100 µl of 2% Na2SO4 and 800 l of -20oC 
100% ethanol, for a final 0.25% Na2SO4 and 66% (v/v) ethanol. The samples 
were then mixed, by inverting, and incubated at -20oC for a minimum of 1 hour. 
Samples were then incubated in a boiling water bath for 2 minutes and cooled on 
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ice for 10 minutes. Glycogen was collected by centrifugation, 17,500 x g for 20 
minutes at 4oC. The supernatant was decanted and tubes were quickly 
centrifuged to collect any remaining supernatant, which was removed. Glycogen 
pellets were dried in a Speed Vac to remove residual ethanol and re-suspended 
by adding 200 µl of MilliQ water and vortexing. Precipitation of glycogen was 
repeated two more times by adding two volumes of -20oC 100% ethanol to the 
re-suspended glycogen and incubating at -20oC for a minimum of 1 hour. After 
each precipitation, the samples were incubated in a boiling water bath, cooled on 
ice, centrifuged and dried in a Speed Vac as described above. Once the last 
precipitation was completed the dried glycogen pellet was re-suspended in 100 – 
200 µl of 0.2 M NaOAc (NaOAc) buffer, pH 4.8, that contains 300 µg/ml 
amyloglucosidase and incubated for a minimum of 4 hours at 40oC to digest the 
glycogen. Glucose equivalents were determined as described above (Glycogen 
Determination).  
 
8. Fractionation of Glycogen by Low Speed Centrifugation and Western 
Blotting Analyses  
 Skeletal muscle was powdered under liquid nitrogen and homogenized 
using a tissue Tearor, ~75 mg for glycogen content and Western blot and 
between 800 -1000 mg for glycogen branching and phosphate determination, in 
10 volumes of buffer consisting of 50 mM Tris-HCl, pH 7.8, 10 mM EDTA, 2 mM 
EGTA, 100 mM NaF, 2 mM benzamidine, 0.1 mM N-Tosyl-L-lysine chloromethyl 
ketone hydrochloride (TLCK), 50 mM β-mercaptoethanol, 0.5 mM 
phenylmethane sulfonyl fluoride (PMSF), 10 µg/ml leupeptin, 1 mM sodium 
orthovanadate and 0.2% Triton-20. Homogenization was done at maximum 
speed for ~30 seconds. After homogenization, 80 µl of the total extract was taken 
and 20 µl of 5X SDS loading buffer (60 mM Tris-PO4 pH 6.8, 40% glycerol, 5% 
SDS (Figure/v), 0.08% Bromophenol Blue, and 5%(v/v) β-mercaptoethanol) was 
added, incubated in a boiling water bath for 5 minutes and frozen for later use. 
The remaining homogenate was subjected to centrifugation at 5,000 X g for 10 
minutes, as previously described (12,14). Following centrifugation, the 
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supernatant was removed and measured. Typically, the removed supernatant 
was ~70% of the original volume of homogenization buffer. The low speed pellet 
(LSP) was re-suspended by adding 70% of the original volume of 
homogenization buffer. Equal amounts (100 µl) of the LSS and LSP were taken 
for western blot analysis, 1/5 the volume of 5X SDS loading buffer was added, 
samples were incubated in a boiling water bath for 5 minutes, cooled on ice and 
stored at -20oC for later use. From the LSS 10 µl of sample was taken and 
diluted 1:30 with water and used to determine protein concentration using the 
Bradford assay (245).  
 For Glycogen determination, equal amounts (350 µl) of the LSS and LSP, 
and boiling 50% KOH was added to the samples for a final 30% KOH (v/v), which 
was heated in a boiling water bath for 30 minutes. The samples were then cooled 
on ice and quickly centrifuged to collect condensation. Glycogen was then 
precipitated by adding 2 volumes of -20oC 100% ethanol and 100 µl of 2% 
Na2SO4, mixed and incubated at -20oC for a minimum of one hour. The glycogen 
was precipitated two more times, similarly to what is described in the measuring 
total glycogen content section. Glucose equivalents were then determined.  
For Western blot analysis an equivalent volume, based on the protein 
concentration of the LSS, of the LSP or total extract was used to separate 
proteins by SDS – PAGE followed by Western blotting (12,189). Typically, 10 – 
40 µg of LSS protein and equivalent samples of LSP or total extracts were 
loaded on to 10% SDS-PAGE gels. Proteins were separated by electrophoresis, 
180 volts for 45 minutes, and transferred to a 0.45 µm nitrocellulose membrane 
at 15 volts overnight at 4oC. Nitrocellulose membranes were then stained with 
Ponceau S (0.5% Ponceau S in 1% glacial acetic acid) to monitor loading and 
proper transfer of proteins to the membrane. Membranes were destained with 
H2O and blocked with 5% non-fat milk powder in 1X Tris-buffered saline, 
consisting of 50 mM Tris-HCl, 150 mM sodium chloride, pH 7.6 with 0.1% 
Tween-20 (TBST). Various antibodies were used to probe the membranes for 
proteins by incubating the membranes in a solution containing the antibody of 
interest diluted into 2% non-fat milk powder solution in 1X TBST and incubated 
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for 3 hours at room temperature or overnight at 4oC. Following incubation with 
antibodies, the membranes were washed three times for 10 minutes with 1X 
TBST. Secondary antibodies, conjugated to horseradish peroxidase, diluted in 2% 
non-fat powdered milk solution in 1X TBST, were incubated at room temperature 
for one hour followed by 3 washes in 1X TBST. Detection of antibodies was 
achieved by chemiluminescence using the Pierce ECL Western blot substrate. 
The levels of proteins were quantitated by densitometric analysis of the 
autoradiograph using Quantity One Software (BioRad). 
Antibodies used were the following: glycogen synthase (Cell Signaling 
Technology #3886), laforin (Abnova, H00007957-M02), phospho-glycogen 
synthase (3a), AMP activated protein kinase α subunit (AMPK) and pAMPK 
(Thr172) (Cell Signaling Technology #3891, #2532 and #2535 respectively).  
 
8.1 Branching Analysis of Purified Glycogen and Glycogen in the 
Low Speed Supernatant and Low Speed Pellet  
Total purified glycogen or glycogen from the low speed supernatant and 
pellets were prepared as described above, except that 700 – -800 mg of skeletal 
muscle from 9-10 month old male wild type and laforin-/- or malin-/- mice were 
used. Once the LSS and LSP were prepared, the glycogen was purified and 
measured as described above. Glycogen solutions were prepare, 100 µl of a 1 
mg/ml glycogen, and treated with 25 µg/ml isoamylase (Sigma, 15284-5MU) in 
100 mM NaOAc pH 4.0 or 4.8 and incubated for 16 hours at 42o C. The reaction 
was terminated by heating in a boiling water bath for 5 minutes, cooled on ice 
and centrifuged at 14,000 x g to remove any denatured proteins. After 
centrifugation, the supernatant was transferred into a new tube. A sample of the 
reaction was diluted 10 x with water and filtered through a centrifuge spin filter 
(Costar SpinX) and loaded onto a Dionex ICS3000 high performance anionic 
exchange chromatography (HPAEC) for branching analysis. The glucose 
polymer chains were then separated by the HPAEC as previously described 
(238). Briefly, 2.5 µg of the debranched glycogen was loaded on to a PA200 
column with a mobile phase of 100mM NaOH, eluent A, and eluted with a eluent 
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B, 100mM NaOH and 1M NaOAc with a continuous gradient of 0 – 50% eluent B 
over 60 minutes with a flow rate of 0.3 ml/min. Data is analyzed as relative peak 
area, the product of the individual area over the sum of all peak areas. Figure 11 
shows HPAEC branching analysis of purified glycogen from WT LSS and laforin-
/- LSP. 
 
9. Synthesis of [β-32P]UDP-Glucose 
The synthesis of [β-32P]UDP-glucose was conducted in two different ways, 
each of which followed a similar protocol to that described previously (16,246). 
The procedure was conducted either in a one step reaction where all the 
enzymes and substrates were added together or a two-step reaction, where the 
hexokinase reaction was carried out first, terminated and transferred to a new 
tube for the second set of enzymatic reactions. 
 
 
 
 
 
 
Figure 11. HPAEC branching analysis. High performance anionic 
exchange chromatography (HPAEC) chromatograph of isoamylase 
treated glycogen. The top panel is a chromatograph of glucose – 
maltoocotaose (M8) and the bottom panel is a chromatograph of glucose 
polymer chains from isoamylase treated glycogen from either WT LSS 
glycogen (blue line) or laforin-/- LSP (red line). 
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9.1 One Step Reaction 
The one step enzymatic synthesis of [γ-32P]UDP-glucose was carried out 
in a single tube that contained ~1.5 mCi of [γ-32P]ATP (Perkin Elmer), which was 
dried under nitrogen. The dried [γ-32P]ATP was dissolved in 160l of a 1.25X 
reaction mixture, which consisted of 62.5 mM Tris-HCl pH 7.6, 6.25 mM glucose, 
7.5 mM MgCl2, 1 mM UTP, 1.125 mM DTT, 0.016 U/µl pyrophosphatase (Roche), 
0.038 U/µl phosphoglucomutase (PGM) (Megazyme) and 17 µg/ml of 
Leishmania UDP-glucose-pyrophosphorylase (LMUGP). The LMUGP 
recombinant enzyme was produced and purified by Dr. Vimbai M. Chikwana as 
previously described (247). The reaction was started by adding 40 µl of 
hexokinase (Roche) for a final concentration of 0.03 U/µl, which brought all other 
reaction components to a final 1X concentration and was incubated at 30oC for 2 
hours. The reaction was terminated by placing the reaction in a boiling water bath 
for 5 minutes, cooled on ice and centrifuged for 10 minutes at 15,000 x g at 4oC 
to pellet denatured proteins. [β-32P]UDP-glucose was purified from the reaction 
mixture as described below.  
 
9.2 Two Step Reaction 
The two step reaction was used for the majority of the [β-32P]UDP -
glucose production because the yields were better than that of the one step 
reaction ( ~50% vs ~70% respectively). One main difference between the two 
step and the one step reaction is that in the two step reaction cold ATP was 
added to the reaction mixture to yield more UDP-glucose total mass, which may 
have contributed to the higher yields with this method. The first step in the 
synthesis of [β-32P]UDP-glucose was to dry ~1.5 mCi of [γ-32P]ATP under 
nitrogen. The dried [γ-32P]ATP was then dissolved in 80  μl of 1.25X hexokinase 
reaction mixture, which consisted of 62.5 mM Tris-HCl pH 7.6, 6.25 mM glucose, 
7.5 mM MgCl2 and 31.25  μM ATP. To start the reaction, 20 μl of hexokinase 
was added for a final concentration of 0.03 U/µl and all other reaction 
components were brought to a final 1X concentrations (100 l of 50 mM Tris-HCl 
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pH 7.6, 5 mM glucose, 6 mM MgCl2 and 25 µM ATP). The reaction was 
incubated at 30oC for one hour and terminated by heating in a boiling water bath 
for 5 minutes. The reaction was then cooled on ice and centrifuged for 10 
minutes at 15,000 x g at 4oC. The reaction mixture was then transferred to a new 
tube and the remaining synthesis components were added for a final 200 µl 
reaction containing 50 mM Tris-HCl pH 7.6, 6 mM MgCl2, 0.9 mM DTT, 0.8 mM 
UTP, 0.013 U/ µl pyrophosphatase, 0.03 U/ µl PGM and 0.136 mg/ml LMUGP. 
The second step of the reaction involved incubation at 30oC for one hour and 
termination by heating in a boiling water bath for 5 minutes. The reaction was 
then cooled on ice and centrifuged for 10 minutes at 15,000 x g at 4oC to pellet 
denatured proteins. [β-32P]UDP-glucose was purified from the reaction mixture as 
described below.  
 
9.3 Purification of [β-32P]UDP-glucose 
Once the enzymatic reactions were terminated, centrifuged and the 
supernatant removed, [β-32P]UDP-glucose was purified by binding  to ~7 mg of 
activated charcoal, vortexing for 1 minute and incubating on ice for 10 minutes. 
The charcoal was collected by centrifugation at 15,000 x g for 2 minutes at 4oC. 
The supernatant was removed and the activated charcoal was washed 3 times 
with 1ml each of ice cold MiliQ water. The mixture was vortexed for 30 seconds, 
centrifuged at 15,000 x g for 2 minutes at 4oC and the supernatant was removed. 
After three washes, the [β-32P]UDP-glucose was eluted by adding 200 µl of 
elution buffer, 0.16 M NH4OH in 50% (v/v) ethanol, vortexing for 30 seconds and 
centrifugation at 15,000 x g for 2 minutes at 4oC for a total of 4 elutions. After 
each elution, the supernatant was removed and transferred to a new tube; all 
eluates were combined. To remove any residual charcoal, the eluates were once 
again centrifuged and the supernatant was passed through a Costar Spin-X 
Centrifuge Tube Filter that had been equilibrated with the elution buffer. The 
filtered eluates were then completely dried in a Speed Vac and the dried material 
was dissolved in 100 µl of 10 mM Tris-HCl pH 7.5, aliquoted and stored at -80oC. 
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10. Radiolabeling and Visualization of Glycogen 
Purified rabbit skeletal muscle (RSM) glycogen was labeled with 
recombinant yeast or human glycogen synthase essentially as described 
previously (16). A 1.25 x glycogen synthase reaction mixture was prepared which 
was composed of 62.5 mM Tris-HCl pH 7.8, EDTA 6.25 mM, glucose-6-
phosphate (G6P) 9 mM, RSM glycogen at 8.3 mg/ml, UDP-glucose added to a 
concentration of 2 - 5 µM with a specific activity of 330-400 cpm/pmol for UDP-
[U14C]-glucose and 75,000-260,000 cpm/pmol for [β-32P]-UDP-glucose. For 
control samples, an aliquot of the 1.25 x reaction mix was taken and GS dilution 
buffer (50 mM Tris-HCl pH 7.8, 0.1% RSM glycogen and 1 mM DTT) was added 
for a final 1 x reaction mixture (50 mM Tris HCL pH7.8, 5 mM EDTA, 7.2 mM 
G6P, 6.7 mg/ml RSM glycogen, and 2-5 µM of UDP-[U14C]-glucose or [β- 32P]-
UDP-glucose). Glycogen synthase reactions were incubated at 30oC with 2 – 5 
µg/ml yeast glycogen synthase or 20 µg/ml human glycogen synthase. At given 
time points, a sample of the glycogen synthase reaction was taken and 
terminated by heating in a boiling water bath for 5 minutes, then cooled on ice 
and centrifuged to collect condensation. From each time point, samples were 
taken for thin layer chromatography (TLC) analysis, typically ~5 µl. From the 
remaining reaction sample, glycogen was precipitated by adding two-volumes of 
cold (-20oC) 100% ethanol, as well as Na2SO4 and LiCl to a final concentration of 
2.8 mM and 20 mM respectively to aid in precipitation. The samples were then 
mixed and incubated at -20oC for a minimum of 4 hours to allow for precipitation, 
heated in a boiling water bath for 2 minutes, cooled on ice for 10 minutes, 
centrifuged at 15,000 x g for 30 minutes, and the supernatant was removed. The 
glycogen pellet was dried with a Speed Vac and dissolved in water or buffer as 
needed, typically to the original sample volume. If further precipitations were 
required, two volumes of cold 100% ethanol were added and LiCl was added to a 
final concentration of 2 mM. For SDS-PAGE, the glycogen pellets were dissolved 
in 25 µl of water or buffer and 1/5 of the volume of 5 x SDS loading buffer (60 
mM Tris-PO4 pH 6.8, 40% glycerol, 5% SDS (Figure/v), 0.08% Bromophenol 
Blue, and 5%(v/v) β-mercaptoethanol) was added. The samples were then 
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heated in a boiling water bath for 5 minutes and loaded into wells of a 10% 
polyacrylamide gel with a 4% stacking gel. Loading corresponded to 250 – 375 
µg of the initial glycogen present in the reactions. Gels were developed at 180 V 
for ~45 minutes. Following electrophoresis gels were incubated in a solution 
containing 20% methanol (v/v) and 5% glycerol (v/v) for a minimum of 10 minutes. 
The gels were then dried and imaged with a FujiFilm FLA-5100 Phosphorimager.  
 
11. Treatments of 32P- and 14C-labeled glycogen 
 32P- and 14C-labeled glycogen produced by glycogen synthase reactions 
was purified through ethanol precipitation(s) and subjected to various additional 
treatments prior to analysis by SDS-PAGE.  
 
11.1. Glucosidase and Laforin Treatment of Labeled Glycogen  
Rabbit skeletal muscle glycogen labeled with UDP-[U-14C]glucose or [β-
32P]UDP-glucose was purified by ethanol precipitation and digested with a 
mixture of α-amylase and amyloglucosidase or treated with either mouse 
recombinant WT or the catalytically inactive C266S laforin, similar to what has 
been previously described (16). Following ethanol precipitation, glycogen was 
dissolved in water and adjusted to 20 mM NaOAc, pH 4.8 for glucosidase or 
laforin treatment. The glycogen was incubated with 25 – 50 µg/ml of recombinant 
laforin at 37oC for 2 hours. For glucosidase treatment, glycogen was incubated 
with or without 0.3 mg/ml of both α-amylase and amyloglucosidase at 42oC for 2 
hours. Reactions were terminated by heating in a boiling water bath for 5 minutes, 
cooled on ice and centrifuged to collect condensation. For analysis of 32Pi release, 
32P-glycogen was purified by ethanol precipitation, treated with PiBindTM resin, 
described below, and subjected to gel filtration. The PiBindTM resin binds and 
removes free phosphate from samples. This step was added to minimize 
inorganic phosphate contamination of the 32P-glycogen. In fact, we observed that 
the resin also chelated and removed UDP and UDP-glucose (data not shown). 
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11.2. Treatment of glycogen with PiBindTM Resin 
Radio labeled glycogen was first purified by ethanol, dissolved in 120 µl of 
water and treated with PiBindTM resin (Innova Biosciences, 501-0051), in order to 
remove contaminating 32Pi. For treatment with PiBindTM resin, 20 µl of settled 
resin was washed with 200 µl water in a 1.5 ml tube by mixing and the resin was 
pelleted by centrifugation (1,000 x g for 1 minute at 16oC). The water was 
completely removed with an insulin syringe. 120 µl of water was added to the 
tubes, with and without PiBindTM resin. The dissolved glycogen was added to the 
tubes (75 µl) and incubated at room temperature, 25oC with rocking on a Nutator 
for 1 hour. Samples were then transferred to a spin column and centrifuged for 2 
minutes at 1,000 x g at 4oC and the flow through was collected in a new tube. 
The flow through was then dried using a Speed Vac and the glycogen was 
dissolved in buffer or water for further treatment or TLC analysis.  
  
11.3. Spin Column and Gel Filtration 
Glycogen synthase reactions were carried out as previously described to 
obtain the 14C and 32P labeled glycogen, and a sample was taken for TLC 
analysis. An equal volume of water was added and LiCl and Na2SO4 were added 
and glycogen was precipitated with ethanol, as described above. The samples 
were incubated at -20oC for a minimum of 4 hours, heated in a boiling water bath 
for 2 minutes, cooled on ice for 10 minutes and centrifuged at 15,000 x g for 30 
minutes at 4oC. The supernatant was removed and the pellet was dissolved in 
H2O 2X the original volume, LiCl was added for a final 6 mM and the sample was 
again precipitated with cold ethanol and incubated at -20oC for a minimum of 4 
hours. The samples were again heated in a boiling water bath, cooled on ice, 
centrifuged and the supernatant was removed. The glycogen pellet was dried in 
a Speed Vac and dissolved in 150 – 160 µl of 10 mM Tris-HCl pH 7.5.  
Once the glycogen was completely dissolved, the sample was split and 70 
µl was transferred to a tube as a “before column” sample and 70 µl was added to 
a spin column (Promega) containing ~1 ml of packed Sephadex G50 (Sigma), 
which had been equilibrated with 10 mM Tris-HCl pH 7.5. Prior to adding the 
 59 
sample to the spin column, excess buffer was removed by centrifuging the 
column at 1,000 x g for 1 minute at 16oC. The sample was loaded onto the G50 
resin, centrifuged at 1,000 x g for 1 minute at 16oC and the flow through collected, 
and referred to as the "after column" sample. Both the samples before and after 
column were dried in a Speed Vac and dissolved in 25 µl of 10 mM Tris-HCl pH 
7.5. Once the glycogen was dissolved 20 µl of the sample was taken and 5 µl of 
5X SDS loading buffer was added, heated in a boiling water bath for 5 minutes, 
and 275 – 375 µg of glycogen was loaded on a SDS page gel. The gel was then 
dried, using a gel dryer and imaged with a phosphorimager. The remaining 5 µl 
of sample was used for TLC analysis and scintillation counting. 
 
11.4. Hydrolysis of UDP with Recombinant Human Soluble Calcium-
Activated Nucleotidase (hSCAN-1)  
hSCAN-1 is a nucleotidase that converts UDP to UMP but does not act on 
UMP (248,249) or UDP-glucose and glucose-6-P (data not shown). 32P- and 14C-
labeled glycogen was purified by three ethanol precipitations. After the last 
precipitation, the glycogen pellet was dried in a SpeedVac and dissolved in 50 
mM Tris-HCl pH 7.5, 0.05% (v/v) Tween-20, and incubated at 37oC for 30 min 
with or without 1.2 µg/ml hSCAN-1 plus 2 mM CaCl2. The reactions were 
terminated by boiling and processed for SDS-PAGE as described above. In other 
experiments, the glycogen synthase reactions were terminated by boiling, 2 mM 
UDP was added and the samples incubated at 37oC for 30 min with or without 
1.2 µg/ml hSCAN-1 plus 2 mM CaCl2 in excess of the EDTA concentration, final 
7 mM CaCl2. Samples were then analyzed by TLC and/or SDS-PAGE. 
 
11.5 Competition with Unlabeled UDP 
   32P- and 14C-labeled glycogen was purified with three cycles of ethanol 
precipitation and dissolved in 50 mM Tris-HCl pH 7.5, 0.05% (v/v) Tween-20. 
Once the glycogen was completely dissolved, 2 mM UDP was added, 1000-fold 
excess compared to labeled UDP-glucose, and incubated at room temperature 
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for 30 min. In other experiments, the UDP was added prior to ethanol 
precipitation. Samples were then processed and analyzed by SDS-PAGE.  
 
11.6 Binding of 32P-UDP to glycogen 
Rabbit skeletal muscle glycogen at 6.7 mg/ml was incubated in 50 mM 
Tris-HCl pH 7.8, 5 mM EDTA, 7.2 mM glucose-6-P, 1 µM UDP-[U-14C]glucose 
(specific activity ~450 cpm/pmol), with or without 4 µM [α-32P]UDP(specific 
activity of ~100,000 cpm/pmol), the reaction was started by adding recombinant 
yeast glycogen synthase (10 µg/ml) or buffer as a control and incubated for 60 
min at 30oC. The reactions were then terminated by boiling for 5 min, cooled on 
ice, and the glycogen precipitated with ethanol as described above. The 
glycogen was dried in a Speed Vac and dissolved in 48 µl of water, 5 mM UDP or 
20 mM NaOAc pH 4.8 for glucosidase digestion. Amyloglucosidase and α-
amylase, each at 60 µg/ml, were added and incubated overnight at 40oC, other 
samples were kept at -20oC during the overnight digestion. All samples were 
boiled for 5 min, cooled on ice and analyzed by SDS-PAGE.  
 
12. Thin Layer Chromatography 
High-performance thin layer chromatography (HPTLC) plates (Merk, Silica 
gel 60 F254) were used for TLC analysis of hSCAN-1 action towards nucleotides. 
One or two µl of sample was spotted on the plate which was developed by 
ascending chromatography with n-propanol:ethyl acetate:water (7:1:4). Plates 
were laid flat and allowed to air dry at room temperature. Visualization of 
radioactivity was achieved by using a phoshorimager or by exposing the plates to 
X-ray film. For visualization of UV signal, TLC plates were placed under a UV 
lamp ( 254 nm), the UV absorbing areas, where nucleotides are present 
were marked, and the plates were photographed. 32Pi release from 32P-glycogen 
by laforin was analyzed using polyethyleneimine (PEI) cellulose plates (Merck, 
1.05725.0001) and developed by ascending chromatography with 1M acetic acid: 
3M LiCl (9:1). Plates were air dried and imaged as described above. 
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13. Recombinant Laforin Purification and Reactions 
 
 13.1 Purification of Recombinant His-Tagged Laforin  
Recombinant His-tagged laforin, wild type or C266S mutant, was 
expressed in Escherichia Coli and purified by affinity chromatography using Ni-
NTA agarose essentially as previously described by Wang and Roach (178). E. 
Coli transformed with a N-terminal His-tagged recombinant laforin was grown in a 
starter culture, 10 ml of Luria broth (LB) containing 50 µg/ml of kanamycin, 
overnight at 37oC with shaking. The starter culture was then added to 1 L of LB 
broth with 50 g/ml of kanamycin and grown to an OD600nm of ~0.500 at 37oC. 
Once the OD was reached, the culture was induced with 2 mM isopropyl β-D-1 
thiogalactopyranoside (IPTG) and incubated overnight at 18oC to induce protein 
production The cell were collected by centrifugation at 10,000 x g for 10 minutes 
at 4oC, the supernatant was decanted, the cell pellet washed by resuspending in 
PBS, re-centrifugation and the PBS was decanted. The cell pellet was then snap 
frozen in liquid nitrogen and stored at -80oC. Buffers used were as follows: 1) 
Lysis buffer consisted of 50 mM Tris – HCL pH 8.0, 300 mM NaCl, 20 mM 
imidazole, 1 mM benzamide, 1 mM PMSF, 1µg/ml aprotinin, 1µg/ml leupeptin, 
1µg/ml pepstatin and 0.05% β-mercaptoethanol. 2) Imidazole wash buffer, 50 
mM Tris – HCL pH 8.0, 300 mM NaCl and 50 mM imidazole. 3) Elution buffer, 50 
mM Tris – HCL pH 8.0, 300 mM NaCl and 250 mM imidazole. Ni-NTA agarose 
beads were equilibrated by washing 3 ml of packed beads with 10 ml of ice cold 
water 3 x followed by one 10 ml wash with the lysis buffer minus the protease 
inhibitors. After the wash with the lysis buffer, the beads were maintained in lysis 
buffer.  
The frozen cell pellets were re-suspended in 20 ml lysis buffer and passed 
through a French press three times or until the lysate was fluid, then Triton X-100 
was added for a final 0.5% (v/v) concentration and the lysate was incubated on 
ice for 5 minutes. The lysate was clarified by centrifugation at 20,000 x g for 20 
minutes at 4oC and the supernatant was removed and placed in  a column 
containing equilibrated Ni-NTA agarose and was rocked on a Nutator at 4oC for 2 
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hours. The lysate was allowed to flow out of the column and collected. The beads 
were washed 2-times with lysis buffer containing 0.5% (v/v) Triton X-100 without 
protease inhibitors and once with the imidazole wash buffer. All washes used 10 
ml of the given solution with a flow rate of 1 ml/minute. Elution of the His-tagged 
laforin was achieved by applying 10 ml of the elution buffer to the column and 
after one ml of liquid had exited the column, it was clamped to allow the beads to 
equilibrate with the elution buffer for 5 minutes after which the clamp was 
removed and 1 ml fractions were collected at a flow rate of 0.5 ml/min. Each 
fraction was then transferred to 12-14,000 MW cutoff dialysis tubing and dialyzed 
at 4oC against 4 L of dialysis buffer consisting of 50 mM Tris – HCL pH 8.0 with 2 
mM DTT and dialyzed overnight with constant stirring. Samples were then 
analyzed by SDS-PAGE gel, stained with Coomassie blue, destained and dried 
to estimate protein purity. The fractions, which contained purified laforin and had 
activity toward pNPP, were pooled and concentrated using an Amicon Ultra 
centrifugal filter with a 10,000 molecular weight cutoff and centrifuged for 5 
minutes at 3,000 x g at 4oC. Protein concentration was determined by the 
Bradford assay and activity was measured against pNPP and purified 
oligosaccharides, described below.  
 
13.2 Laforin Phosphatase Activity using pNPP as a Substrate 
Hydrolysis of p-nitrophenylphosphate (pNPP) was performed in a 100 µL 
reaction volume containing phosphatase buffer, 500 mM NaOAc, 250 mM Bis-
Tris, 250 mM Tris - HCL pH 6.5, with 15 µg/mL recombinant laforin and varying 
amounts of pNPP, 0 – 30 mM. Reactions were incubated at 37oC for 5 minutes 
and terminated by adding 400 µl of 0.25 M NaOH. An additional 500 µl of water 
was added and the absorbance was read at 410 nm. Activity was measured by 
the extinction coefficient of pNPP  as 18.3 mM-1cm-1. 
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13.3 Dephosphorylation of Phospho-oligosaccharides with Laforin 
and HPAEC Analysis 
Phospho-oliogsaccharides purified from either rabbit skeletal muscle or 
from amylopectin were used as substrates for laforin, similarly to what was 
described by Tagliabracci et al. (16). The reaction consisted of phosphatase 
buffer or of 100 mM NaOAc pH4.8, with 10 – 100 µM of phospho-
oliogsaccharides, based on phosphate content. The reactions were started by 
the addition of recombinant laforin, either wild type or C226S catalytically inactive, 
at 25 – 50 µg/ml and incubated in a 37oC for a minimum of one hour, terminated 
by heating in a boiling water bath for 5 minutes and cooled on ice. Denatured 
protein was pelleted by centrifugation at 17,500 x g for 10 minutes at 4oC. The 
supernatant was then filtered through a Costar SpinX column. Phosphorylated 
oligosaccharides, 0.25 – 2.5 nmols, from rabbit skeletal muscle glycogen and 
amylopectin were analyzed by high performance anionic chromatography 
(HPAEC) using a Dionex ICS3000 with a PA200 column and detected by pulse 
amperometric detection. Phospho-oligosaccharides were loaded based on 
phosphate concentration and 2.5 nmol were analyzed. Standards, 2.5 nmol, of 
glucose, maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose, 
maltoheptaose, and maltooctaose were also analyzed using the HPAEC. All 
samples and standards were filtered through a Costar Spin-X spin filter (Coastar 
Spin-X, 8160) prior to being loaded into a 25 μl injection loop. Eluent A consisted 
of 100 mM NaOH and eluent B consisted of 100 mM NaOH and 1 M NaOAc. 
Phospho-oligosaccharides and standards were eluted off the PA200 column 
using a continuous gradient of eluent B from 0-50% over 60 minutes with a flow 
rate of 0.350 ml/min.  
 
13.4 Assay of Potential Laforin substrates by HPAEC Analysis 
 Uridine diphosphate and UDP-glucose were treated with laforin to 
determine whether laforin is capable of hydrolyzing the phosphate ester bonds in 
these compounds. Reaction mixtures with recombinant WT laforin or C226S 
laforin contained 25 µg/ml of each enzyme, 20 mM NaOAc pH 4.8 and 2.5 mM of 
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either UDP or UDP-glucose. The reactions were incubated at 37oC for 2 hours 
and were terminated by heating in a boiling water bath for 5 minutes. A sample of 
the reaction was taken and diluted to 50 µM of either UDP or UDP-glucose. The 
samples were then passed through a centrifuge filter (Coastar Spin-X, 8160) and 
the sample was loaded on to a Dionex high-performance anion exchange 
chromatography (HPAEC) ICS 3000 and 25 µl of the sample was loaded onto a 
PA200 column. The mobile phase, eluent A, consisted of 100 M NaOH and the 
nucleotides were eluted off the column with Eluent B, 100 M NaOH/1M NaOAc, 
with a gradient set at 20 – 50% from 0 – 10 minutes, 55 – 85% from 10 – 35 
minutes and from 85 – 100% from 35 – 40 minutes and flow rate of 0.30 ml/min. 
The nucleotides were detected by UV absorption at 262nm. 
 
14. Phosphooligosaccharide Purification and Analysis 
The procedure was as previously reported by Tagliabracci et al (16). 
Rabbit skeletal muscle, purified by the TCA method and KOH method, or 
amylopectin was extensively digested with α-amylase and amyloglucosidase. 
Rabbit skeletal muscle glycogen, approximately 250 mg, was first dissolved in 
2.4 ml of water then CaCl2 and a mixture of α-amylase and amyloglucosidase 
was added for a final volume of 3 ml with final concentrations of 1 mM CaCl2 and 
300 μg/ml of each enzyme in 10 mM NaOAc pH 4.8. For amylopectin, 
approximately 250 mg was dissolved in 2.4 ml of 1.25% DMSO and CaCl2, α-
amylase and amyloglucosidase, and NaOAc were added to a final volume of 3 ml 
with equal concentrations as described above. The reaction was incubated 
overnight at 42oC, centrifuged at 10,000 x g for 5 minutes to remove any 
insoluble material and the supernatant was transferred to 2 ml screw cap tubes. 
The supernatant was then placed in a boiling water bath for 5 minutes, cooled on 
ice and centrifuged for 10 minutes, 15,500 x g at 4oC. The supernatant was 
added to 2 ml (bed volume) DEAE Sepharose that had been extensively washed 
with ice cold H2O, equilibrated with 10 mM NaOAc pH 4.8 and placed on a 
Nutator at 4oC overnight. The DEAE Sepharose resin mixture was transferred to 
a 3 ml column, washed with 40 ml of H2O, and the flow rate was adjusted to 0.5 
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ml/minute. Phosphorylated species were eluted stepwise, collecting 1 ml 
fractions, with 4 ml of 10 mM, 50 mM, 100 mM, 500 mM and 1 M of NH4HCO3. 
From each fraction an aliquot of 75-100 µl was taken for phosphate 
determination. Briefly, 25-30 µl of the aliquot taken from each fraction was 
transferred to borosilicate glass tubes in triplicate, one non-hydrolyzed and two 
hydrolyzed, which were then dried in a Speed Vac. For hydrolysis, 40 μl of a 3:1 
solution of 60% HClO4:10N H2SO4 was added to the glass tubes and incubated 
at 190oC for 2 hours. Phosphate amounts were determined using the Malachite 
green assay described above. Fractions containing phosphate were pooled, 
dried in a Speed Vac and re-suspended in water for a final concentration of 1 mM 
of phosphate for NMR analysis. Figure 12 shows the phosphate content of each 
elution.  
 
14.1 HPAEC Analysis of Phospho-Oligosaccharides 
hosphorylated oligosaccharides, 2.5 nmol based on phosphate 
concentration, from rabbit skeletal muscle glycogen and amylopectin were 
analyzed by HPAEC using a Dionex ICS3000 with a PA200 column and 
detected by pulse pulsed amperometric detection. All samples were filtered 
through a spin filter before loading into a 25-µl injection loop. Eluent A consisted 
of 100  
mM NaOH, and eluent B consisted of 100 mMNaOH and 1 M NaOAc. Phospho-
oligosaccharides and standards were eluted from the PA200 column using a 
continuous gradient of eluent B from 0-to 50% over 60 min at a flow rate of 0.35 
ml/min. Polyglucose standards from glucose up to maltooctaose were also 
analyzed at 0.25 nmol of each. 
 
 14.2 Analysis of Phospho-oligosaccharides by Mass Spectrometry 
MALDI-TOF-MS analysis was performed by the Complex Carbohydrate 
Research Center, The University of Georgia essentially as previously describe 
(16). Briefly, 1µL of 1 mM phosphate of purified phosphorylated oligosaccharides 
was mixed with the same volume of matrix solution containing 2,4,6-
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trihydroxyacetophenone and spotted onto a MALDI plate. The analysis was 
performed in reflector negative ion mode. All spectra were obtained using a 
Microflex LRF (Bruker). 
 
14.3 Analysis of Phospho-oligosaccharides by NMR Spectroscopy 
NMR analysis was performed by the Complex Carbohydrate Research 
Center, The University of Georgia essentially as previously described (16). 
Phospho-oligosaccharides from glycogen and from amylopectin were lyophilized 
and deuterium-exchanged by lyophilization from D2O (99.9% deuterium; Sigma), 
dissolved in D2O (99.96% deuterium, Cambridge Isotope), and transferred to a 5-
mm NMR tube with magnetic susceptibility plugs matched to D2O (Shigemi). 
Proton-proton (correlation spectroscopy (gCOSY), total correlation spectroscopy 
(zTOCSY), rotating frame nuclear overhauser effect spectroscopy (ROESY)) and 
proton-carbon (gHSQC) correlated spectra were acquired on a Varian Inova 600-
MHz spectrometer equipped with a 5-mm cryoprobe, and proton-phosphorus-
correlated spectra were acquired on a Varian Inova 500 MHz spectrometer 
equipped with an 8-mm XH room temperature probe. All spectra were taken at 
25 °C. Proton chemical shifts were referenced to internal acetone (δ  2.218 ppm) 
(250). Carbon and phosphorus chemical shifts were referenced using the 
absolute chemical shift scale with Ξ values of 0.25144953 (13C) and 0.40480742 
(31P) in MNova. All experiments except the 1H,31P-correlated spectra were 
acquired with standard Varian pulse sequences. For 1H,31P-correlated 
experiments, the regular HMQC and HMQC-TOCSY experiments were modified 
for 31P in the X channel, with a π pulse of 13.5 µs at a level of 60 db and a 3JH-
P coupling constant of 7 Hz. The spectral width was 2000 Hz in f2 and 8000 Hz in 
f1. 24 increments were acquired with 512 transients each. Acquisition time was 
300 ms, and the mixing time in the 1H,31P-HMQC-TOCSY experiment was 60 ms. 
The gCOSY experiment was acquired in 8 transients and 400 increments, with 
an acquisition time of 150 ms. The zTOCSY experiment was acquired in 16 
transients and 128 increments, with an acquisition time of 150 ms and a mixing 
time of 80 ms. The ROESY experiment was acquired in 16 transients and 128 
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increments, with an acquisition time of 150 ms and a mixing time of 200 ms. For 
the 13C,1H gHSQC with adiabatic 180-degree carbon pulses experiment, the 
spectral width was 3378 Hz in f2 and 10555 Hz in f1. 64 increments were 
acquired with 200 transients each. The acquisition time was 150 ms, and the 1-
bond C-FIGURE coupling constant was set to 140 Hz. The sample was 280 ml of 
a solution 2 mM with respect to phosphate. The raw data were processed in 
MNova using a 7-Hz gaussian function in f2 and a 90°-sine2 function in f1 (1H,31P 
spectra) and 7- and 80-Hz Gaussian functions in f2 and f1 (13C,1H spectra), 
respectively, as well as linear prediction in f1. 
  
15. Recombinant Glycogen Branching Enzyme Purification 
Purification of mammalian N-terminally glutathione S-transferase (GST) 
tagged human glycogen branching enzyme (GST-GBE) was as follows. The 
procedure typically yielded approximately one milligram of purified enzyme from 
one liter of bacterial culture. E. Coli transformed with the GST-GBE were grown 
in a 10 ml starter culture overnight at 30oC in Luria Broth (LB) with 100 µg/ml of 
ampicillin. The starter culture was then added to 1 L of Terrific Luria Broth (TLB) 
with ampicillin, 100 µg/ml and grown at 30o C with shaking until the OD600 
reached 0.600. At this time, the bacteria culture was placed on ice for 20 minutes 
to stop growth. The culture was then placed back into the 30o C incubator with 
shaking and allowed to grow over night, approximately 16 hours. Optimal 
expression of the GST-GBE was obtained under non-induced, no IPTG, 
conditions using the TLB media. Cells were collected by centrifugation, 5,000 x g 
for 10 minutes, washed with PBS and then either immediately lysed or snap 
frozen and stored at -80o C. The lysis buffer consisted of PBS with protease 
inhibitors (200 mM PMSF, 1 mM benzamine, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 
1 µg/ml aprotonin). The cell pellet was resuspended in 35 ml of lysis buffer, 
freshly prepared lysozyme was added for a 1 mg/ml concentration and incubated 
on ice for 2 hours. Cells were then lysed using a French press, and passed 
through three times. The lysate was then clarified by centrifugation at 10,000 x g 
for 15 minutes at 4oC, if lysate remained cloudy after initial centrifugation the 
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sample was centrifuged at 20,000 x g for 30 minutes. The supernatant was then 
passed over 2 layers of Miracloth, transferred to a 50 ml screw cap tube, 44 mg 
of swollen GST-Agarose beads, previously washed with water and equilibrated 
with the lysis buffer, were added to the lysate supernatant and incubated on a 
Nutator for 1 hour at 4oC. Agarose beads were collected by centrifugation, 
10,000 x g for 2 minutes at 4oC. The beads were washed 3 times by 
resuspending in 10 ml of the wash buffer (50 mM Tris-HCl pH 7.6, 100 mM NaCl, 
0.2% Triton X-100, and protease inhibitors), After each wash the beads were 
collected by centrifugation, 10,000 x g for 2 minutes at 4oC, and the supernatant 
was transferred to a new tube until the purification process was complete. After 
the last wash the beads were collected and transferred to a 1.5 ml tube and 
quickly centrifuged to collect any remaining wash buffer, which was removed. 
Elution buffer (500 µl), 50 mM Tris-HCl and 200 mM glutathione, was added to 
the beads, mixed and incubated on a Nutator for 10 minutes at 4oC. The beads 
were pelleted by centrifugation, the eluted material was transferred to a new tube 
and the beads were eluted again with 500 µl elution buffer. The eluates were 
combined and dialyzed using Spectra/Por (Spectrum) 10 mm diameter, 12-
14,000 MW cutoff dialysis tubing at 4oC against 50 mM Tris – HCL pH 8.0, 100 
mM NaCl and 2 mM DTT. Following dialysis protein concentration was measured 
and the samples were snap frozen with liquid nitrogen and stored at -80oC 
 
16. Branching Enzyme Activity 
 
 16.1 Indirect Branching Enzyme Activity 
The glycogen branching enzyme activity was measured indirectly by 
monitoring the incorporation of [U14C]-glucose by the actions of either glycogen 
phosphorylase or glycogen synthase similar to the procedure described by 
Hawker et al. (251). Phosphorylase b, purified from rabbit skeletal muscle (224), 
and recombinant yeast glycogen synthase were used to monitor the 
incorporation of [U14C]-glucose into glycogen from either [U14C]-glucose-1-
phosphate or from UDP-[U14C]-glucose for the respective enzymes. As the GBE 
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introduces branch points, there will be new non-reducing ends for phosphorylase 
or glycogen synthase to incorporate a new glucose molecule that allows 
monitoring of the GBE activity indirectly. When using phosporylase b, a reaction 
mixture was made at 1.25 x the final concentration and consisted of 125 mM 
sodium citrate pH 7.0, rabbit skeletal muscle glycogen 1.25 mg/ml, 12.5 mM 
AMP, 62.5 mM glucose-1-phosphate with a specific activity ~75 cpm/pmol 
[U14C]-glucose-1-phosphate in 500 – 700 µl. The reactions were started by 
adding a 5 x solution containing 50 mM citrate, 250 µg/ml of GBE and 0.5 mg/ml 
phosphorylase b. The final reaction mix consisted of 100 mM citrate pH 7.0, 
rabbit skeletal muscle glycogen 1.0 g/ml, 10 mM AMP, 50 mM glucose-1-
phosphate with a specific activity ~60 cpm/pmol [U14C]-glucose-1-phosphate, 
100 µg/ml phosporylase b and 50 g/ml GBE. Reactions using glycogen 
synthase were prepared similarly and the final reaction conditions consisted of 25 
mM Tris-HCl pH 7.6, 5 mM EDTA, 50 mM UDP-glucose, UDP-[U14C]-glucose 
specific activity of ~15 cpm/pmol, rabbit skeletal muscle glycogen 100 µg/ml, 26 
µg/ml recombinant yeast glycogen synthase and 26 -  50 µg/ml GBE in 500 -700 
µl. At given time points, 20 µl of the reaction was spotted, in duplicate, on ET3 
filter paper and placed in cold, -20oC, 66% (v/v) ethanol to terminate the reaction 
and wash off any unreacted [U14C]-glucose-1-phosphate or UDP-[U14C]-glucose. 
The filter papers were washed a total of 3 times, 15 min per wash, in 66% (v/v) 
ethanol, the first wash at -20oC, 66% (v/v) ethanol and the others at room 
temperature. A magnetic stirring bar stirred the ethanol. The filter papers were 
finally washed with acetone for 5 minutes and dried under a heat lamp. [U14C]-
Glucose incorporation was determined by measuring the radioactivity at the 
given time points. Figures 13 shows the activity of the GBE using either 
phosphorylase b or recombinant yeast glycogen synthase.  
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Figure 13. Branching enzyme activity. Branching enzyme activity 
determined by monitoring the incorporation of 14C-glucose by either glycogen 
phosphorylase (A) or glycogen synthase (B).  
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16.2 Branching Enzyme Activity Using Amylose and HPAEC 
Monitoring the changes in oligosaccharide chain length with HPAEC 
analysis provides a means to monitor the activity and determine the chain length 
The procedure was similar to that described by Devillers et al (252). Reactions 
could either be set up to monitor the action of the GBE as a function of time, 
enzyme concentration or substrate concentration. The reaction mixtures were 
prepared in 50 mM Tris-HCl pH 7.6, 1 – 5 mg/ml amylose and started by adding 
the GBE for a final 70 µg/ml, which could also vary depending on the experiment, 
in 100 µl. The amylose used in the experiments was dissolved in a 1 N NaOH 
solution at 50 mg/ml, which was diluted to 10 mg/ml with 50 mM Tris – HCL pH 
7.6 and was neutralized with 1 N HCl to pH 7.6. After neutralization the amylose 
was added to the GBE reaction. At given time points, samples were removed and 
heated in a boiling water bath for 5 minutes to terminate the reaction, cooled on 
ice and quickly centrifuged to collect condensation. Debranching by isoamylase 
was carried out by adding one volume, typically 50 µl, of isoamylase in NaOAc 
buffer for a final of 200 mM NaOAc pH 3.5 with 20 µg/ml isoamylase, which was 
incubated at 40oC overnight. Reactions were terminated by heating in a boiling 
water bath for 5 minutes, cooled on ice and centrifuged, 15,500 x g for 10 
minutes at 4oC to collect condensation and pellet denatured proteins. The 
supernatant was transferred to a new tube and diluted to 0.1 mg/ml of initial 
amylose concentration, filtered through a Coastar SpinX spin column and 25 µl of 
the resulting glucose polymers were loaded onto a PA1 or a PA-200 column and 
separated by high-performance anion exchange chromatography (HPAEC) using 
a Dionex ICS3000 with pulsed amperometric detection. For standards, from 
monomeric glucose to maltooctaose, 25 µl of a 0 – 10 µM solution was loaded on 
to the colum for quantitation. Eluent A consisted of 100 mM NaOH and eluent B 
100 mM NaOH with 1M NaOAc. The samples were eluted with a continuous 
gradient from 0%–50% of Eluent B over 60 min with a flow rate of 0.3 ml/min. 
Data was expressed as the sum of the integral of a given polymer length divided 
by the sum of all polymer signals, shown as a relative peak area. Additionally, the 
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relative peak area can be plotted as a change in a given peak area by 
normalizing to a control sample that did not contain the GBE.  
 
17. Measuring Reducing Ends of Carbohydrates 
 Reducing ends of carbohydrates can be used to determine the amount of 
reducing carbohydrates present in a heterogenous mixture or to analyze the 
production of new reducing ends. To measure the reducing ends a procedure 
similar to that described in Waffenschmidt and Jaenicke (253) was used. Two 
solutions were prepared; solution A consisted of 5 mM bicinchoninic acid (BCA), 
512 mM sodium carbonate and 288 mM sodium bicarbonate, solution B 
consisted of 5 mM copper sulfate and 12 mM L-serine. Maltotriose was used to 
generate a standard curve, which was linear up to 50 nmol. To 100 µl of the 
standards 250 µl of solution A and B were added to the tubes and incubated in a 
boiling water bath for 15 minutes and allowed to cool at room temperature for 20 
minutes, which was then quickly centrifuged to collect condensation and 100 µl of 
water was added to the reaction. The reaction produces a purple color, which 
has an absorbance maximum at 560nm, and a standard curve can be generated. 
Unknown samples were prepared similarly to the standards and the 
concentration of reducing ends was determined from the linear regression curve 
of the standards.  
 
18. Synthesis of Glucose-1,2-Cyclic Phosphate and Glucose-3,6 and 4,6-
Cyclic Phosphate  
 Cyclic phosphate compounds were synthesized essentially as previously 
described by Zmudzka and Shugar (254). Starting material, either glucose-1-
phosphate, 1 g, or glucose-6-phosphate, 0.5 g, was dissolved in 5 ml of water. 
Glucose-1-phosphate yields the glucose-1,2-cyclic phosphate compound and 
glucose-6-phosphate yields a mixture of glucose-3,6-cyclic phosphate and 
glucose-4,6-cyclic phosphate. After dissolving the starting glucose monoester in 
water, it was converted to its free acid by cation exchange chromatography using 
Dowex 50W-X8 resin. The resin was washed with water and the free glucose 
 73 
monophosphate sugar was neutralized immediately with pyridine, and 
concentrated in borosilicate glass tubes with a Speed Vac to a volume of 
approximately 10 ml. For glucose-1-phosphate, 30 ml of pyridine and 3 g of 
dicyclohexylcarbodiimide (DCC) was added, mixed and incubated at 0oC for 48 
hours. Glucose-6-phosphate received 10 ml of pyridine and 1.5 g of DCC and 
was incubated at room temperature, ~25oC, for 72 hours. After the DCC reaction 
was complete 10 ml of water was added and precipitated cyclohexylurea was 
filtered away by vacuum filtration. The filtrate was extracted 3 times with an equal 
volume of diethyl ether, the aqueous phase was collected and concentrated with 
a Speed Vac to about 5 ml in borosilicate glass tubes. Any insoluble material 
present was removed by vacuum filtration and the filtrate was passed over a 
Dowex cation exchange resin and rapidly neutralized with a saturated solution of 
barium hydroxide to pH 8.0. The solution was concentrated in borosilicate glass 
tubes using a Speed Vac to ~1ml, centrifuged at 5,000 x g for 5 minutes to clarify 
the solution. The barium salt of the glucose cyclic phosphate was precipitated 
with 3 ml of acetone and centrifuged for 5 minutes at 5,000 x g to pellet the 
precipitate. The cyclic phosphate was washed 3 times with 10 ml of -20oC 100% 
ethanol by mixing well and centrifugation at 5,000 x g for 5 minutes followed by 3 
washed with and equal volume of acetone. The barium salt of the glucose cyclic 
phosphate was dried using a Speed Vac and stored at -20oC until use.  
 
19. Synthesis of Glucose-2-Phosphate 
Acid hydrolysis of glucose-1,2-cyclic phosphate was used to produce 
glucose-2-phosphate and purified as the barium salt (255,256). The acid 
hydrolysis was performed under conditions that would open the ring, hydrolyze 
glucose-1-phosphate but not hydrolyze the phosphate from glucose-2-phosphate 
(256). To produce glucose-2-phosphate 100 µmoles of glucose-1,2-cyclic 
phosphate was dissolved in water (9 ml) and HCL was added for a final 1 N 
concentration. The solution was then incubated in a boiling water bath for 5 
minutes and cooled on ice. A saturated solution of barium hydroxide was used to 
adjust the pH between 9-10 and kept on ice to allow for barium phosphate to 
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form and precipitate out of solution, which was collected by centrifugation at 
10,000 x g for 10 minutes at 4oC and the supernatant was transferred and saved 
in a different tube. The precipitate was redissolved in 0.1 N HCl and the pH 
adjusted between 9-10 with a saturated barium hydroxide solution, cooled on ice, 
the precipitated collected by centrifugation and the supernatant transferred. This 
process was repeated once more and the supernatants were combined. The 
barium salt of glucose-2-phosphate was precipitated by adding and 3 volumes of 
100% ethanol to the combined supernatants and was incubated at 4oC overnight. 
The precipitate was collected by centrifugation, washed with 100% ethanol, dried 
with a Speed Vac and stored at -20oC until use.  
 
20. Mouse Exercise Protocol 
 Mice were exercised to exhaustion on a treadmill (Exer6M, Columbus 
Instruments) following a procedure similar to that described previously (140). 
Briefly, 11.5— 12.8 month-old (will be referred to as 12 month old) male wild type, 
laforin-/- and malin-/- mice were trained and acclimated to the treadmill and the 
exercise to exhaustion was conducted essentially as described (140) except that 
on the last day of training the incline was kept at 15 degrees and the speed did 
not exceed 25.2 m/min. The mice were placed on the treadmill and the incline 
was set at 15 degrees. The speed was increased as described previously but did 
not exceed 25.2 m/min. Once the mice could no longer remain on the treadmill 
belt, they were removed, body weight and blood glucose levels were measured. 
Mice in one group were given a bolus of glucose (3.6 g of glucose/kg of body 
weight) by oral gavage and placed in a cage with food and water. Mice were 
sacrificed at different times post-exercise by cervical dislocation and tissues were 
harvested and immediately frozen in liquid nitrogen and stored at -80 oC for 
analysis of glycogen, glycogen phosphate content and Western Blotting. Blood 
glucose was measured using a Breeze 2 glucometer (Bayer) pre- and post-
exercise.  
 
 
 75 
21. Tissue Staining 
Visualization of Lafora bodies in quadriceps from mice was performed as 
previously described (189). Briefly, quadriceps were fixed in 10% formalin and 
embedded in paraffin. Slices, 5 µm, were deparaffinized and treated with a 
solution containing 0.1% Diastase in 20mM NaOAc (pH 6.0) for 1 hour at 40 oC, 
which effectively degrades normal glycogen. Sections were then oxidized with 
0.5% periodic acid for 5 minutes, stained with Schiff reagent for 15 minutes and 
counterstained with hematoxylin and eosin for 15 minutes. Tissues were 
sectioned at the Histology Core at Indiana University School of Medicine 
Department of Anatomy and Cell Biology.  
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RESEARCH OBJECTIVES  
 A major focus of Lafora disease research has been to identify the 
functions of both laforin and malin so as to understand the mechanism of the 
disease and thereby seek rationale strategies for its treatment. It is becoming 
accepted that one role of laforin is as a glycogen phosphatase (13), while the 
function of malin remains less clear at this time. A hallmark of Lafora disease 
is the appearance of Lafora bodies, which are composed of poorly branched, 
insoluble glycogen like material, also known as polyglucosan. Normally, 
glycogen contains trace amounts of phosphate. Analysis of glycogen from 
mouse models of Lafora disease has shown that there is an accumulation of 
poorly branched and hyperphosphorylated glycogen. The increase in 
phosphate has been associated with decreased solubility and may contribute 
to Lafora body formation (12,14,19). Because of the increased 
phosphorylation of glycogen in mouse models of Lafora disease, it is 
important to understand the amount and location of the phosphate in order to 
understand the mechanism for glycogen phosphorylation and is a part of the 
data presented in this thesis (Results, 1. Glycogen Phosphate). How 
phosphate is incorporated into glycogen has been an area of ongoing 
research and in this thesis I confirm that glycogen synthase is capable of 
incorporating phosphate into glycogen (Results, 2. Incorporation of 
Phosphate into Glycogen by Glycogen Synthase). Disruption of the PTG gene 
in a laforin-/- or malin-/- background alleviates Lafora body formation and I 
report on analyses of the amount and structure of glycogen in these double 
knockout mouse models. The results indicate that elevated glycogen 
phosphate alone may not always be sufficient to cause Lafora body formation 
(Results, 3. Glycogen Phosphate, Branching and Solubility) as has also been 
suggested recently by Nitschke et al (257). The final question I asked was 
whether the abnormal glycogen accumulated in Lafora disease is subject to 
normal metabolism. For this study, we used exercise of mouse models of 
Lafora disease as a means to provoke glycogen breakdown in muscle 
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(Results, 4. Glycogen Metabolism in Mouse Models of Lafora Disease 
Subjected to Exercise).  
 78 
RESULTS 
 
1. Glycogen Phosphate  
 
1.1 Phosphate Chemistry and Abundance 
 Glycogen is a branched polymer of glucose but it also contains trace 
amounts of phosphate, about one phosphate for every 650 – 2000 glucose 
residues, depending on the source (18,28). In 2011 Tagliabracci et al (16) 
showed, by NMR analysis of phospho-oligosaccharides purified from rabbit 
skeletal muscle glycogen, that phosphate existed as a phosphomonoester at C2 
and C3. However, Nitschke et al (15) challenged those results and concluded 
that C6 phosphorylation was the dominant site for phosphorylation in glycogen. 
This discrepancy in observations and conclusions prompted us to further 
investigate our initial findings. Glycogen phosphorylation had become a point of 
interest because of its association with Lafora disease, an early onset fatal form 
of juvenile epilepsy (157,209,214,258,259) as described in the Introduction. In 
particular, there is an association between hyper-phosphorylation and abnormal 
glycogen formation, such that glycogen becomes less branched and water 
insoluble (12). The location of phosphate in glycogen is therefore an important 
part of understanding how the phosphate may be affecting glycogen structure or 
how, mechanistically, the phosphate is introduced into glycogen. The first phase 
of this thesis research was therefore directed at re-evaluating the 
phosphorylation of glycogen in normal animals as well as in the mouse models of 
Lafora disease. We therefore revisited the question of the location of the 
phosphate in glycogen, specifically asking whether the method for glycogen 
purification affected the experimental results. Phosphate and other ester 
migration is a known phenomenon in sugar chemistry (229,231). 
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Phosphate ester migrations under acidic conditions have been documented, but 
it has also been observed under alkaline conditions (230). Because of this, 
glycogen from rabbit skeletal muscle was prepared using two methods to 
determine whether the purification procedure had any effect on the distribution of 
phosphate. A relatively mild procedure, where the most extreme treatment is 
exposing tissue homogenates to 10%(v/v) TCA at 4oC, was used, designated the 
“TCA” method. The second method involved subjecting skeletal muscle tissue to 
boiling 30%(w/v) KOH, designated the “KOH” method. Measurement of glycogen 
phosphate from either procedure gave a similar glycogen phosphate content 
(Figure 14). Rabbit skeletal muscle glycogen, purified by the procedures 
described above, and amylopectin, were hydrolyzed enzymatically with 
glucosidases to produce glucose and limit dextrin. Phospho-oligosaccharides 
were separated from neutral sugars by anion exchange chromatography. 
Phosho-oligosaccharides from potato amylopectin were processed similarly and 
used as a known source for phosphorylation of C6 (17,235,260). Analysis of the 
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Figure 14. Rabbit skeletal 
muscle glycogen content. 
Rabbit skeletal muscle 
(RSM) glycogen purified by 
either the “TCA” or “KOH” 
method phosphate content. 
Data is the average of two 
measurements from the 
same sample of glycogen.  
n 1  
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phospho-glucans from glycogen by HPAEC (Figure 15, B and C) gave identical 
profiles for the TCA and KOH methods while the profile for amylopectin had a 
similar but unique profile (Figure 15, D). Mass spectroscopy analysis of the 
phospho-oligosaccharides gave spectra that were dominated by signals 
corresponding to species with one phosphate plus n hexoses, with n reaching up 
to around 12 hexose residues (Figure 16). Although the mixtures of phospho-
oligosaccharides were complex they were similar in chemical composition, in that 
they were composed of glucose polymers with a covalently linked phosphate. 
The HPAEC and mass spectroscopy data were similar to our previous 
observation (16). Analysis of the phospho-oligosaccharides by two-dimensional 
homonuclear 1H NMR (COSY, TOCSY and ROESY), heteronuclear 13C,1H NMR 
(HSQC) and heteronuclear 1H,31P NMR (HMQC and HMQC-TOCSY) produced 
chemical shifts of the signals found in the oligosaccharide mix (Table 1) and most 
of the signals were present in phosphooligosaccharide samples from glycogen 
and amylopectin. The 13C,1H NMR (HSQC) spectra show that phospho-
oligosaccharides from glycogen had phosphates located at C2, C3 and C6 
(Figure 17, A) while amylopectin only had signals for C3 and C6 phosphate 
(Figure 17, D), which are indicated by circles.  
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Figure 15. HPAEC  analysis of phospho-oligosaccharides from 
glycogen and amylopectin. Oligosaccharides were separated by HPAEC 
using a PA200 column. A, polyglucose standards (0.25 nmol) from glucose 
(G1) up to moltooctaose (G8). B, phospho-oligosacharides purified from 
rabbit skeletal muscle glycogen by the TCA method. C, phospho-
oligosacharides purified from rabbit skeletal muscle glycogen by the KOH 
method. D, phospho-oligosaccharides purified from amylopectin. nC, 
nanoCoulomb. 
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Figure 16. Analysis of phospho-oligosaccharides purified from 
glycogen by MALDI-TOF mass spectrometry. A 1-μL aliquot of 
phospho-oligosaccharide solution (1 mM in phosphate ester), prepared 
by the “TCA” (A) or KOH” (B) protocol, was analyzed using THAP 
matrix in negative ion mode. MALDI spectra are shown in which a 
series of glycogen phosphate peaks from both preparations was 
detected. The main signals observed are series of glucose oligomers 
with one mole of phosphate, starting with 3 hexose units. 
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The glycogen samples had relatively weak C6-P signals but this was the major 
signal in the phospho-oligosaccharide samples from amylopectin. 
 To determine whether these residues were phosphorylated, 1H,31P HMQC 
(Figure 17, B and E) and HMQC – TOCSY (Figure 17, C and F) spectra of both 
samples were obtained. The 1H,31P HMQC spectra show peaks for protons that 
are at the most three bonds away from phosphorus atoms, which confirmed the 
assignments and showed the 31P chemical shift of the different phosphate groups. 
The spectrum of amylopectin phospho-oligosaccharides was dominated by Glc-
6-P with a small contribution from the Glc-3-P and no detectable Glc-2-P. The 
glycogen phospho-oligosaccharide spectrum showed similar signals Glc-2-P, 
Glc-3-P and Glc-6-P. The 1H,31P HMQC – TOCSY experiments were acquired 
to provide a reliable assignment of the signals found in the 1H,31P HMQC 
spectra, and was able to show protons up to four bonds away from phosphorus 
atoms. 1H,31P HMQC – TOCSY spectra gave the following signals, Glc-2P gave 
cross peaks between 31P and H-1 and H-2, Glc-3-P showed correlations 
between 32P and H-2, H-3 and H-6. All assignments derived from COSY, 
TOCSY, 13C,1H HSQC and 1H,31P HMQC – TOCSY were in agreement 
between the spectra (Table 1). An approximate quantitation of the NMR signals 
for the glycogen phospho-oligosaccharides (Table 2) showed roughly equal 
proportions of C2, C3 and C6 phosphate for the TCA and KOH prepared 
samples. However, the previous TCA (16) sample had a lower level of C6 
phosphate. Additionally, C6 phosphate in amylopectin was the dominant location 
for phosphate, ~85% of the total, which would be expected from previous reports. 
These data suggest, that use of KOH to purify glycogen does not influence the 
phosphate distribution as determined by NMR. Why the 2010 sample had ~19% 
of the phosphate at C6 versus ~30% in the 2013 remains an unknown. However, 
the average of the two samples is ~24%, which is in line with the enzymatic 
quantitation for C6 phosphorylation, as discussed in the next section (Figure 18).  
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Figure 17. Analysis of phospho-oligosaccharides purified from glycogen 
and amylopectin by NMR. 
Two-dimensional heteronuclear NMR spectra were acquired as described in 
“Experimental Procedures” with D2O as solvent from samples 2 mM with 
respect to phosphate. A. 1H-13C-gHSQC spectrum of purified glycogen 
phospho-oligosaccharides, prepared by the “KOH” protocol. The signals from 
H/C pairs of phosphorylated positions are circled and labeled. The contribution 
of each isomer was estimated by measuring the peak volumes of the labeled 
signals; B. 1H-31P-HMQC-TOCSY spectrum of purified glycogen phospho-
oligosaccharides, showing phosphorus correlations to H-1 and H-2 of Glc-2-P 
and to H-2, H-3, and H-4 of Glc-3-P; C. 1H-31P-HMQC spectrum of purified 
glycogen phospho-oligosaccharides, showing phosphorus correlations to H-2 
of Glc-2-P, H-3 of Glc-3-P, and H-6 of Glc-6-P;  D. gHSQC spectrum of 
purified amylopectin phospho-oligosaccharides. The same areas as in Panel A 
are circled although no C2 phosphate was detected in amylopectin. The 
contribution of each isomer was estimated by measuring the peak volumes of 
the labeled signals; E. 1H-31P-HMQC-TOCSY spectrum of purified amylopectin 
phospho-oligosaccharides, showing phosphorus correlations to H-5 and H-6 of 
4-Glc-6-P, to H-4, H-5, and H-6 of t-Glc-6-P, and to H-2, H-3, and H-4 of Glc-
3-P; F. 1H-31P-HMQC spectrum of purified glycogen phospho-
oligosaccharides, showing phosphorus correlations to H-3 of Glc-3-P and H-6 
of Glc-6-P. The lines connecting the signals are coded to the different 
phosphorylated glucose residues; e and f: solid, g: dashed, a: dash-dot lines. 
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Table 1. Proton, carbon, and phosphorus chemical shifts (in ppm) of 
phosphorylated amylopectin and glycogen oligosaccharides 
 
 Residue  1 2 3 4 5 6 
a1 t-α-Glc-2-P-(1→) 1H 5.67 3.98 3.76 3.49 3.70 3.83/3.77 
  13C 100.0 77.3 74.7 71.8 75.3 63.3 
  31P  1.12     
b t-α-Glc-(1→4) 1H 5.60 3.57 3.66 3.43 3.66 3.83/3.77 
  13C 101.1 74.0 75.4 72.1 75.4 63.3 
c2 t-α-Glc-(1→4-Glc-6-
P) 
1H 5.48 3.56 3.70 3.35 n.d.3 3.92/3.80 
  13C 101.6 74.1 75.4 72.4 n.d. 63.5 
d 4-α-Glc-(1→4) 1H 5.39 3.59 3.97 3.64 3.84 3.83/3.77 
  13C 102.2 74.1 76.0 79.7 73.8 63.3 
e t-α-Glc-6-P 1H 5.38 3.61 3.68 3.51 3.81 4.05/4.05 
  13C 102.4 74.1 75.4 71.5 74.5 66.2 
  31P      2.07 
f 4-α-Glc-6-P 1H 5.37 3.63 n.d. 3.71 3.98 4.12/4.03 
  13C 102.2 74.1 n.d. 78.1 73.0 66.6 
  31P      1.02 
g 4-α-Glc-3-P 1H 5.35 3.75 4.46 3.81 3.87 n.d. 
  13C 102.4 74.6 79.9 76.4 73.8 n.d. 
  31P   2.81    
h 4-α-Glcred 1H 5.21 3.56 3.95 3.64 n.d. n.d. 
  13C 94.5 74.0 76.0 79.7 n.d. n.d. 
i 4-β-Glcred 1H 4.64 3.27 3.75 3.64 n.d. n.d. 
  13C 98.5 76.6 78.8 79.7 n.d. n.d. 
j1 4,6-α-Glcred 1H 5.22 3.55 3.96 3.64 3.93 3.98/3.83 
  13C 94.6 74.2 76.0 79.7 72.7 69.7 
k1 t-α-Glc-(1→6) 1H 4.99 3.54 3.74 3.44 3.86 n.d. 
  13C 101.5 74.7 74.2 72.1 73.8 n.d. 
l1 4-α-Glc-(1→6) 1H 4.95 3.59 4.01 3.63 3.85 n.d. 
  13C 100.7 74.1 73.0 80.6 74.0 n.d. 
m1 4,6-β-Glcred 1H 4.65 3.25 3.77 3.62 3.60 3.97/3.73 
  13C 98.5 76.7 78.9 80.6 77.3 68.8 
1only observed in glycogen phospho-oligosaccharides 
2only observed in amylopectin phospho-oligosaccharides 
3n.d.not determined 
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Table 2. Phosphomonester distribution in phospho-oligosaccharides from 
glycogen and amylopectin based on NMR analyses. 
 
Sample C2 phosphate 
(%) 
C3 phosphate 
(%) 
C6 phosphate 
(%) 
Glycogen 
  TCA (2010) 
  TCA (2013) 
  KOH 
 
28 
30 
29 
 
53 
39 
37 
 
19 
31 
34 
Amylopectin 0 13 87 
 
The relative proportions of C2, C3 and C6 phosphorylation were estimated by 
integrating the corresponding signals in NMR experiments such as shown in Fig. 
17. Samples were oligosaccharides prepared from the indicated source as 
described under "Methods". In the case of the glycogen "TCA" samples, the data 
refer to re-evaluation of a previous sample   as well as a new sample analyzed in 
the present study.  
 
1.2 Phosphorylation of Glycogen at C6 in Mouse and Rabbit Muscle 
Glycogen 
The data obtained by NMR is a powerful means to determine phosphate 
location on specific glucose carbon atoms in the phospho-oligosaccharides 
however, it requires a significant amount of material and is limited in its 
quantitative measurements. Because of this, Dr. DePaoli-Roach in the laboratory 
developed a sensitive enzymatic fluorescence-based assay for glucose-6-
phosphate in hydrolysates of purified glycogen samples, described in the 
“Methods section.” This highly sensitive assay allows for the measurement of 
glucose-6-phosphate in small glycogen sample. Additionally, because the 
enzymatic assay requires less time and sample material it is possible to obtain 
measurements from multiple samples and obtain reliable statistics, unlike the 
NMR analysis. We were able to couple the measurements of total glycogen 
phosphate, measured by the malachite green protocol (12,14,243), with the 
amount of glucose-6-phosphate from individual samples for direct comparison. 
The measured total phosphate content of mouse skeletal muscle is significantly 
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lower than that of rabbit muscle glycogen, similar to what has been previously 
observed (12,13). Additionally, when using the malachite green assay to 
measure glycogen phosphate, there is undetectable phosphate in un-hydrolyzed 
samples, indicating the purity of the glycogen and lack of phosphate 
contamination. Measurements of glucose-6-phosphate, in our hands, were 
similar to those reported by Nitschke et al (15). Interestingly, mouse and rabbit 
skeletal muscle glycogen contained similar proportions of glucose-6-phosphate, 
~20% (Figure 18). For rabbit skeletal muscle, the levels of glucose-6-phosphate 
measured were in agreement with the values obtained from the NMR analysis 
(Table 2). Similar analyses of amylopectin indicated that C6-phosphate is the 
dominant phospho-monoester at ~75% of the total, again in agreement with the 
NMR data.  
 
1.3 C6 Phosphorylation of Glycogen from Mouse Models of Lafora 
Disease 
There are several reports that glycogen phosphate levels are elevated in 
mouse models of Lafora disease (13,14,18,19). The increase in glycogen 
phosphate content has also been shown to increase with age along with 
decreased branching (12). Nitschke et al (15) had proposed that C6 is the most 
important site of phosphorylation in glycogen in mouse models of Lafora disease 
and this could possibly lead to decreased branching and abnormal glycogen 
formation. Therefore, it was of interest to determine whether there is a specific 
increase in C6 relative to C2/C3 phosphate. In 9-10 month-old laforin-/- and 
malin-/- mice total skeletal muscle glycogen phosphate increased 7.5 and 4.3 
fold, respectively, over that of wild type mice. The lesser elevation in glycogen 
phosphate content in the malin-/-, compared to laforin-/- mice is consistent with 
other reports (19). The absolute amounts of C6 phosphate in the knockouts were 
increased to 4.0 and 9.2 fold over the wild type animals (Table 3). However, 
considering the proportion of C6 phosphate to the total phosphate content, the 
increase of C6 phosphate was in strict proportion, ~20%. Therefore, we cannot 
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assess whether C6 or C2/C3 phosphate contributes more to the formation of 
abnormal glycogen.  
 
 
Table 3. Determination of total phosphate and glucose-6-P in glycogen and 
amylopectin  
 
Sourcea Glycogen phosphate 
(mol/mol) x 10-3 
% C6 
phosphat
e 
Glucose residues per  Fold increase 
over WT 
 Total C6  Total P C6 P Total 
P 
C6 P 
WT (4) 0.371 ± 
0.03 
0.063 ± 
0.007 17 2700 15800 
1 1 
Malin-/- 
(5) 
1.612 ± 
0.19 
0.263 ± 
0.015 16 620 3800 4.3 4.0 
Laforin-/- 
(4) 
2.785 ± 
0.09 
0.582 ± 
0.021 21 360 1720 7.5 9.2 
Rabbit  
(5-11) 
1.525 ± 
0.10 
0.324 ± 
0.001 21 650 3090 
 
NAb 
 
NA 
Amylo-
pectin 
(4) 
4.403 ± 
0.18 
3.307 ± 
0.034 76 227 300 
 
NA 
 
NA 
 
aFor the analyses of muscle glycogen from wild type (WT), malin-/- and laforin-/- 
mice, the numbers in parentheses refer to the number of samples, each from a 
separate mouse, that were analyzed. For the analyses of rabbit muscle glycogen 
and amylopectin, the numbers in parentheses refer to the number of independent, 
replicate analyses made from the same starting material. 
bNA, not applicable   
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Figure 18. Total phosphate and C6 phosphate content of rabbit and 
mouse glycogen and amylopectin. The total inorganic phosphate (open 
bars) and glucose-6-P (filled bars) in hydrolysates of glycogen or amylopectin 
were measured as described under " Experimental Procedures". Shown are 
analyses of glycogen purified from wild type (4), malin-/- (5) and laforin-/- (4) 
mouse muscle, where the numbers in parentheses denote the number of 
animals analyzed. For rabbit muscle glycogen (5-11) and potato amylopectin 
(4), the number of replicate analyses is indicated. The percentage of C6 
phosphorylation is shown above the filled bars. The error bars indicate the 
standard error of the mean; asterisks denote p ≤ 0.01 with respect to wild type 
mouse glycogen phosphate. 
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2. Incorporation of Phosphate into Glycogen by Glycogen Synthase  
 It was originally proposed that an enzyme other than glycogen synthase 
was responsible for the incorporation of phosphate into glycogen (261). In an 
attempt to find such an enzyme, our laboratory discovered that glycogen 
synthase was capable of incorporating phosphate into glycogen as a minor side 
reaction and we proposed a mechanism for the phosphate addition (16). 
However, our findings were challenged by Nitschke (15) et al. who concluded 
that glycogen synthase does not incorporate phosphate but rather that our 
observations were the result of 32P-labeled UDP, a product of the normal reaction, 
binding to glycogen. Because of this discrepancy in results, we therefore re-
evaluated our initial findings to verify that glycogen synthase can incorporate 
phosphate and that our observations were not the result of nonspecific binding of 
UDP to glycogen.  
 
 2.1 Assay for monitoring incorporation of the β-phosphate of UDP 
glucose into glycogen  
 The assay for monitoring phosphate incorporation into glycogen is based 
on a procedure developed for measuring the activity of glucose-1-
phosphotransferase, which is involved in glycoprotein synthesis (262). Glycogen 
synthase activity, traditionally, is measured by the incorporation of [U14C]-glucose 
from UDP-[U14C]-glucose using a filter paper assay. With a similar approach but 
using [β-32P]UDP-glucose as a substrate, we can monitor the incorporation of the 
β-phosphate into glycogen (16). Tagliabracci et al determined that only ~1 
phosphate for every 10,000 catalytic cycles resulted in the transfer of the β-32P 
into glycogen (16). However, measuring the phosphate when [β-32P]UDP-glucose 
is the substrate is technically challenging, due to the fact that [β-32P]UDP formed 
by the normal glycogen synthase reaction can bind to the filter paper.  
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Therefore, the [β-32P]UDP needs to be removed from the reaction mixture by 
precipitation of glycogen with ethanol followed by re-dissolving in aqueous 
solution (once or multiple times) and/or by SDS-PAGE. Tagliabracci et al (16) 
had demonstrated that these methods were effective at removing the [β-32P]UDP 
from glycogen and was able to obtain the rate of phosphate incorporation 
mentioned above using SDS-PAGE as the final assay. However, Nitschke et al. 
(15) challenged those findings and suggested that glycogen synthase was not 
incorporating 32P into glycogen from [β-32P]UDP-glucose. Rather, Nitschke et al. 
(15) claimed that the 32P signal that we had observed associated with glycogen 
was simply [β-32P]UDP, produced during the glycogen synthase reaction, tightly 
bound to glycogen. We therefore performed several experiments to address 
whether or not the 32P-glycogen signal was due to covalent phosphorylation or 
not.  
      
 
Figure 19. Time-dependent incorporation of 32P into synthesized 
glycogen by glycogen synthas. Glycogen synthase (yeast Gsy2p, 5 µg/ml) 
was incubated with glycogen, and 2 µM [β-32P]UDP-glucose or UDP-[U-
14C]glucose, aliquots were removed at the indicated times, precipitated with 
ethanol and analyzed by SDS-PAGE (see Materials and Methods). C indicates 
a control reaction that lacking enzyme. Dried gels were analyzed by a 
Phosphorimager. The bottom of the gel wells and the stacking/separating gel 
interfaces are indicated with arrows.  
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The first goal was to repeat our initial experiment, which involved labeling 
glycogen with either [U14C]-glucose or 32P with purified recombinant yeast 
glycogen synthase and visualizing the labeled glycogen after SDS-PAGE, as 
reported previously (16). Our observations were consistent and we observed, by 
phosphorimaging of SDS-PAGE, a time dependent increase of either 14C or 32P 
glycogen labeling when glycogen synthase was incubated with UDP-[U14C]-
glucose or [β-32P]UDP-glucose (Figure 19). High molecular weight glycogen is 
typically retained at the bottom of the SDS-PAGE well, but presumably smaller 
molecular weight polysaccharides, give signals that extend into the stacking gel 
and sometimes accumulate at the stacking-separating gel interface. Negatively 
charged, small molecules such as nucleotides would be expected to migrate 
through the separating gel, which had no detectable radioactivity (Figure 19). A 
noticeable amount of signal is observed at the bottom of the well of control 
samples lacking enzyme when [β-32P]UDP-glucose is present and to a much 
lesser extent with UDP-[U14C]-glucose. We consider the signal observed in the 
control wells to be a background signal. 
2.2 Evidence that Phosphate Incorporated by Glycogen Synthase is 
Associated with Glycogen  
 2.2.1 Gel Filtration 
Nitschke et al. (15) had observed similar results regarding 14C and 32P 
incorporation from UDP-glucose. However, when Nitschke et al (15) subjected 
the glycogen synthase reaction to gel filtration, a common means to remove 
small molecules from macromolecules, prior to SDS-PAGE analysis, they 
reported that the 14C labeled glycogen was unaffected but that the 32P signal was 
lost. Based on this observation, Nitschke et al (15) concluded that the 32P signal 
was due to non-specific binding of [β-32P]UDP to glycogen.  
To test whether the observed radioactive 32P signal could be eliminated by gel 
filtration we applied this technique to analyze elongated glycogen by incubating 
recombinant yeast (Figure 20, A) and human glycogen synthase (Figure 20, B) 
with UDP-[U14C]-glucose or [β-32P]UDP-glucose. Following glycogen synthase 
reactions the glycogen was precipitated with ethanol, to remove the glycogen 
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from the reaction mixture, and dissolved in an aqueous solution and split into two 
samples, one for gel filtration and one as a control. One set of samples was then 
passed through Sephadex G50 prior to SDS-PAGE. After gel filtration, a small 
sample of the 14C sample was taken for quantitation and we determined a 
recovery of >95% of the input (data not shown), indicating that the labeled 
glycogen passed freely through the Sephadex G50. The samples both before 
column and after gel filtration were dried in a Speed Vac and redissolved in an 
equal amount of buffer and subjected to SDS-PAGE. In our hands, both 32P and 
14C labeling was minimally influenced by gel filtration. We observed the expected 
time-dependent incorporation of both 14C and 32P signals. Note that in control 
lanes (lanes “C”), incubations with [β-32P]UDP-glucose present but lacking 
glycogen synthase, there was a background signal that was reduced after gel 
filtration but still detectable. Therefore, we conclude that the majority of the 32P 
and 14C radioactivity associated with the glycogen in SDS-PAGE is not removed 
by gel filtration.  
  2.2.2 Laforin Removal of 32P from Glycogen and UDP 
Hydrolysis 
To confirm that glycogen synthase was incorporating phosphate into 
glycogen, we tested the ability of laforin to remove the incorporated label. 
Catalytically active wild type laforin can remove 32P introduced into glycogen by 
glycogen synthase (16). When we incubated glycogen, labeled with either 14C or 
32P, with wild type, catalytically active laforin, the signal from the 32P labeled 
glycogen was reduced to background levels while the 14C signal was unchanged 
(Figure 21, A). There was no change in the signal of the 14C or 32P 
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Figure 20. Effect of gel filtration on 32P-labeled glycogen. Reactions with 2 
µM [β-32P]UDP-glucose (right panels) or [U-14C]glucose (left panels), glycogen 
and yeast (A) or human (B) glycogen synthase (2 µg/ml) were sampled at the 
indicated times, aliquots precipitated with ethanol two times, and treated or not 
by gel filtration over Sephadex G50 and analyzed by SDS-PAGE (see 
Materials and Methods). C indicates a control reaction lacking enzyme. Dried 
gels were analyzed by a Phosphorimager. 
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Figure 21. Effect of treating 32P-labeled glycogen with laforin or 
glucosidases. A Glycogen was labeled by incubation with 5 µM [β-32P]UDP-
glucose (lower panel) or [U-14C]glucose (upper panel) and yeast glycogen 
synthase (2 µg/ml) for 30 min. Glycogen was precipitated with ethanol, 
dissolved in buffer and treated with α-glucosidases (α-amylase and 
amyloglucosidase) (α-G), inactive mutant laforin (C266S Laf) or wild type 
laforin (WT Laf) as indicated, and analyzed by SDS-Page (see Materials and 
Methods). Dried gels were analyzed by a Phosphorimager. C, control 
reaction lacking glycogen synthase; NT, not treated. B UDP-glucose and 
UDP were incubated with active (WT) or inactive (C266S) laforin as 
indicated and analyzed by HPAEC. Chromatograms of UDP, UMP and UDP-
glucose standards are shown in the lowermost panel.  
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labeled glycogen when incubated with the catalytically inactive C266S laforin 
mutant. Incubation of the labeled glycogen with glucosidase enzymes, α-amylase 
and amyloglucosidase, resulted in the elimination of both the 14C and 32P signals, 
which is expected as the enzymes hydrolyze the polysaccharides. These data 
were similar to our previous observations (16).  
 The argument was made that laforin might be removing the β-phosphate 
from [β-32P]UDP that is bound to glycogen (15). Therefore, we tested whether the 
laforin can hydrolyze UDP and UDP-glucose. UDP and UDP-glucose were 
incubated with either wild type or catalytically inactive C266S laforin and the 
reaction analyzed by HPAEC, monitoring the UV absorbance (Figure 21, B). We 
observed that even commercially available UDP with high purity (99.2%) had 
detectable trace amounts of UMP by this analysis (Figure 21, B). However, 
incubation of UDP with either wild type or C266S laforin caused no decrease in 
UDP nor any increase in UMP. Similarly, there was no observed decrease or 
hydrolysis of UDP-glucose by laforin. These data suggest that UDP and UDP-
glucose are not substrates for laforin and that our observations of decreased 32P 
signal from labeled glycogen were due to laforin hydrolyzing phospho-
monoesters from glycogen. 
In other experiments, we showed that laforin is capable of releasing 
inorganic phosphate (32Pi) from 32P labeled glycogen (Figure 22). Similar to 
previous experiments recombinant laforin was utilized to release incorporated 
phosphate from glycogen. However, when using SDS-PAGE to analyze glycogen 
we are only able to observe a reduced signal after laforin treatment. Therefore, 
we utilized thin layer chromatography (TLC) to separate the released 32P 
phosphate, which was incorporated by glycogen synthase. The 32P-glycogen for 
this experiment was purified by ethanol precipitation, gel filtration and treated 
with PiBindTM resin to eliminate phosphate and to remove any [β-32P]UDP from 
the glycogen synthase reaction. Thin layer chromatography (TLC) was used to 
analyze the reaction products using PEI-cellulose plates. Labeled glycogen was 
concentrated at the origin and migrated through the matrix giving a “comet trail” 
like appearance (Figure 22). After incubation with active laforin there was a 
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reduction in the 32P-glycogen signal and a 32P signal with the mobility of inorganic 
phosphate was produced (Figure 22 A). The 14C-glycogen signal was unchanged 
(Figure 22, B). When laforin was absent (“C”) or when it was heat inactivated 
(“HI”), no 32Pi signal was observed. Therefore, we conclude that 32P, introduced 
by glycogen synthase, is covalently attached to glucose residues of glycogen by 
phospho-monoester linkages and that laforin is capable of hydrolyzing and 
releasing inorganic phosphate from glycogen.  
 
 
 
   
 
 
 
 
 
 
Figure 22. Release of 32Pi from 32P-glycogen by laforin. Glycogen was 
labeled by incubation with 5 µM [β-32P]UDP-glucose (A) or [U-14C]glucose (B) 
and yeast glycogen synthase (5 µg/ml) for 30 min. Glycogen was precipitated 
3 times with ethanol, treated with PiBindTM resin, purified by gel filtration and 
dissolved in buffer. The glycogen was incubated for 2 hours with 50 µg/ml 
laforin (WT Laf) or laforin inactivated by boiling for 5 min (HI Laf). A control (C) 
lacked laforin. The reaction mixtures were analyzed by TLC using PEI-
cellulose plates. Standards of 14C-glucose-1-P (14C-G1P), 14C-glucose (14C-
Glu) and inorganic phosphate (Pi), labeled with the indicated isotope, were 
also analyzed. 
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  2.2.3 Further Investigations of Potential [β-32P]UDP Binding to 
Glycogen 
To further address the possibility that [β-32P]UDP could bind to glycogen, 
we conducted three other types of experiment. The first was an attempt to 
compete 32P associated with glycogen by adding unlabeled UDP. We added a 
1,000-fold molar excess of unlabeled UDP after the glycogen synthase reactions 
but before SDS-PAGE (Figure 23). If [β-32P]UDP was binding to glycogen non-
specifically, then we would expect that diluting with unlabeled UDP would 
compete and the 32P signal should be reduced. However, this was not what we 
observed (Figure 23). Additionally, as expected the excess unlabeled UDP had 
no effect on the 14C signal (Figure 23). 
The second approach took advantage of the action of hSCAN-1 enzyme, 
a UDPase that can hydrolyze UDP but has no action towards UDP-glucose or 
UMP (248,249). Glycogen was labeled either with 14C or 32P, samples were 
removed at given time points and the reaction terminated by boiling for 5 minutes 
before being incubated with hSCAN-1. The reaction products were analyzed by 
TLC, visualized under UV light and quantitated with a phosphorimager (Figure 
24). During the time course, we observed a time dependent consumption of 
UDP-glucose, both 14C and 32P, along with the generation of [β-32P]UDP (Figure 
24, A). Once reactions were terminated, unlabeled UDP was added to each 
reaction for a final 1 mM concentration, to give a sufficient amount for analysis by 
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Figure 23. Effect of unlabeled UDP on 32P-labeling of glycogen. Glycogen 
was labeled by incubation with 2 µM [β-32P]UDP-glucose (lower panel) or [U-
14C]glucose (upper panel) and yeast glycogen synthase (5 µg/ml) for the 
indicated times. Unlabeled UDP (2 mM, a 1000-fold excess of UDP-glucose) 
was added prior to SDS-PAGE (see Methods). C, control reaction lacking 
glycogen synthase. 
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UV. Incubation with hSCAN-1 clearly converted UDP to UMP as judged by the 
UV signal (Figure 24, B). As the [β-32P]UDP decreased, a corresponding 32Pi 
signal was generated. We did not observe any change in the migration of UDP-
glucose, indicating that hSCAN-1 did not have any activity towards UDP-glucose. 
When the glycogen from the glycogen synthase reaction, followed by hSCAN-1 
treatment, was analyzed by SDS-PAGE (Figure 25) we did not see any decrease 
in the 32P signal. Since hSCAN-1 was active and able to hydrolyze UDP to UMP, 
but did not have any effect on the 32P glycogen signal, it suggests that the 
observed 32P signal is not due to [β-32P]UDP hydrolysis.  
 Our third experimental approach tested whether binding of 32P-UDP to 
glycogen could be detected after SDS-PAGE. For these experiments, we used 
 
 
Figure 24. Analysis of the progress of glycogen synthesis by glycogen 
synthase. Glycogen was synthesized by incubation with 2 µM [β-32P]UDP-
glucose (A,B) or [U-14C]glucose (C,D) and yeast glycogen synthase (5 µg/ml), 
and aliquots removed at the indicated times. C corresponds to reactions 
lacking glycogen synthase. After addition of 2 mM mM UDP, the aliquots were 
analyzed by TLC and visualized either by Phosphorimager (A,C) or UV (B, D). 
Standards of UDP-glucose, UMP, UDP and [32P] phosphate were run in the 
left most tracks and their migrations indicated. Prior to chromatography, the 
aliquots were treated or not with the UDPase SCAN for 30 min, as indicated 
(see Methods). 
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commercially available [α-32P]UDP. The amount of radioactivity for [α-32P]UDP 
was higher (~550,000 cpm/µl) than that of [β-32P]UDP-glucose used in other 
experiments (~180,000 – 400,000 cpm/µl) and UDP-[U14C]-glucose was present 
at 400 – 1,800 cpm/µl for glycogen labeling. In comparison to the reaction 
containing only UDP-[U14C]-glucose, inclusion of [α-32P]UDP with glycogen 
seemed to contribute to a slight increase in the background, which corresponded 
to the region where glycogen runs at the bottom of the well (Figure 26 A and B, 
comparing lanes 4 and 8). A faint diffuse signal was also seen above the 
stacking-separating gel interface and was not detected when [α-32P]UDP was 
absent. The presence of a 1,000-fold molar excess of unlabeled UDP had no 
effect on the 32P signal (Figure 26 B, lanes 5 and 9 to lanes 4 and 8, respectively), 
suggesting that the background radioactivity is associated with neither glycogen 
 
 
Figure 25. Effect of hSCAN-1 treatment on 32P-labeling of glycogen. 
Glycogen was labeled by incubation with 2 µM [U-14C]glucose (upper panel) or 
[β-32P]UDP-glucose (lower panel) and yeast glycogen synthase (5 µg/ml), and 
aliquots removed at the indicated times. After ethanol precipitation, samples 
were treated with hSCAN-1(+hSCAN-1) or without (-hSCAN-1) for 30 min prior 
to analysis by SDS-PAGE (see Methods). C corresponds to reactions lacking 
glycogen synthase. 
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nor UDP. To replicate the elongation of glycogen by glycogen synthase in the 32P 
glycogen labeling experiments, [α-32P]UDP was included in incubations where 
glycogen was being elongated (i.e. with glycogen synthase present). The 
argument is that UDP might be trapped as the glycogen is synthesized. Thus, 
lanes 6 in Figure 26 A and B indicates the control 14C-labeling of glycogen. In the 
presence of [α-32P]UDP, there was no increase in 32Psignal (Figure 26 A and B, 
comparing lands 2 and 6). The presence of unlabeled UDP also had no effect on 
the signal (Figure 26 B, comparing lanes 3 and 7 to lanes 2 and 6 respectively). 
However, treatment with glucosidases returned the signals to background levels 
(Figure 26 A, lanes 3 and 7).  
 In conclusion, based on the experiments described above, we found no 
evidence that 32P-UDP binding to glycogen could account for the 32P signal 
generated when [β-32P]UDP-glucose is incubated with glycogen synthase and 
therefore consider that our original conclusion that glycogen synthase is capable 
of adding phosphate to glycogen is valid. 
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Figure 26. Test for 32P-UDP binding to glycogen. Glycogen was incubated 
with [α-32P]UDP and with (lanes 2 and 3) or without (lanes 4 and 5) glycogen 
synthesis by 10 µg/ml glycogen synthase (GS) for 30 min. Samples were 
analyzed by SDS-PAGE and dried gels visualized with a Phosphorimager (see 
Methods). Controls lacked [α-32P]UDP (lanes 6-9). In A, samples were treated 
or not with α-amylase and amyloglucosidase (α-G) and in B, unlabeled UDP 
(4 mM, a 1,000-fold excess over [α-32P]UDP) was added to some samples 
prior to SDS-PAGE. 
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3. Glycogen Phosphate, Branching and Solubility 
 
 3.1 Analysis of Glycogen and Glycogen Phosphate from Laforin/PTG 
and Malin/PTG Double Knockout Mice 
 Laforin and malin knockout mice over-accumulate glycogen, develop 
Lafora bodies and have neurological defects (13,14,19,189,263-266) and thus 
are useful models for human Lafora disease. The targeting subunit of type 1 
protein phosphatase, PTG, binds to glycogen, thus recruiting the catalytic subunit 
and activating glycogen synthase. Disruption of the PTG gene in mice results in 
decreased glycogen in muscle, liver and brain (241). In an attempt to suppress 
glycogen accumulation in mouse Lafora disease models, PTG knockout mice 
were crossed with laforin and malin knockout mice. The resulting double 
knockout mice, PTG/laforin-/- or PTG/malin-/- do not over-accumulate skeletal 
muscle or brain glycogen, have suppressed Lafora body formation and alleviated 
neurological symptoms (210,211). Because of the association of elevated 
phosphate, reduced branching and solubility of glycogen in Lafora disease, we 
therefore undertook a more detailed analysis of the glycogen of the double 
knockout mice.  
  3.1.1 Skeletal Muscle Glycogen Levels in WT, Single and 
Double Knockout Mice 
 First, we analyzed the amount of skeletal muscle glycogen in wild type, 
single PTG-/-, laforin-/-, malin-/-, and double PTG/laforin-/- and the PTG/malin-/- 
9-10 month old male mice (Figure 27). Similar to previous observations (241), the 
PTG knockouts had lower levels of skeletal muscle glycogen compared to wild 
type animals. The laforin-/- and malin-/- mice had an increase in skeletal muscle 
glycogen content with 1.7 and 4.5- fold increases over wild type, respectively 
(Figure 27, A and B), consistent with previous reports (12,14). Interestingly, when 
PTG was knocked out along with either malin or laforin, glycogen levels are 
normalized (Figure 27, A and B). Analyses of Lafora body formation in the double 
knockout mice, showed almost complete absence of Lafora bodies both in 
skeletal muscle and brain (data not shown).  
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Figure 27. Skeletal muscle glycogen content. Analysis of total skeletal 
glycogen expressed as µmol of glucose/g of tissue. A, Skeletal muscle 
glycogen levels of wild type (WT), PTG knockout, the laforin knockout and 
laforin/PTG double knockout. B, Skeletal muscle glycogen levels of wild type 
(WT), PTG knockout, the laforin knockout, and PTG/malin double knockout. 
The error bars indicate the standard error of the mean; double symbols denote 
p ≤ 0.01; * with respect to wild type mouse glycogen, # with respect to the 
PTG-/- glycogen, $ with respect to the double knockout, either PTG/laforin-/- 
or PTG/malin. Numbers within bars represent the number of mice per group.  
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(210,211). Therefore, reducing glycogen levels prevents or reduces the amount 
of Lafora bodies formed, as expected.  
  3.1.2 Skeletal Muscle Glycogen Phosphate in WT, Single Malin 
or Laforin Knockout and PTG/Laforin and PTG/Malin Double Knockout Mice 
 In addition to the accumulation of glycogen, there is also a correlation 
between glycogen hyperphosphorylation, abnormal branching and Lafora body 
formation (12,13). Therefore, we wanted to determine the phosphate content of 
the glycogen from the double knockout mice. Highly purified glycogen was 
prepared from skeletal muscle and glycogen concentration and phosphate 
content was determined. The glycogen phosphate content, expressed as the 
molar ratio of phosphate to glucose, can be viewed as the glycogen 
phosphorylation density. The PTG-/- mice had glycogen phosphate content 
similar to that of wild type animals (Figure 28, A and B). Similar to what we had 
previously reported (12,14), the laforin-/- and malin-/- mice had elevated 
glycogen phosphate content, with the laforin -/- mice having a higher glycogen 
phosphate content than the malin -/- mice, with 4 and 3-fold increases over the 
wild types, respectively (Figure 28, A and B). The PTG/laforin-/- mice had similar 
levels of glycogen phosphate content when compared to the laforin-/- mice, 
having an ~4 fold increase over the wild type (Figure 28, A), consistent with both 
lines lacking laforin. The glycogen phosphate content of the PTG/malin-/- mice, 
however, was similar to that of the wild type levels. It has been proposed that 
laforin's function is dependent on malin (187,205,207,208). However, the 
phosphate content of the PTG/malin-/- mice suggests that laforin is functioning in 
vivo and its glycogen phosphatase activity is not dependent on malin.  
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 Another way to express glycogen phosphorylation is to consider the total 
amount of phosphate per tissue mass expressed as nmol phosphate/g tissue, 
which is referred to as “total glycogen phosphate” (Figure 29). The total glycogen 
phosphate content of the laforin-/- and malin-/- mice, like the total glycogen 
content, is elevated over the wild type, with 14 and 8-fold increases, respectively. 
The PTG-/- mice had similar total glycogen phosphate levels as the wild type 
animals (Figure 29, A and B). PTG/malin-/- mice have a total glycogen 
phosphate levels that are similar to wild type and PTG-/- mice (Figure 29, B), 
which would be expected since both the glycogen and molar glycogen phosphate 
measurements were restored to wild type levels. The total glycogen phosphate of 
the PTG/laforin-/- mice (Figure 29, A) mice was significantly less than that of the 
laforin-/- mice but not as low as the wild type or PTG-/-mice. Since the 
 
 
Figure 28. Skeletal muscle glycogen phosphate content. Analysis of total 
skeletal glycogen phosphate content expressed as µmol Phosphate (Pi)/mol 
glucose. A, skeletal muscle glycogen levels of wild type (WT), PTG knockout, 
the laforin knockout and laforin/PTG double knockout. B, Skeletal muscle 
glycogen levels of wild type (WT), PTG knockout, the laforin knockout, and 
PTG/malin double knockout. The error bars indicate the standard error of the 
mean; double symbols denote p ≤ 0.01,; * with respect to wild type mouse 
glycogen, # with respect to the PTG-/- glycogen, $ with respect to the double 
knockout, either PTG/laforin-/- or PTG/malin. Numbers within bars represent 
the number of mice per group. Numbers within bars represent the number of 
mice per group.  
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laforin/PTG-/- have normalized glycogen levels but with elevated glycogen 
phosphate content (mmol Pi/mol glucose) the levels of phosphate per gram of 
tissue should be higher than the wild type. However, there is a 70% decrease of 
total glycogen phosphate in the PTG/laforin-/- mice compared to the laforin-/- 
mice. These results are as expected based on the glycogen content and 
glycogen phosphorylation state in the different mouse models. In regard to Lafora 
body formation, one can propose that there needs to be an over-accumulation of 
glycogen as well as an increase in glycogen phosphate which may somehow 
contribute to the abnormal branching and solubility of glycogen associated with 
Lafora bodies.  
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 3.2 Glycogen Solubility and Branching in the Double Knockout Mice 
 As previously mentioned, glycogen solubility and branching seemed to be 
related to the phosphate content of glycogen in the laforin-/- mice (12,18). Here 
we subjected skeletal muscle tissue extracts to low speed centrifugation to 
produce a low speed supernatant and pellet, and glycogen content in both were 
quantitated. If glycogen is normally branched and soluble, the majority of the 
glycogen should be in the low speed supernatant whereas if it is insoluble it 
would be found in the low speed pellet. Thus, abnormal insoluble glycogen 
generated in the Lafora disease mouse models would be expected in the low 
speed pellet. We also analyzed the branching pattern of glycogen from wild type, 
 
Figure 29. Total skeletal muscle glycogen phosphate. Analysis of total 
skeletal glycogen phosphate content represented as mmol Phosphate (Pi)/mol 
glucose A, skeletal muscle glycogen levels of wild type (WT), PTG knockout, 
the laforin knockout and laforin/PTG double knockout. B, Skeletal muscle 
glycogen levels of wild type (WT), PTG knockout, the laforin knockout, and 
PTG/malin double knockout.. The error bars indicate the standard error of the 
mean; double symbols denote p ≤ 0.01, ; * with respect to wild type mouse 
glycogen, # with respect to the PTG-/- glycogen, $ with respect to the double 
knockout, either PTG/laforin-/- or PTG/malin.. Numbers within bars represent 
the number of mice per group.  
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single and double knock mice to correlate any branching abnormalities with 
glycogen phosphate content.  
   3.2.1 Skeletal Muscle Glycogen Solubility  
 Fractionation of skeletal muscle tissue extracts by low speed 
centrifugation results in a low speed pellet (LSP) and a soluble fraction, the low 
speed supernatant (LSS). The LSP is mainly composed of contractile proteins 
and other insoluble components, while the LSS contains mostly soluble proteins. 
Glycogen can be detected in both the LSS and LSP of mouse skeletal muscle 
extracts. This separation operationally defines what fraction of glycogen is 
soluble. Tagliabracci et al (12) reported that a majority of the glycogen in skeletal 
muscle extracts form laforin -/- mice was found in the LSP suggesting that it was 
insoluble and was poorly branched. We analyzed the glycogen distribution of the 
double knockout mice to determine whether their glycogen would be found in the 
soluble LSS fraction or in the LSP. Typically, we observe that 75 – 80% of the 
total glycogen from wild type muscle is present in the soluble fraction, the LSS 
(Figure 30), similar to previous reports (12,189). When measuring the volume of 
the LSS after low speed centrifugation, typically, about ~70% of the initial volume 
is recovered (data not shown). The PTG-/- mice have a glycogen distribution 
similar to the wild type animals, with most of the glycogen found in the soluble 
fraction (Figure 30). With laforin-/- and malin-/- mice, the glycogen distribution 
was nearly opposite of wild type, with 75 – 80% of the total glycogen being 
present in the LSP. This suggests that a majority of the glycogen is poorly 
branched and insoluble, similar to what has been previously reported (12). The 
laforin/PTG-/- and malin/PTG-/- mice have a distribution of glycogen between the 
LSS and LSP more like wild type. In the double knockout mice, the majority of 
the muscle glycogen is found in the soluble fraction, suggesting that it is normally 
branched and soluble.  
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The laforin/PTG-/- mice had glycogen phosphate content similar to that of the 
laforin-/- mice, on a mol Pi/mol glucose basis, which could suggest that 
phosphate content alone does not determine solubility. Possibly the lower 
glycogen synthase activity of the double knockouts allows for the branching 
enzyme to properly branch the glycogen.  
 3.2.2 Skeletal Muscle Glycogen Branching  
To prove that less branched glycogen predominated in the LSP fraction, 
glycogen branching was analyzed by high performance anionic exchange 
chromatography (HPAEC) to determine the distribution of the polyglucose chain 
lengths of glycogen from different mouse lines. Glycogen was purified as for 
measurement of glycogen phosphate (described in Methods) and treated with 
 
Figure 30. Low speed supernatant and pellet glycogen content. 
Analysis of skeletal muscle glycogen content in the low speed supernatant 
(LSS) or pellet (LSP) of tissue homogenates. A and C, Glycogen content in 
LSS and LSP of skeletal muscle of wild type (WT), PTG knockout, laforin 
knockout and Laforin/PTG double knockout mice B and D, Percent 
glycogen distribution in LSS and LSP of skeletal muscle of wild type (WT), 
PTG knockout, malin andMalin/PTG double knockout mice. The error bars 
indicate the standard error of the mean. The n for each group is 4.  
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isoamylase to hydrolyze the α-1,6-glycosidic bonds thus producing a mixture of 
polymeric glucose chains. The HPAEC separates the mixture according to chain 
length, shorter chains eluting earlier. The eluate is monitored by amperimetric 
pulse detection. Figure 31, A and B, shows a branching profile for glycogen from 
the skeletal muscle of mice and is expressed as relative peak area, which is the 
percentage of the area for a given peak over the sum of all peak areas. For 
further analysis, data are represented as a relative change in abundance, where 
the data has been normalized to the wild type for each chain length. Therefore, 
any difference from the wild type glycogen is represented by bars above or below 
the x axis, a positive value meaning more representation than wild type and a 
negative value, less than wild type. Both laforin-/- and malin-/- mice have fewer 
short chains, from 4 – 15 glucose residues long, and more long chains, from 15 – 
34 glucose residues long (Figure 31, C and D). This indicates that the glycogen 
in the laforin-/- and malin-/- mice is less branched and has an overall increase in 
chain length. Also, the PTG-/- mice have a branching pattern that is slightly 
different than the wild type, with more short chains and fewer long chains. This 
could be due to the reduced activity of glycogen synthase resulting in shorter 
glucose polymer chains. Consistent with the LSS/LSP distribution (Figure 30), 
the double knockout mice have glycogen that is more like the PTG-/-, in terms of 
the branching pattern. Figure 31 shows that the laforin/PTG-/- or malin/PTG-/- 
mice have a branching pattern with more shorter branches, 5 – 14 glucose 
residues long, and fewer long branches, 16 – 30 glucose residues. These data 
are consistent with the observed solubility and distribution of glycogen between 
the LSS and LSP (Figure 30). 
The results from this section confirm that deletion of PTG in laforin-/- or 
malin-/- mice normalizes muscle glycogen levels in both models. In a malin-/- 
background, glycogen phosphorylation is normalized but phosphorylation 
remains elevated in laforin-/- mice. The reduced branching of glycogen was 
essentially restored to normal by the absence of PTG in both models. Therefore, 
increased glycogen phosphorylation was not always correlated with increased 
branching.  
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Figure 31. HPAEC analysis of skeletal muscle glycogen Analysis of 
purified skeletal muscle glycogen. A and B. HPAEC analysis of glycogen 
chain lengths after isoamylase treatment, represented as the percent of the 
total PAD signal for 4 – 25 glucose residues. C and D. HPAEC analysis of 
skeletal muscle glycogen that has been normalized to the WT glycogen.  
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 4. Glycogen Metabolism in Mouse Models of Lafora Disease Subjected to 
Exercise 
 Lafora bodies, the hallmark of Lafora disease, are largely composed of 
poorly soluble glycogen and can accumulate to high levels in muscle. Two 
questions come immediately to mind. Can the build up of Lafora bodies affect 
muscle function and is the glycogen contained in Lafora bodies susceptible to 
normal metabolism? 
 
4.1 Exercise Performance and Blood Glucose 
Lafora bodies accumulate in the skeletal muscle of both laforin and malin 
knockout mice. If Lafora bodies and excess glycogen accumulation had a 
negative impact on muscle contraction, we might expect the knockout animals to 
have an impaired ability to exercise. However, older laforin and malin knockout 
animals displayed the same exercise capacity as wild type mice, whether judged 
by exercise time or work performed (Table 4), suggesting that the accumulation 
of Lafora bodies did not affect muscle function. The average time to reach 
exhaustion was ~ 45 minutes and there was no significant difference between the 
knockout animals and their wild type littermates (Table 4). This result is 
consistent with previous studies showing that young laforin-/- mice, 3 month old, 
did not have impaired ability to exercise (238) and had no cardiac or metabolic 
abnormalities (240).  
 To test whether exercise elicited any abnormalities in glucose handling in 
Lafora mice, blood glucose was monitored pre- and post-exercise. Mice that 
were not immediately sacrificed after exercise were given an oral glucose gavage, 
at a dose of 3.6 g/kg of body weight, and blood glucose was monitored for up to 
3 hours post exercise, during which time they had access to food and water. Both 
laforin-/- mice and their wild type littermates had increased blood glucose 
following exercise; the levels further increased after receiving the oral glucose 
gavage (Table 5). There was no difference in glucose profiles between the 
laforin-/- mice and wild type littermates. The glucose profiles for the malin-/- mice 
were similar, trending to an increase in blood glucose after exercise, although the 
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differences did not reach statistical significance. We conclude that there was no 
major defect in whole body glucose handling with either knockout mouse line. 
 
 
 
 
Table 4. Exercise performance 
Body weights and exercise performance. Body weights are expressed in 
grams (g), exercise time is expressed in minutes (min) and work is expressed 
in Joules (J). Data are presented as the mean ± the standard error. a: p < 0.05 
compared to wild type  
 
Exercise Performance 
  Laforin+/+ Laforin-/- Malin+/+ Malin-/- 
n 16 20 8 10 
Body Weight 
(g) 37.7 ± 1.4 37.6 ± 1.1 36.4 ± 1.0 40.3 ± 1.2 a 
Exercise 
Time (min) 41.1 ± 3.0 44.0 ± 3.7 56.5 ± 4.7 43.2 ± 5.4 
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4.2 Effect of Exercise on Enzyme Phosphorylation and Distribution 
It is well established that adenosine monophosphate activated kinase 
(AMPK) is activated by phosphorylation at Thr172 after exercise (130,189,267-
270) and therefore can serve as a molecular indicator of a normal muscle 
response to muscular activity. Previous reports on young, 3 month old, laforin-/- 
mice had shown that there were no defects in AMPK phosphorylation in 
Table 5. Blood glucose pre- and post-Exercise 
Blood glucose  (BG) analysis of mice before and after exercise. After mice 
were exercised until exhaustion some were given an oral glucose gavage and 
blood glucose was monitored for 15-180 minutes post gavage (PG). Blood 
glucose is expressed as mg per deciliter and the data are presented as the 
mean ± the standard error. b: p < 0.05 compared to the pre-exercise blood 
glucose levels b*: p < 0.001 compared to the pre-exercise blood glucose 
levels. There was no significant difference between the knockout animals and 
their respective wild types 
 
Exercise Blood Glucose 
Blood 
Glucose 
(mg/dl) 
Laforin+/+ Laforin-/- Malin+/+ Malin-/- 
n Average n Average n 
Averag
e n Average 
BG Pre-EX 16 
134  
± 5.0 20 
133  
± 2.4 8 
140  
± 7.5 10 
144  
± 5.5 
BG Post EX 16 
174  
± 8.4b* 20 
164  
± 8.5 b* 8 
167  
± 19.8 10 
164  
± 10.0 
BG 15 min PG 8 
248  
± 20.6 b* 6 
229  
± 15.7 b* 3 
176 ± 
25.3 4 
153  
± 26.2 b* 
BG 30 min PG 8 
207  
± 11.3 b* 8 
217 ± 
15.6 b* 3 
197 ± 
17.3 4 
249  
± 21.5 b* 
BG 60 min PG 8 
209  
± 18.2 b* 8 
233 ± 
14.1 b* 3 
217 ± 
9.3 b 4 
226  
± 14.8 b* 
BG 180 min 
PG 8 
158  
± 14.8 b* 8 
127  
± 5.0 b* 3 
136  
± 23.3 4 
113  
± 9.7 b 
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response to exercise (238). In the present study, we find similar results with older, 
12 month old mice, namely no impairment of exercise-induced AMPK 
phosphorylation in either the laforin-/- or malin-/- mice as compared to wild type 
mice (Figure 31).  
A number of reports describe the activation, via dephosphorylation, of 
glycogen synthase following exercise, (127,128,189,270) although the exact 
mechanisms are complex and not fully understood (57). Therefore, we analyzed 
glycogen synthase after exercise of the laforin and malin knockout mice (Figure 
32). In the 12 month old laforin and malin knockout mice, there was a noticeable 
increase in glycogen synthase protein levels over wild type (Figure 32), 
consistent with previous results in the laforin-/- mice (13). In response to exercise, 
the laforin-/- mice had a blunted dephosphorylation of glycogen synthase and the 
malin-/- mice had a complete inhibition of glycogen synthase dephosphorylation 
(Figure 32). Even though AMPK activation in the skeletal muscle of the knockout 
mice may indicate a normal response to exercise, the impaired activation of 
glycogen synthase could indicate defects more specific to glycogen metabolism.  
The knockout animals have increased total glycogen synthase protein 
levels and the bulk of the protein is associated with the LSP fraction of the 
muscle extracts (Figure 33). The levels of glycogen synthase in the LSS were 
similar to that in the wild type animals (Figure 33, A, B, C and D). The wild type 
animals from the laforin background had a significant decrease in glycogen 
synthase phosphorylation in both the LSS and LSP fractions in response to 
exercise (Figure 33 A and E), while the wild types from the malin background 
only showed a significant decrease in glycogen synthase dephosphorylation in 
the LSS. 
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Figure 32. Effect of exercise on AMPK phosphorylation. Western analysis 
of AMPK and phosphorylation at Thr172 from skeletal muscle total extracts of 
12 month old mice. A. Laforin+/+ and laforin-/- control (C) and post-exercise 
(EX) B. Malin+/+ and Malin-/- control (C) and post-exercise (EX) C. 
Quantitation of the ratio of P-AMPK over AMPK by densitometry of the control 
and exercise laforin+/+ and laforin-/- mice (n  4-6). D. Quantitation of the ratio 
of P-AMPK over AMPK by densitometry of the control and exercise malin+/+ 
and malin-/- mice (n  4). ). Data are means +/- SEM, * indicates significance 
compared to the control with p < 0.05 and ** indicates p<0.01 
 
 
 119 
 
 
 
 
 
Figure 33. Effect of exercise on glycogen synthase and glycogen. 
synthase phosphorylation Western analysis glycogen synthase protein 
and phosphorylation of total extracts of skeletal muscle from12 month old 
laforin+/+, laforin-/-, malin+/+ and malin-/- mice. A. Laforin+/+, laforin-/- 
control (C) and post-exercise (EX). B. Malin+/+ and Malin-/- control (C) and 
post-exercise (EX). C and D. Quantitation of the ratio of GS over GAPDH 
by densitometry of the control and exercise E and F. Quantitation of the 
ratio of P-GS over GS by densitometry of the control and exercise (n  4). 
Data are means +/- SEM, * indicates significance compared to the control 
and # indicates significance compared to wild type with p < 0.05 double 
symbols ** or ## indicate p < 0.01.  
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Figure 34. Effect of exercise on glycogen synthase and glycogen. 
synthase phosphorylation in the LSS and LSP Western blot analysis of 
12 month old laforin+/+ and laforin-/- (A) and malin+/+ and malin-/- (B) mice 
skeletal muscle LSS and LSP with antibodies against glycogen synthase 
(GS) and phospho-GS. C and D. Quantitation of GS in either the LSS or 
LSP of skeletal muscle extracts. E and F. Quantitation of the ratio of 
phospho-GS over GS densitometry of the control and exercise (n  4). Data 
are means +/- SEM, * indicate significance compared to the control and # 
indicate significance compared to wild type with p < 0.05 double symbols ** 
or ## indicate p < 0.01.  
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The malin-/- mice had a small, but not statistically significant, decrease in 
glycogen synthase phosphorylation in the LSS and no change in the LSP (Figure 
34, B and F). The malin samples for the glycogen synthase and phosphorylated 
form of glycogen synthase, in the LSS and LSP, posed some technical 
challenges that may have contributed to the observed data, but from multiple 
attempts what is presented here is the best representation for such data. In both 
cases it would appear that glycogen synthase associated with the LSP, where 
the majority of glycogen synthase was found, the phosphorylation status of 
glycogen synthase does not appear to change in response to exercise, 
suggesting that it may not be subject to normal metabolism. After exercise, 
glycogen synthase associated with the LSP in the laforin-/- mice trended towards 
a decrease in phosphorylation but was not statistically significant (Figure 34, A 
and E). Exercise-induced glycogen synthase dephosphorylation in the LSS 
fraction of the laforin-/- mice suggest that solubility of glycogen and its associated 
proteins is required for normal metabolism 
In the malin-/- mice there was a basal increase in laforin protein levels 
(Figure 35) similar to previous reports for young animals (189). The bulk of the 
laforin protein tracks in the LSP of skeletal muscle extracts with depletion from 
the LSS (Figure 36) and is associated with the abnormal glycogen found in the 
LSP (Figure 39), similar to previous observations (189). Exercise did not affect 
the distribution of laforin in the malin-/- mice (Figure 37). Since there was no 
observable decrease in glycogen phosphate content in the malin-/- mice, even 
with exercise (Figure 40 and 42), it is likely that the majority of laforin in the 
malin-/- mice is most likely sequestered in the insoluble fraction and not active, 
as previously proposed (189).  
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Figure 35. Laforin protein levels in the malin knockout mice. Western 
blot analysis of 12 month old malin+/+ and malin-/- mice total skeletal 
muscle extracts analyzing laforin protein levels. A. Skeletal muscle extract 
western blots for antibodies against laforin and GAPDH. B. Quantitation of 
the ratio of laforin over GAPDH densitometry of the control and exercise (n 
 4). Data are means +/- SEM,  # indicate significance compared to wild 
type with p < 0.05 double symbols ** or ## indicate p < 0.01.  
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Figure 36. Laforin protein levels in the LSS and LS of malin knockout 
mice. Western blot analysis on 12 month old malin+/+ and malin-/- mice 
skeletal muscle LSS and LSP. A. Skeletal muscle LSS and LSP western 
blots for antibodies against laforin. B. Quantitation of laforin in the LSS and 
LSP. Data are means +/- SEM, ## indicate significance compared to the wild 
type with p < 0.01. 
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4.3 Effect of Exercise on Glycogen and Glycogen Phosphate 
Metabolism 
During exhaustive exercise glycogen is utilized as a major source of 
energy in the skeletal muscle, while liver glycogen is broken down in order to 
maintain blood glucose levels (4). The laforin-/- and the malin-/- mice had an 
increase in total skeletal muscle glycogen content of 3 or 2.6-fold increase over 
wild type, respectively (Figure 38, A and B). Wild type animals consumed 75-80 % 
of their total muscle glycogen during the exercise protocol while the knockout 
animals had no statistically significant decrease in the levels of their skeletal 
muscle glycogen though there was a trend to be slightly lower than the non-
exercised group (Figure 37, A). However, there is a relatively large error 
associated with the measurement of skeletal muscle glycogen in the laforin-/- 
mice. The wild type mice consumed 15 µmol glucose/g tissue during exercise, a 
decrease that may be lost within the measurement errors of the much higher 
glycogen levels in the laforin-/- mice. A similar argument can be made for the 
malin-/- mice (Figure 37 B). Skeletal muscle glycogen levels were restored 3 
hours post exercise but there was minimal or no supercompensation, unlike what 
was observed in younger mice (238).  
The glycogen levels in the liver were decreased by exercise but there was 
no difference between the wild type and knockout animals (Figure 37, C and D). 
On the other hand, although the brain glycogen was higher in the knockout mice 
as previously reported (13,189,210) (Figure 37, E and F), no difference was 
observed between control and exercise animals. Consistent with no significant 
decrease of total glycogen we also did not observe a noticeable decrease in 
Lafora bodies in the skeletal muscle of laforin-/- mice after exercise (Figure 38) 
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Figure 37. Effect of exercise on glycogen. Total glycogen content 
expressed as µmol of glucose/g tissue in the 12 month old male laforin-/- (red 
bars), malin/- (blue bars) and in the corresponding wild type litter mate (black 
bars) mice. A and B. Total skeletal muscle glycogen in response to exercise 
and post exercise. C and D. Total liver glycogen in response to exercise and 
post exercise. E and F. Total brain glycogen in response to exercise. The 
number in the data bar indicates the number of mice for each group. Data are 
means +/- SEM, * indicate significance compared to the control and # indicate 
significance compared to wild type with p < 0.05 double symbols ** or ## 
indicate p < 0.01.  
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In response to exercise, the wild type animals utilized glycogen both from 
the LSS and LSP (Figure 39, A and B), suggesting that both pools of glycogen 
are metabolically active and likely explained by the fact that the LSP glycogen is 
normal glycogen that is trapped in the pellet during centrifugation. The LSS 
glycogen, from both knockout mouse lines, was clearly utilized during exercise. 
In both knockout mouse lines, the LSP glycogen is elevated and does not 
significantly decrease in response to exercise although a small amount of 
utilization would not have been detectable.  
   
  
 
 
Figure 38. Lafora bodies and response to exercise. Sections quadriceps 
muscle from a control laforin-/- mouse A and an exercise laforin-/- B were 
stained with periodic acid/Schiff/diastase (PASD) to visualize Lafora bodies as 
α-amylase resistant polysaccharide, visualized as dark purple spots. 
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Figure 39. Skeletal muscle glycogen distribution in response to 
exercise. Total skeletal muscle extracts were subjected to low speed 
centrifugation to generate a low speed supernatant (LSS) and pellet (LSP). 
Glycogen content was measured and expressed as µmol of glucose/g tissue 
in the LSS and LSP for the (A) laforin+/+, laforin-/- (n  4-8), (B) Malin+/+ 
and malin-/- (n  5-6) for the control exercised mice. Data are means +/- 
SEM, * indicate significance compared to the control with p < 0.05 and ** 
indicating p < 0.01. 
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Figure 40. Glycogen phosphate levels in response to exercise. Glycogen 
phosphate (mmol of phosphate/mol glucose) in laforin-/- (red bars) (A), malin-
/- (blue bars) (B) and corresponding wild type littermates (black bars). The 
number in the data bar indicates the number of mice for each group. Data are 
means +/- SEM, * indicate significance compared to the control and # indicate 
significance compared to wild type with p < 0.05 double symbols ** or ## 
indicate p < 0.01.  
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Glycogen phosphorylation was also measured through the exercise 
protocol. In the old, 12 month old, wild type mice glycogen phosphate content, 
expressed as the molar ratio of phosphate to mole of glucose, tended to increase 
after exercise and then decreased 3 hours post-exercise following glucose 
gavage (Figure 40). Irimia et al. (238) observed similar results in 3 month old 
mice and interpreted the decrease in glycogen phosphorylation following 
exercise as due to resynthesis with little phosphate introduction by glycogen 
synthase. Thus, even though glycogen levels have been restored, the steady 
state phosphorylation state has not yet been re-established. Total glycogen 
 
 
Figure 41. Total glycogen phosphate in response to exercise. 
A, Total glycogen phosphate expressed as nmol phosphate/g tissue in 
laforin+/+ (A), malin+/+ (B), laforin-/- (C), and malin-/- (D) in response to 
exercise and post exercise. The number in the data bar indicates the 
number of mice for each group. Data are means +/- SEM, * indicate 
significance compared to the control with p < 0.05 and ** indicating p < 
0.01. 
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phosphate (nmol phosphate/g tissue) was reduced after exercise and restored 
over time (Figure 41).  
As previously mentioned, glycogen can be fractionated by subjecting 
tissue extracts to low speed centrifugation to define a soluble fraction in the low 
speed supernatant (LSS) and an insoluble fraction in the low speed pellet (LSP). 
In wild type mice, the distribution of glycogen between the LSS and LSP is about 
70% to 30%, respectively (Figure 42, D). This is in agreement with previous 
observations, and there was no change in the distribution of glycogen from wild 
type animals as they aged, at least up to 12 months of age (12). However, at 9-
10 months of age the laforin-/- and malin-/- mice have a glycogen distribution that 
is different from wild type, with ~70% of the glycogen being present in the 
insoluble, LSP, fraction (Figure 39, D). Analysis of branching of glycogen from 
the LSS and LSP by HPAEC indicated that skeletal muscle glycogen from wild 
type was identically branched in both fractions, as indicated by the 
superimposable profiles (Figure 42, A). Interestingly, the branching profiles of the 
LSS glycogen from the laforin and malin knockout mice were also 
superimposable (Figure 42, B), indicating that the soluble glycogen in the 
knockout mice is normally branched. The HPAEC profiles for the laforin-/- or 
malin-/- of the LSP were strikingly different from the profile of the wild type 
animals (Figure 42, C). Both knockout LSP profiles have fewer short chain length 
branches and more long chains (DP 14 and above), suggesting that the glycogen 
in the LSP is less branched and the average chain length is increased, which 
contribute to its insolubility.  
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Figure 42. Skeletal muscle glycogen distribution and branching. High 
performance anionic exchange chromatography (HPAEC) analysis of the 
chain length distribution from glycogen purified from either the LSS or LSP 
fractions of skeletal muscle extracts and digested with isoamylase. A, chain 
length distribution of the LSS and LSP for the laforin+/+ and malin+/+, 
indicated as WT with n  6 for the LSS and n  5 for the LSP. B, Is the chain 
length analysis for the LSS of the WT, malin-/- (n 3) and the laforin-/- (n  
3). C, Represents the chain length analysis for the LSP of the WT, malin-/- (n 
3) and the laforin-/- (n  3). D, Shows the percent of glycogen found in the 
LSS or LSP from the 10-11 month old mice used for the LSS/LSP branching 
analysis (n  4-5). Data are means +/- SEM 
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DISCUSSION 
 
1. Location of the Phosphate in Glycogen  
 We had previously reported that glycogen contained phosphate at the C2 
and C3 locations (16). Nitschke et al (15) reported that C6 was the major site of 
phosphorylation in glycogen and that C6 phosphorylation would effectively block 
the action of the branching enzyme and result in the poorly branched glycogen 
found in Lafora disease. To address the discrepancy in the results we re-
evaluated the location of glycogen phosphate by NMR analysis. One possibility 
for the difference in results between the two studies could be due to glycogen 
purification process. Therefore, we purified glycogen by two methods, one being 
a more gentle method and the other being a more harsh method, which involved 
hydrolyzing skeletal muscle in hot KOH. The rationale was to determine whether 
the purification process for glycogen affected the outcome and in particular 
whether harsh conditions promoted phosphate ester migration, a known 
phenomenon in sugar phosphates chemistry (229-231). Based on the NMR 
analyses, the glycogen preparation method did not seem to effect the distribution 
of phospho-monoesters found in the phospho-oligoshacharides. Additionally, in 
this study, we observed phosphate monoester at the C2, C3 and C6 locations, 
which is in agreement with the study of Nitschke et al. (15).  
 In addition to the NMR analysis, a newly developed, highly sensitive assay 
that measures glucose-6-P in hydrolysates of glycogen was used to quantitate 
C6 phosphorylation. From our results, in glycogen isolated from skeletal muscle 
of either rabbit or mouse, the proportion of C6 phosphorylation was ~20% of the 
total arguing that C6 is not the dominant location of the phosphate. Furthermore, 
even when glycogen phosphorylation was significantly increased in the mouse 
models of Lafora disease, the proportion of C6 phosphate remained the same. 
We argue, therefore, that there are no grounds to propose that C6 
phosphorylation is any more or less important to the altered glycogen structure 
associated with Lafora disease. A phospho-monoester at C6 of a glucose residue 
within glycogen would obviously block the formation of C1-C6 branchpoint. 
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However, considering the model for glycogen structure, described in the 
Introduction, where a full size glycogen molecule, consisting of ~55,000 glucose 
residues arranged in a series of tiers, there would be ~4,000 branch points and 
with C6 phosphate accounting for ~20% of the total phosphate found in glycogen, 
there would be 3 – 4 C6 phosphates per glycogen molecule and ~17 phosphates 
located at C2 and C3. Therefore, C6 phosphorylation could only block no more 
than 0.1% of the potential branch points, which makes it hard to imagine that C6 
phosphorylation would be directly responsible for wide spread reduction of 
branching. Rather, we favor the idea that phosphate has a wider ranging effect 
on the overall structure of glycogen (12,214) by disrupting hydrogen bonding and 
interactions that are needed for glucose helix stabilization (202). The idea that 
phosphate interferes with glucose polymer helical structure has been described 
as part of the degradative process for amylopectin (17,233,235,236), where C3 
phosphorylation induces helical strain and C6 phosphorylation can affect the 
packing of the helix (236). This may provide an explanation for the physical 
chemical properties of glycogen in Lafora disease but the exact mechanism by 
which elevated phosphorylation of glycogen is linked to the decreased branching 
of glycogen is unknown and remains an important unanswered question in the 
field.  
 
2. Origin of the Phosphate in Glycogen. 
 The source of the phosphate in glycogen remains an active area of 
investigation. Lomako et al had proposed that an uncharacterized enzyme, 
distinct from glycogen synthase, was responsible for phosphate incorporation 
into glycogen (2). They suggested that the enzyme, a glucose-1-P-transerase, 
would form the proposed C1-C6 phosphodiester bond by transferring a glucose-
1-P moiety, including the β-phosphate, from UDP-glucose (2). Tagliabracci et al 
(16) demonstrated such an activity in skeletal muscle extracts from wild type 
mice but not from mice lacking the muscle isoform of glycogen synthase, 
suggesting that glycogen synthase may be capable of incorporating phosphate 
into glycogen. Additionally, Tagliabracci et al (16) proposed a mechanism for 
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phosphate incorporation, where a glucose cyclic phosphate compound would be 
formed in the active site of glycogen synthase and result in the transfer of 
glucose-2 or glucose-3 phosphate into glycogen. The event was rare, occurring 
at a rate of one phosphate per 10,000 glucose residues incorporated into 
glycogen. As noted, Nitschke et al (15) suggested that the 32P signal we had 
observed in glycogen was due to non-specific binding of the [β32P]-UDP that is 
produced during the normal glycogen synthase reaction. We preformed many 
experiments to address this issue and we have provided evidence that glycogen 
synthase can incorporate phosphate into glycogen. However, this would only 
provide a possible mechanism for C2 and perhaps C3 phosphate incorporation 
by glycogen synthase via a cyclic phosphodiester intermediate. How phosphate 
is introduced at the C6 position remains unknown at this time and is incompatible 
with a cyclic phosphate mechanism. There are several possibilities (18). One, is 
that the phosphate can be introduced by an uncharacterized phosphotransferase 
enzyme, which would most likely use ATP or some other high-energy molecule 
as a phosphate donor. The second would be the existence of a mutase, which 
could transfer phosphate groups similar to the phosphoglucomutase reaction of 
intermediary metabolism. However, no evidence for either mechanism has 
appeared to date. 
 
3. Glycogen Metabolism in Mouse Models of Lafora Disease 
 There is a correlation between glycogen accumulation, insolubility and 
phosphate levels in mouse models of Lafora disease (12,14,15,19). We therefore 
investigated the skeletal muscle branching, solubility and phosphate content of 
glycogen from the double knockout mice. As expected, the double knockout, 
PTG/laforin-/- and the PTG/malin-/-, mice had reduced or normalized skeletal 
muscle glycogen levels, similar to that of the PTG-/- animals. The glycogen 
phosphate content of the PTG/laforin-/- mice was still elevated and at the same 
level as the laforin-/- mice, consistent with laforin acting as a glycogen 
phosphatase in vivo. Interestingly, even though the phosphate content, 
expressed as the molar ratio of phosphate to glucose, was not rescued by PTG 
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KO and remained the same as in the laforin-/- mice, the branching of the 
glycogen from the PTG/laforin-/- mice was rescued and became similar to that of 
the PTG-/- mice. Additionally, knockout of PTG improved glycogen solubility in 
the laforin knockout mice, as a majority of the glycogen was found in the soluble 
LSS fraction in the double knockout mice. The distribution of glycogen between 
the LSS and LSP in the PTG/laforin KO mice was similar to that of the wild type 
or PTG-/- mice. These data suggest that increased phosphate alone is not 
sufficient to impair glycogen solubility and result in formation of Lafora bodies. 
The branching of the double knockout skeletal muscle glycogen was similar to 
the PTG-/- mice, which is also consistent with the solubility properties of the 
glycogen. Therefore we favor the idea that Lafora body formation is dependent 
on the accumulation of poorly branched and highly phosphorylated glycogen, 
which would aggregate and form Lafora bodies. However, increased glycogen 
branch length alone does not seem to result in Lafora body formation or Lafora 
disease. For instance, in Anderson disease, GSD IV, where there is impaired or 
loss of function of the branching enzyme (148), the result is poorly branched 
glycogen but patients do not develop Lafora disease, but rather have a different 
pathology. Tagliabracci et al (12) showed, by electron microscopy, that glycogen 
from laforin-/- mice has a drastically different physical appearance, where wild 
type glycogen was visualized as rosette like structures whereas the laforin-/- 
glycogen had a "globular” appearance, in some areas forming massive 
aggregates containing many glycogen molecules. After treating the glycogen with 
recombinant laforin, thus removing at least the superficial and accessible 
phosphate, the glycogen particles changed to resemble more, though not 
completely, the rosette-like appearance of the wild type glycogen. However, the 
removal of the phosphate, presumably, would not affect branch length and 
solubility. These results argue that the high glycogen phosphate content along 
with decreased branching both contribute to aggregation and the formation of 
Lafora bodies. 
 The PTG/malin-/- mice gave similar results as the PTG/laforin-/- mice, in 
that they had normalized glycogen levels, branching was similar to the PTG-/- 
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mice and glycogen solubility was also normalized. However, there was one 
distinct difference between the PTG/laforin-/- and the PTG/malin-/- and that is the 
phosphate content of glycogen. The malin-/- mice had elevated glycogen and 
glycogen phosphate in skeletal muscle but the phosphate content of the 
PTG/malin-/- mice was normalized, similar to the levels of the wild type and PTG-
/- mice. Several reports have proposed that malin regulates laforin, either by 
regulating its protein levels or because it is needed for laforin activity 
(187,205,207,208). We have previously observed that the levels of laforin 
increase in the malin-/- mice and that the majority of the laforin protein is 
sequesterd with the abnormal glycogen in the LSP (189). In our current studies, 
the glycogen phosphate levels of the PTG/malin-/- mice were normalized, 
arguing that laforin activity is not dependent on malin. Additionally, in the skeletal 
muscle of the PTG/malin-/- mice, the levels of laforin protein were normalized 
and a majority of the laforin was associated with the soluble LSS fraction (data 
not shown, unpublished data), suggesting that laforin is not a malin substrate in 
vivo. This also supports our hypothesis that in the malin-/- mice, and most likely 
in humans with malin mutations, that the increase in laforin is due to its 
association with the insoluble abnormal glycogen (189), which is likely 
metabolically inactive. 
 A number of studies have probed the role of laforin phosphatase activity in 
the development of Lafora bodies. In the first, Chan et al. (175) characterized 
mice over-expressing a human laforin C266S mutant, demonstrated the 
generation of Lafora bodies and concluded that the mutant allele acted as a 
dominant negative even though no neurological defects were noted. They also 
suggested that laforin preferentially bound to polyglucosan and that laforin’s role 
in preventing Lafora body formation occurs after polyglucosan starts to form. 
Tiberia et al (271) observed the formation of diastase resistant material that 
stained positive with PAS, similar to Lafora bodies, when overexpressing either 
wild type or catalytically inactive laforin in cells in culture. However, they did not 
see Lafora body like aggregates in cells where laforin with a non-functional 
carbohydrate domain was overexpressed. Therefore, Tiberia et al concluded that 
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the physical binding of excess laforin contributed to the formation of Lafora 
bodies. Gayarre et al (272), however, reported that when a catalytically inactive 
C265S mutant of murine laforin, is expressed in laforin-/- mice, the animals did 
not develop Lafora bodies or have any neurological abnormalities. Therefore, 
they concluded that the pathogenic process causing abnormal glycogen 
accumulation requires the interaction of laforin and malin to form a complex but 
not the phosphatase activity of laforin. They did not, however, measure glycogen 
phosphorylation. More recently, Nitschke et al (257) revisited this issue and 
reported results similar to those of Gayarre et al. (272). By crossing either the 
Gayerre et al. (272) mice or a previously generated mouse line (175) over-
expressing the human laforin C266S catalytically inactive mutant with laforin-/- 
mice, Lafora body formation was suppressed in the resulting double knockout 
animals. Additionally, analysis of glycogen from the transgenic mice showed that 
in the laforin-/- background, when the catalytically inactive laforin is expressed, 
the phosphate content of the glycogen remained elevated but the branching of 
glycogen was rescued and is similar to the wild type controls. Interestingly, when 
the catalytically inactive laforin was expressed in the malin-/- mice, Lafora body 
formation and glycogen branching was not restored to wild type levels. From this 
study, Nitschke et al (257) concluded that laforin’s action to prevent Lafora body 
formation is mediated through malin and that laforin phosphatase activity is not 
needed to prevent Lafora body formation. 
 The studies described above yielded some complex, interesting and 
sometimes conflicting results. A priori, it is difficult to imagine that the evolved 
phosphatase activity of laforin, the only human protein with a phosphatase 
domain housed in the same polypeptide as a glycogen binding module, is 
dispensable and does not have any role in Lafora body formation or in Lafora 
disease. However, besides being a glycogen phosphatase, there may be other 
roles for laforin that are not yet understood. The first of these studies (175) 
suggested that expression of a catalytically inactive laforin acted as a dominant 
negative and Lafora body formation was observed in those mice. Gayarre et al 
(272) performed a similar experiment and took it a step further to express the 
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catalytically inactive laforin in mice lacking laforin, where they observed a 
rescuing effect and minimal to no Lafora body formation. The authors even 
monitored mice out to two years of age and still did not observe significant Lafora 
body formation. A rationalization of the Chan et al study (175) with the later ones 
is that there may have been some Lafora body formation but not close to the 
frequency observed in laforin-/- mice. Nitschke et al (257) took the investigation a 
step further, in that they expressed the catalytically inactive laforin also in malin 
knockout mice, and observed a rescuing affect in the laforin knockout 
background but not in the malin knockout, which suggests that malin and laforin 
protein must both be present to prevent Lafora body formation. However, not 
addressed is whether expressing wild type laforin in the malin knockout mice 
would rescue the Lafora disease phenotype. In comparison to data presented in 
this thesis, mainly with the PTG/laforin-/- and PTG/malin-/- double knockout mice, 
we can also agree that glycogen phosphate does not seem to be the sole 
contributor to the insolubility of glycogen. However, our observation with the 
PTG/malin-/- mice that Lafora body formation is rescued, glycogen phosphate 
content is normalized and branching is also normalized is in contrast to the 
results presented by Nitschke et al (257). Our data would suggest that laforin can 
act independently of malin and that the reduction of overall glycogen levels is key 
to preventing Lafora body formation. The same argument can be made for the 
laforin-/-PTG-/- mice since the decrease of glycogen levels was sufficient to 
prevent Lafora body formation. The relevance of reducing glycogen levels to 
prevent Lafora body formation is consistent with the data of Nitschke et al (257) 
who reported that over-expression of catalytically inactive laforin in  laforin-/- 
mice restored glycogen to wild type levels, although the mechanism is unknown. 
There is clearly much more to be learned about the mechanism of Lafora body 
formation, the relative significance of glycogen branching and phosphorylation, 
and the normal physiological roles of laforin and malin. However, even without a 
consensus on mechanism, reducing glycogen levels seems a key to preventing 
Lafora body formation  
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4. Glycogen Metabolism During Exercise in Mouse Models of Lafora 
Disease 
In 9 – 12 month old laforin-/- or malin-/- mice there is a significant increase 
in glycogen, Lafora bodies are abundantly present and glycogen is hyper-
phosphorylated (12,14,19). One goal of this work was to determine if the 
abnormal glycogen in the older laforin-/- and malin-/- mice could be metabolized 
during exhaustive exercise. We have shown that the soluble fraction of glycogen 
in both the laforin-/- and malin-/- mice is clearly utilized during exercise. The 
soluble fraction of glycogen from the laforin-/- and malin -/- mice accounts for 
only ~25% of the total skeletal muscle glycogen, making it difficult to measure 
any significant utilization of glycogen from the total glycogen pool. Additionally, 
there was no significant depletion of glycogen in the LSP of either the laforin-/- or 
malin-/- mice after exercise, suggesting that the insoluble and poorly branched 
glycogen found in the LSP is not subject to normal metabolism. Interestingly, in 
the laforin -/- mice there was a clear difference in glycogen synthase 
phosphorylation state between the LSS and LSP in response to exercise. The 
glycogen synthase associated with the LSS was dephosphorylated in response 
to exercise in both the wild type and laforin-/- mice, while the glycogen synthase 
in the LSP of the laforin-/- mice did not respond to exercise, supporting the idea 
that enzymes associated with the abnormal glycogen are also not metabolically 
active. In the malin-/- mice, there is an increase in laforin level associated with 
the LSP, presumably sequestered by the abnormal glycogen; given that there 
was no change in glycogen phosphate content after exercise, it is likely that a 
majority of laforin is inactive.  
Besides knowing the location of the phospho-monoesters on carbon 
atoms of glucose residues, we also know that ~25% of the phosphate is located 
on the outer tiers of glycogen and that the majority is found in the inner tiers of 
the glycogen molecules (12). Studies of exercised 3-month-old mice have shown 
that as glycogen is utilized the glycogen phosphorylation (mmol phosphate/mol 
glucose) increases after exercise (238), which is consistent with the phosphate 
being more concentrated in the inner tiers of glycogen. In wild type animals, after 
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a bout of exercise followed by a period of rest, the phosphorylation of the 
exercised mice decreased, as the glycogen was being resynthesized and 
remodeled, suggesting that laforin was able to access and remove the exposed 
phosphate from glycogen. However, in 3-month-old mice lacking laforin, the 
phosphate levels remained high and the remodeling of glycogen was slower than 
in the wild type mice. Additionally, there was no noticeable loss of glycogen 
phosphate in response to exercise despite a significant loss of total skeletal 
muscle glycogen. These results were also consistent in older laforin-/- and malin-
/- mice and suggest that the phosphate in glycogen could affect its degradation 
and inhibit its remodeling.  
 
5. Overall Discussion 
Loss of function mutations in either the EPM2A or EPM2B genes, which 
encode the laforin or malin proteins respectively, result in Lafora disease with 
similar clinical outcomes. Therefore, much of the focus of Lafora disease 
research has been to determine the function(s) of both laforin and malin so as to 
understand the mechanism underlying the disease and hence the design of 
potential therapy. At the present time, there is no cure available for Lafora 
disease and the only treatments are aimed at alleviating epileptic symptoms with 
antiepileptic drugs (273). A hallmark of Lafora disease is the accumulation of 
Lafora bodies in various tissues. There is now growing evidence that glycogen 
over-accumulation is a major factor in the formation of Lafora bodies, and 
therefore that Lafora disease is a type of glycogenosis (198,210-212,214). At the 
outset of this thesis research, the hypothesis had evolved, largely from work of 
our laboratory, that glycogen phosphorylation played a leading role in the 
generation of Lafora bodies and Lafora disease. Increased glycogen 
phosphorylation correlated with many of the properties of the polyglucosan in 
Lafora bodies, although the connection between phosphorylation and decreased 
glycogen branching was never understood. Work from this thesis, as well as from 
other laboratories, has now shown that matters are more complex since 
hyperphosphorylation of glycogen alone does not guarantee Lafora body 
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formation. The evidence strongly supports the idea that laforin can function as a 
glycogen phosphatase in vivo but the question now emerging is whether it has 
other roles relevant to glycogen metabolism and Lafora body formation. There is 
a disease causing mutation in laforin that disables the carbohydrate binding 
domain (174,239), while phosphatase activity is still present, which may suggest 
that binding of laforin to glycogen is necessary for preventing Lafora body 
formation. Glycogen from old laforin -/- mice aggregates and treatment with 
laforin makes the glycogen appear more rosette-like and more similar to wild type 
{Tagliabracci, 2008 #9}, which supports the idea that phosphate has a role in 
glycogen aggregation. However, this is an area that merits further exploration. 
The exact function of malin also remains largely undefined. Further work to 
understand the detailed mechanism for the formation of Lafora bodies and/or the 
development of Lafora disease is clearly necessary.  
However, as shown by work in this thesis, reducing the accumulation of 
abnormal glycogen in Lafora mouse models does reduce or eliminate Lafora 
body formation leading to a good consensus within the Lafora research 
community that suppression of glycogen storage may be, at this time, one of the 
most promising therapeutic directions to follow. Several laboratories are following 
this lead, ours pursuing small molecules that can inhibit glycogen synthase or 
glycogen synthase dephosphorylation. Inhibiting glycogen synthesis in Lafora 
disease patients could minimally prevent further progression of the disease and 
in the best case scenario allow for the clearance of the abnormal glycogen that 
makes up Lafora bodies. In any event, this is a therapeutic approach that is worth 
pursuing. 
 
  
 142 
References 
 
1. Gambetti, P., Di Mauro, S., Hirt, L., and Blume, R. P. (1971) Myoclonic 
epilepsy with Lafora bodies: some ultrastructural, histochemical, and 
biochemical aspects. Archives of neurology 25, 483-493 
2. Lomako, J., Lomako, W. M., Whelan, W. J., and Marchase, R. B. (1993) 
Glycogen contains phosphodiester groups that can be introduced by 
UDPglucose: glycogen glucose 1-phosphotransferase. FEBS letters 329, 
263-267 
3. Lomako, J., Lomako, W. M., Kirkman, B. R., and Whelan, W. J. (1994) 
The role of phosphate in muscle glycogen. Biofactors 4, 167-171 
4. Roach, P. J., Skurat, A. V., and Harris, R. A. (2010) Regulation of 
Glycogen Metabolism. in Comprehensive Physiology, John Wiley & Sons, 
Inc. pp  
5. Gunja-Smith, Z., Marshall, J. J., Mercier, C., Smith, E. E., and Whelan, W. 
J. (1970) A revision of the Meyer-Bernfeld model of glycogen and 
amylopectin. FEBS letters 12, 101-104 
6. Melendez-Hevia, E., Waddell, T. G., and Shelton, E. D. (1993) 
Optimization of molecular design in the evolution of metabolism: the 
glycogen molecule. Biochemical Journal 295 ( Pt 2), 477-483 
7. Melendez, R., Melendez-Hevia, E., and Cascante, M. (1997) How did 
glycogen structure evolve to satisfy the requirement for rapid mobilization 
of glucose? A problem of physical constraints in structure building. Journal 
of molecular evolution 45, 446-455 
8. Goldsmith, E., Sprang, S., and Fletterick, R. (1982) Structure of 
maltoheptaose by difference Fourier methods and a model for glycogen. 
Journal of molecular biology 156, 411-427 
9. Shearer, J., and Graham, T. E. (2004) Novel aspects of skeletal muscle 
glycogen and its regulation during rest and exercise. Exerc Sport Sci Rev 
32, 120-126 
10. Kirkman, B. R., and Whelan, W. J. (1986) Glucosamine is a normal 
component of liver glycogen. FEBS letters 194, 6-11 
11. Fontana, J. D. (1980) The presence of phosphate in glycogen. FEBS 
letters 109, 85-92 
12. Tagliabracci, V. S., Girard, J. M., Segvich, D., Meyer, C., Turnbull, J., 
Zhao, X., Minassian, B. A., Depaoli-Roach, A. A., and Roach, P. J. (2008) 
Abnormal metabolism of glycogen phosphate as a cause for Lafora 
disease. J Biol Chem 283, 33816-33825 
13. Tagliabracci, V. S., Turnbull, J., Wang, W., Girard, J. M., Zhao, X., Skurat, 
A. V., Delgado-Escueta, A. V., Minassian, B. A., Depaoli-Roach, A. A., 
and Roach, P. J. (2007) Laforin is a glycogen phosphatase, deficiency of 
which leads to elevated phosphorylation of glycogen in vivo. Proc Natl 
Acad Sci U S A 104, 19262-19266 
14. DePaoli-Roach, A. A., Contreras, C. J., Segvich, D. M., Heiss, C., Ishihara, 
M., Azadi, P., and Roach, P. J. (2015) Glycogen phosphomonoester 
 143 
distribution in mouse models of the progressive myoclonic epilepsy, lafora 
disease. J Biol Chem 290, 841-850 
15. Nitschke, F., Wang, P., Schmieder, P., Girard, J. M., Awrey, D. E., Wang, 
T., Israelian, J., Zhao, X., Turnbull, J., Heydenreich, M., Kleinpeter, E., 
Steup, M., and Minassian, B. A. (2013) Hyperphosphorylation of glucosyl 
C6 carbons and altered structure of glycogen in the neurodegenerative 
epilepsy Lafora disease. Cell Metab 17, 756-767 
16. Tagliabracci, V. S., Heiss, C., Karthik, C., Contreras, C. J., Glushka, J., 
Ishihara, M., Azadi, P., Hurley, T. D., DePaoli-Roach, A. A., and Roach, P. 
J. (2011) Phosphate incorporation during glycogen synthesis and Lafora 
disease. Cell Metab 13, 274-282 
17. Blennow, A., Nielsen, T. H., Baunsgaard, L., Mikkelsen, R., and Engelsen, 
S. B. (2002) Starch phosphorylation: a new front line in starch research. 
Trends Plant Sci 7, 445-450 
18. Roach, P. J. (2015) Glycogen phosphorylation and Lafora disease. 
Molecular aspects of medicine 46, 78-84 
19. Turnbull, J., Wang, P., Girard, J. M., Ruggieri, A., Wang, T. J., Draginov, A. 
G., Kameka, A. P., Pencea, N., Zhao, X., Ackerley, C. A., and Minassian, 
B. A. (2010) Glycogen hyperphosphorylation underlies lafora body 
formation. Ann Neurol 68, 925-933 
20. Cavanagh, J. B. (1999) Corpora-amylacea and the family of polyglucosan 
diseases. Brain Res Rev 29, 265-295 
21. Rosai, J., and Lascano, E. F. (1970) Basophilic (mucoid) degeneration of 
myocardium: a disorder of glycogen metabolism. Am J Pathol 61, 99-116 
22. Agius, L. (2008) Glucokinase and molecular aspects of liver glycogen 
metabolism. Biochemical Journal 414, 1-18 
23. McGarry, J., Kuwajima, M., Newgard, C., Foster, D., and Katz, J. (1987) 
From dietary glucose to liver glycogen: the full circle round. Annual review 
of nutrition 7, 51-73 
24. Thorens, B., and Mueckler, M. (2010) Glucose transporters in the 21st 
Century. American Journal of Physiology-Endocrinology and Metabolism 
298, E141-E145 
25. Kennedy, L. D., Kirkman, B. R., Lomako, J., Rodriguez, I. R., and Whelan, 
W. J. (1985) The biogenesis of rabbit-muscle glycogen. Membranes and 
Muscle. IRL Press, Oxford, 65-84 
26. KRISMAN, C. R., and BARENGO, R. (1975) A Precursor of Glycogen 
Biosynthesis: α1, 4GlucanProtein. European Journal of Biochemistry 
52, 117-123 
27. PITCHER, J., SMYTHE, C., CAMPBELL, D. G., and COHEN, P. (1987) 
Identification of the 38kDa subunit of rabbit skeletal muscle glycogen 
synthase as glycogenin. European Journal of Biochemistry 169, 497-502 
28. Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D., and Tagliabracci, V. S. 
(2012) Glycogen and its metabolism: some new developments and old 
themes. The Biochemical journal 441, 763-787 
29. Hirschhorn, R., and Reuser, A. J. (2000) Glycogen Storage Disease Type 
II: Acid alpha-Glucosidase (Acid Maltase) Deficiency. in he Metabolic and 
 144 
Molecular Basis of Inherited Disease. (Scriver, C. R., Beaudet, A. L., Sly, 
W. S., and Valle, D. eds.), McGraw-Hill, New York. pp 3389-3420 
30. Cori, C. F. C. G. T. (1939) The activating effect of glycogen on the 
enzymatic synthesis of glycogen from glucose-1-phosphate. J Biol Chem 
131, 397-398 
31. Kennedy, L., Kirkman, B., Lomako, J., Rodriguez, I., and Whelan, W. 
(1985) The biogenesis of rabbit-muscle glycogen. Membranes and muscle, 
65-84 
32. Butler, N. A., Lee, E. Y., and Whelan, W. J. (1977) A protein-bound 
glycogen component of rat liver. Carbohydrate research 55, 73-82 
33. Alonso, M., Lomako, J., Lomako, W., and Whelan, W. (1995) A new look 
at the biogenesis of glycogen. The FASEB journal 9, 1126-1137 
34. Gannon, M., and Nuttall, F. (1997) Effect of feeding, fasting, and diabetes 
on liver glycogen synthase activity, protein, and mRNA in rats. 
Diabetologia 40, 758-763 
35. Henrissat, B., and Davies, G. (1997) Structural and sequence-based 
classification of glycoside hydrolases. Current Opinion in Structural 
Biology 7, 637-644 
36. Campbell, J. A., Davies, G. J., Bulone, V., and Henrissat, B. (1997) A 
classification of nucleotide-diphospho-sugar glycosyltransferases based 
on amino acid sequence similarities. Biochemical Journal 326, 929 
37. Mu, J., Skurat, A. V., and Roach, P. J. (1997) Glycogenin-2, a novel self-
glucosylating protein involved in liver glycogen biosynthesis. J Biol Chem 
272, 27589-27597 
38. Zhai, L., Schroeder, J., Skurat, A. V., and Roach, P. J. (2001) Do Rodents 
Have a Gene Encoding Glycogenin2, the Liver Isoform of the Self
Glucosylating Initiator of Glycogen Synthesis? IUBMB life 51, 87-91 
39. Moslemi, A. R., Lindberg, C., Nilsson, J., Tajsharghi, H., Andersson, B., 
and Oldfors, A. Glycogenin-1 deficiency and inactivated priming of 
glycogen synthesis. N Engl J Med 362, 1203-1210 
40. Lomako, J., Mazuruk, K., Lomako, W. M., Alonso, M. D., Whelan, W. J., 
and Rodriguez, I. R. (1996) The human intron-containing gene for 
glycogenin maps to chromosome 3, band q24. Genomics 33, 519-522 
41. Gibbons, B. J., Roach, P. J., and Hurley, T. D. (2002) Crystal structure of 
the autocatalytic initiator of glycogen biosynthesis, glycogenin. Journal of 
molecular biology 319, 463-477 
42. Roach, P. J., and Skurat, A. V. (1997) Self-glucosylating initiator proteins 
and their role in glycogen biosynthesis. Prog Nuc Acid Res Mol Biol 57, 
289-316 
43. Lomako, J., Lomako, W. M., and Whelan, W. J. (2004) Glycogenin: the 
primer for mammalian and yeast glycogen synthesis. Biochim Biophys 
Acta 1673, 45-55 
44. Smythe, C., and Cohen, P. (1991) The discovery of glycogenin and the 
priming mechanism for glycogen biogenesis. European Journal Of 
Biochemistry. 200, 625-631 
 145 
45. Cao, Y., Skurat, A., DePaoli-Roach, A., and Roach, P. (1993) Initiation of 
glycogen synthesis. Control of glycogenin by glycogen phosphorylase. J 
Biol Chem 268, 21717-21721 
46. Skurat, A. V., Cao, Y., and Roach, P. (1993) Glucose control of rabbit 
skeletal muscle glycogenin expressed in COS cells. J Biol Chem 268, 
14701-14707 
47. Caudwell, F. B., and Cohen, P. (1980) Purification and subunit structure of 
glycogen-branching enzyme from rabbit skeletal muscle. European 
Journal Of Biochemistry. 109, 391-394 
48. Gibson, W. B., Illingsworth, B., and Brown, D. H. (1971) Studies of 
glycogen branching enzyme. Preparation and properties of -1,4-glucan- -
1,4-glucan 6-glycosyltransferase and its action on the characteristic 
polysaccharide of the liver of children with Type IV glycogen storage 
disease. Biochemistry 10, 4253-4262 
49. Abad, M. C., Binderup, K., Rios-Steiner, J., Arni, R. K., Preiss, J., and 
Geiger, J. H. (2002) The X-ray crystallographic structure of Escherichia 
coli branching enzyme. J Biol Chem 277, 42164-42170. 
50. Pal, K., Kumar, S., Sharma, S., Garg, S. K., Alam, M. S., Xu, H. E., 
Agrawal, P., and Swaminathan, K. (2010) Crystal structure of full-length 
Mycobacterium tuberculosis H37Rv glycogen branching enzyme: insights 
of N-terminal beta-sandwich in substrate specificity and enzymatic activity. 
J Biol Chem 285, 20897-20903 
51. Friedman, D. L., and Larner, J. (1963) Studies on Udpg-Alpha-Glucan 
Transglucosylase. Iii. Interconversion of Two Forms of Muscle Udpg-
Alpha-Glucan Transglucosylase by a Phosphorylation-Dephosphorylation 
Reaction Sequence. Biochemistry 2, 669-675 
52. Roach, P. J., and Larner, J. (1977) Covalent phosphorylation in the 
regulation of glycogen synthase activity. Molecular and cellular 
biochemistry 15, 179-200 
53. Bai, G., Zhang, Z., Werner, R., Nuttall, F., Tan, A., and Lee, E. (1990) The 
primary structure of rat liver glycogen synthase deduced by cDNA cloning. 
Absence of phosphorylation sites 1a and 1b. J Biol Chem 265, 7843-7848 
54. Nuttall, F. Q., Gannon, M. C., Bai, G., and Lee, E. Y. (1994) Primary 
structure of human liver glycogen synthase deduced by cDNA cloning. 
Archives of biochemistry and biophysics 311, 443-449 
55. Farkas, I., Hardy, T. A., Goebl, M. G., and Roach, P. J. (1991) Two 
glycogen synthase isoforms in Saccharomyces cerevisiae are coded by 
distinct genes that are differentially controlled. J Biol Chem 266, 15602-
15607 
56. Zhang, W., Browner, M., Fletterick, R., DePaoli-Roach, A., and Roach, P. 
(1989) Primary structure of rabbit skeletal muscle glycogen synthase 
deduced from cDNA clones. The FASEB journal 3, 2532-2536 
57. Roach, P. J. (2002) Glycogen and its metabolism. Current Molecular 
Medicine 2, 101-120 
58. Hardy, T. A., and Roach, P. J. (1993) Control of yeast glycogen synthase-
2 by COOH-terminal phosphorylation. J Biol Chem 268, 23799-23805 
 146 
59. Roach, P. J. (1990) Control of glycogen synthase by hierarchal protein 
phosphorylation. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 4, 2961-2968 
60. Roach, P. J. (1991) Multisite and hierarchal protein phosphorylation. J Biol 
Chem 266, 14139-14142 
61. Picton, C., Woodgett, J., Hemmings, B., and Cohen, P. (1982) Multisite 
phosphorylation of glycogen synthase from rabbit skeletal muscle. 
Phosphorylation of site 5 by glycogen synthase kinase-5 (casein kinase-II) 
is a prerequisite for phosphorylation of sites 3 by glycogen synthase 
kinase-3. FEBS letters 150, 191-196 
62. DePaoli-Roach, A. A., Ahmad, Z., Camici, M., Lawrence, J. C., Jr., and 
Roach, P. J. (1983) Multiple phosphorylation of rabbit skeletal muscle 
glycogen synthase. Evidence for interactions among phosphorylation sites 
and the resolution of electrophoretically distinct forms of the subunit. J Biol 
Chem 258, 10702-10709 
63. Roach, P. J., DePaoli-Roach, A. A., and Larner, J. (1978) Ca2+-stimulated 
phosphorylation of muscle glycogen synthase by phosphorylase b kinase. 
J Cyclic Nucleotide Res 4, 245-257 
64. Huang, T. S., and Krebs, E. G. (1977) Amino acid sequence of a 
phosphorylation site in skeletal muscle glycogen synthetase. Biochem 
Biophys Res Commun 75, 643-650 
65. Flotow, H., and Roach, P. J. (1989) Synergistic phosphorylation of rabbit 
muscle glycogen synthase by cyclic AMP-dependent protein kinase and 
casein kinase I. Implications for hormonal regulation of glycogen synthase. 
J Biol Chem 264, 9126-9128 
66. Flotow, H., Graves, P. R., Wang, A. Q., Fiol, C. J., Roeske, R. W., and 
Roach, P. J. (1990) Phosphate groups as substrate determinants for 
casein kinase I action. J Biol Chem 265, 14264-14269 
67. Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W., and Roach, P. J. 
(1987) Formation of protein kinase recognition sites by covalent 
modification of the substrate. Molecular mechanism for the synergistic 
action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 
262, 14042-14048 
68. Carling, D., and Hardie, D. G. (1989) The substrate and sequence 
specificity of the AMP-activated protein kinase. Phosphorylation of 
glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1012, 
81-86 
69. Wilson, W. A., Skurat, A. V., Probst, B., de Paoli-Roach, A., Roach, P. J., 
and Rutter, J. (2005) Control of mammalian glycogen synthase by PAS 
kinase. Proc Natl Acad Sci U S A 102, 16596-16601 
70. Skurat, A. V., and Dietrich, A. D. (2004) Phosphorylation of Ser640 in 
muscle glycogen synthase by DYRK family protein kinases. J Biol Chem 
279, 2490-2498 
71. Kuma, Y., Campbell, D. G., and Cuenda, A. (2004) Identification of 
glycogen synthase as a new substrate for stress-activated protein kinase 
2b/p38beta. The Biochemical journal 379, 133-139 
 147 
72. Skurat, A. V., Wang, Y., and Roach, P. J. (1994) Rabbit skeletal muscle 
glycogen synthase expressed in COS cells. Identification of regulatory 
phosphorylation sites. J Biol Chem 269, 25534-25542 
73. Skurat, A. V., and Roach, P. J. (1995) Phosphorylation of sites 3a and 3b 
(Ser640 and Ser644) in the control of rabbit muscle glycogen synthase. J 
Biol Chem 270, 12491-12497 
74. Rutter, J., Probst, B. L., and McKnight, S. L. (2002) Coordinate regulation 
of sugar flux and translation by PAS kinase. Cell 111, 17-28 
75. Bollen, M. (2001) Combinatorial control of protein phosphatase-1. Trends 
in Biochemical Sciences 26, 426-431 
76. Ceulemans, H., and Bollen, M. (2004) Functional diversity of protein 
phosphatase-1, a cellular economizer and reset button. Physiol Rev 84, 1-
39 
77. Gasa, R., Jensen, P. B., Berman, H. K., Brady, M. J., DePaoli-Roach, A. 
A., and Newgard, C. B. (2000) Distinctive regulatory and metabolic 
properties of glycogen-targeting subunits of protein phosphatase-1 (PTG, 
GL, GM/RGl) expressed in hepatocytes. J Biol Chem 275, 26396-26403 
78. Tang, P. M., Bondor, J. A., Swiderek, K. M., and DePaoli-Roach, A. A. 
(1991) Molecular cloning and expression of the regulatory (RG1) subunit 
of the glycogen-associated protein phosphatase. J Biol Chem 266, 15782-
15789 
79. DOHERTY, M. J., Cadefau, J., Stalmans, W., Bollen, M., and COHEN, P. 
T. (1998) Loss of the hepatic glycogen-binding subunit (GL) of protein 
phosphatase 1 underlies deficient glycogen synthesis in insulin-dependent 
diabetic rats and in adrenalectomized starved rats. The Biochemical 
Journal 333, 253-257 
80. Doherty, M. J., Moorhead, G., Morrice, N., Cohen, P., and Cohen, P. T. 
(1995) Amino acid sequence and expression of the hepatic glycogen-
binding (G L-subunit of protein phosphatase-1. FEBS letters 375, 294-298 
81. Kelsall, I. R., Voss, M., Munro, S., Cuthbertson, D. J., and Cohen, P. T. 
(2011) R3F, a novel membraneassociated glycogen targeting subunit of 
protein phosphatase 1 regulates glycogen synthase in astrocytoma cells in 
response to glucose and extracellular signals. Journal of Neurochemistry 
118, 596-610 
82. Baskaran, S., Roach, P. J., DePaoli-Roach, A. A., and Hurley, T. D. (2010) 
Structural basis for glucose-6-phosphate activation of glycogen synthase. 
Proceedings of the National Academy of Sciences 107, 17563-17568 
83. Zeqiraj, E., Tang, X., Hunter, R. W., García-Rocha, M., Judd, A., Deak, M., 
von Wilamowitz-Moellendorff, A., Kurinov, I., Guinovart, J. J., and Tyers, 
M. (2014) Structural basis for the recruitment of glycogen synthase by 
glycogenin. Proceedings of the National Academy of Sciences 111, 
E2831-E2840 
84. Mahalingan, K. K., Baskaran, S., Depaoli-Roach, A. A., Roach, P. J., and 
Hurley, T. D. (2016) Redox switch for the inhibited state of yeast glycogen 
synthase mimics regulation by phosphorylation. Biochemistry  
 148 
85. Pederson, B. A., Csitkovits, A. G., Simon, R., Schroeder, J. M., Wang, W., 
Skurat, A. V., and Roach, P. J. (2003) Overexpression of glycogen 
synthase in mouse muscle results in less branched glycogen. Biochem 
Biophys Res Commun 305, 826-830. 
86. Cameron, J. M., Levandovskiy, V., MacKay, N., Utgikar, R., Ackerley, C., 
Chiasson, D., Halliday, W., Raiman, J., and Robinson, B. H. (2009) 
Identification of a novel mutation in GYS1 (muscle-specific glycogen 
synthase) resulting in sudden cardiac death, that is diagnosable from skin 
fibroblasts. Molecular genetics and metabolism 98, 378-382 
87. Kollberg, G., Tulinius, M., Gilljam, T., Östman-Smith, I., Forsander, G., 
Jotorp, P., Oldfors, A., and Holme, E. (2007) Cardiomyopathy and 
exercise intolerance in muscle glycogen storage disease 0. New England 
Journal of Medicine 357, 1507-1514 
88. Orho, M., Bosshard, N. U., Buist, N. R., Gitzelmann, R., Aynsley-Green, A., 
Blumel, P., Gannon, M. C., Nuttall, F. Q., and Groop, L. C. (1998) 
Mutations in the liver glycogen synthase gene in children with 
hypoglycemia due to glycogen storage disease type 0. J Clin Invest 102, 
507-515 
89. McCue, M. E., Valberg, S. J., Miller, M. B., Wade, C., DiMauro, S., Akman, 
H. O., and Mickelson, J. R. (2008) Glycogen synthase (GYS1) mutation 
causes a novel skeletal muscle glycogenosis. Genomics 91, 458-466 
90. Irimia, J. M., Meyer, C. M., Peper, C. L., Zhai, L., Bock, C. B., Previs, S. F., 
McGuinness, O. P., DePaoli-Roach, A., and Roach, P. J. (2010) Impaired 
glucose tolerance and predisposition to the fasted state in liver glycogen 
synthase knock-out mice. J Biol Chem iological Chemistry 285, 12851-
12861 
91. Hudson, J. W., Golding, G. B., and Crerar, M. M. (1993) Evolution of 
allosteric control in glycogen phosphorylase. Journal of molecular biology 
234, 700-721 
92. Newgard, C. B., Hwang, P. K., and Fletterick, R. J. (1989) The Family of 
Glycogen Phosphorylases: Structure and Functio. Critical Reviews in 
Biochemistry and Molecular Biology 24, 69-99 
93. Newgard, C. B., Littman, D., van Genderen, C., Smith, M., and Fletterick, 
R. (1988) Human brain glycogen phosphorylase. Cloning, sequence 
analysis, chromosomal mapping, tissue expression, and comparison with 
the human liver and muscle isozymes. J Biol Chem 263, 3850-3857 
94. Titani, K., Koide, A., Ericsson, L. H., Kumar, S., Hermann, J., Wade, R. D., 
Walsh, K. A., Neurath, H., and Fischer, E. H. (1978) Sequence of the 
carboxyl-terminal 492 residues of rabbit muscle glycogen phosphorylase 
including the pyridoxal 5'-phosphate binding site. Biochemistry 17, 5680-
5695 
95. Johnson, L. (1992) Glycogen phosphorylase: control by phosphorylation 
and allosteric effectors. The FASEB journal 6, 2274-2282 
96. Johnson, L., and Barford, D. (1990) Glycogen phosphorylase. The 
structural basis of the allosteric response and comparison with other 
allosteric proteins. J Biol Chem 265, 2409-2412 
 149 
97. Madsen, N. B. (1986) 9 Glycogen Phosphorylase. The Enzymes 17, 365-
394 
98. Nakano, K., Hwang, P. K., and Fletterick, R. J. (1986) Complete cDNA 
sequence for rabbit muscle glycogen phosphorylase. FEBS letters 204, 
283-287 
99. Fischer, E., Pocker, A., and Saari, J. (1970) The structure, function and 
control of glycogen phosphorylase. Essays in biochemistry 6, 23-68 
100. Fischer, E., and Heilmeyer, L. (1971) Jr. & RH Haschke: Curr. Topics Cell. 
Reg 4, 211 
101. Graves, D. J., and Wang, J. H. (1972) 15 α-Glucan Phosphorylases–
Chemical and Physical Basis of Catalysis and Regulation. The Enzymes 7, 
435-482 
102. Krebs, E. G., and Fischer, E. H. (1956) The phosphorylase b to a 
converting enzyme of rabbit skeletal muscle. Biochimica et Biophysica 
Acta 20, 150-157 
103. Kasvinsky, P. J., Fletterick, R. J., and Madsen, N. B. (1981) Regulation of 
the dephosphorylation of glycogen phosphorylase a and synthase b by 
glucose and caffeine in isolated hepatocytes. Canadian journal of 
biochemistry 59, 387-395 
104. Heilmeyer, L. M. (1991) Molecular basis of signal integration in 
phosphorylase kinase. Biochimica et Biophysica Acta (BBA)-Molecular 
Cell Research 1094, 168-174 
105. Meyer, W. L., Fischer, E. H., and Krebs, E. G. (1964) Activation of skeletal 
muscle phosphorylase b kinase by Ca2+. Biochemistry 3, 1033-1039 
106. Cohen, P. (1973) The role of phosphorylase kinase in the nervous and 
hormonal control of glycogenolysis in muscle. in Biochemical Society 
symposium  
107. Sutherland, E. W., and Robison, G. A. (1969) The role of cyclic AMP in the 
control of carbohydrate metabolism. Diabetes 18, 797-819 
108. Gilboe, D. P., Larson, K. L., and Nuttall, F. Q. (1972) Radioactive method 
for the assay of glycogen phosphorylases. Anal Biochem 47, 20-27 
109. Stalmans, W., Bollen, M., and Mvumbi, L. (1987) Control of glycogen 
synthesis in health and disease. Diabetes/Metabolism Research and 
Reviews 3, 127-161 
110. White, M. F. (1998) The IRS-signalling system: a network of docking 
proteins that mediate insulin action. in Insulin Action, Springer. pp 3-11 
111. Pessin, J. E., and Saltiel, A. R. (2000) Signaling pathways in insulin action: 
molecular targets of insulin resistance. The Journal of clinical investigation 
106, 165-169 
112. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006) Critical nodes in 
signalling pathways: insights into insulin action. Nature reviews Molecular 
cell biology 7, 85-96 
113. Dent, P., Lavoinne, A., Nakielny, S., Caudwell, F. B., Watt, P., and Cohen, 
P. (1990) The molecular mechanism by which insulin stimulates glycogen 
synthesis in mammalian skeletal muscle. Nature 348, 302-308 
 150 
114. Armstrong, C. G., Browne, G. J., Cohen, P., and Cohen, P. T. (1997) 
PPP1R6, a novel member of the family of glycogen-targetting subunits of 
protein phosphatase 1. FEBS letters 418, 210-214 
115. Suzuki, Y., Lanner, C., Kim, J. H., Vilardo, P. G., Zhang, H., Yang, J., 
Cooper, L. D., Steele, M., Kennedy, A., Bock, C. B., Scrimgeour, A., 
Lawrence, J. C., Jr., and DePaoli-Roach, A. A. (2001) Insulin control of 
glycogen metabolism in knockout mice lacking the muscle-specific protein 
phosphatase PP1G/RGL. Molecular & Cellular Biology 21, 2683-2694 
116. Printen, J. A., Brady, M. J., and Saltiel, A. R. (1997) PTG, a protein 
phosphatase 1-binding protein with a role in glycogen metabolism. 
Science 275, 1475-1478 
117. Brady, M. J., and Saltiel, A. R. (2001) The role of protein phosphatase-1 in 
insulin action. Recent Progress in Hormone Research 56, 157-174 
118. EMBI, N., PARKER, P. J., and COHEN, P. (1981) A Reinvestigation of the 
Phosphorylation of Rabbit SkeletalMuscle Glycogen Synthase by Cyclic
AMPDependent Protein Kinase. The FEBS Journal 115, 405-413 
119. PARKER, P. J., EMBI, N., CAUDWELL, F. B., and COHEN, P. (1982) 
Glycogen synthase from rabbit skeletal muscle. The FEBS Journal 124, 
47-55 
120. POULTER, L., ANG, S. G., GIBSON, B. W., WILLIAMS, D. H., HOLMES, 
C. F., CAUDWELL, F. B., PITCHER, J., and COHEN, P. (1988) Analysis 
of the in vivo phosphorylation state of rabbit skeletal muscle glycogen 
synthase by fastatombombardment mass spectrometry. The FEBS 
Journal 175, 497-510 
121. Sheorain, V. S., Khatra, B., and Soderling, T. (1982) Hormonal regulation 
of glycogen synthase phosphorylation in rabbit skeletal muscle. J Biol 
Chem 257, 3462-3470 
122. FOULKES, J. G., and COHEN, P. (1979) The hormonal control of 
glycogen metabolism. European Journal of Biochemistry 97, 251-256 
123. Alemany, S., and Cohen, P. (1986) Phosphorylase a is an allosteric 
inhibitor of the glycogen and microsomal forms of rat hepatic protein 
phosphatase1. FEBS letters 198, 194-202 
124. Moorhead, G., MacKintosh, C., Morrice, N., and Cohen, P. (1995) 
Purification of the hepatic glycogenassociated form of protein 
phosphatase1 by microcystinSepharose affinity chromatography. FEBS 
letters 362, 101-105 
125. Ørtenblad, N., Westerblad, H., and Nielsen, J. (2013) Muscle glycogen 
stores and fatigue. The Journal of physiology 591, 4405-4413 
126. Bergström, J., Hermansen, L., Hultman, E., and Saltin, B. (1967) Diet, 
muscle glycogen and physical performance. Acta Physiologica 
Scandinavica 71, 140-150 
127. Nielsen, J. N., and Richter, E. A. (2003) Regulation of glycogen synthase 
in skeletal muscle during exercise. Acta Physiologica Scandinavica 178, 
309-319 
 151 
128. Nielsen, J. N., and Wojtaszewski, J. F. (2004) Regulation of glycogen 
synthase activity and phosphorylation by exercise. Proceedings of the 
Nutrition Society 63, 233-237 
129. Shulman, R., and Rothman, D. (2001) The “glycogen shunt” in exercising 
muscle: a role for glycogen in muscle energetics and fatigue. Proceedings 
of the National Academy of Sciences 98, 457-461 
130. Wojtaszewski, J. F., Higaki, Y., Hirshman, M. F., Michael, M. D., Dufresne, 
S. D., Kahn, C. R., and Goodyear, L. J. (1999) Exercise modulates 
postreceptor insulin signaling and glucose transport in muscle-specific 
insulin receptor knockout mice. The Journal of clinical investigation 104, 
1257-1264 
131. McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro, N., 
Marquez, R., and Alessi, D. R. (2005) Role that phosphorylation of GSK3 
plays in insulin and Wnt signalling defined by knockin analysis. The EMBO 
journal 24, 1571-1583 
132. Aschenbach, W. G., Suzuki, Y., Breeden, K., Prats, C., Hirshman, M. F., 
Dufresne, S. D., Sakamoto, K., Vilardo, P. G., Steele, M., Kim, J. H., Jing, 
S. L., Goodyear, L. J., and DePaoli-Roach, A. A. (2001) The muscle-
specific protein phosphatase PP1G/R(GL)(G(M))is essential for activation 
of glycogen synthase by exercise. J Biol Chem 276, 39959-39967 
133. Lai, Y.-C., Stuenæs, J. T., Kuo, C.-H., and Jensen, J. (2007) Glycogen 
content and contraction regulate glycogen synthase phosphorylation and 
affinity for UDP-glucose in rat skeletal muscles. American Journal of 
Physiology-Endocrinology and Metabolism 293, E1622-E1629 
134. Richter, E. A., and Ruderman, N. B. (2009) AMPK and the biochemistry of 
exercise: implications for human health and disease. Biochemical Journal 
418, 261-275 
135. Hardie, D. G. (2007) AMP-activated/SNF1 protein kinases: conserved 
guardians of cellular energy. Nature reviews Molecular cell biology 8, 774-
785 
136. McBride, A., and Hardie, D. G. (2009) AMP-activated protein kinase--a 
sensor of glycogen as well as AMP and ATP? Acta Physiol (Oxf) 196, 99-
113 
137. McBride, A., Ghilagaber, S., Nikolaev, A., and Hardie, D. G. (2009) The 
glycogen-binding domain on the AMPK β subunit allows the kinase to act 
as a glycogen sensor. Cell metabolism 9, 23-34 
138. Milan, D., Jeon, J.-T., Looft, C., Amarger, V., Robic, A., Thelander, M., 
Rogel-Gaillard, C., Paul, S., Iannuccelli, N., and Rask, L. (2000) A 
mutation in PRKAG3 associated with excess glycogen content in pig 
skeletal muscle. Science 288, 1248-1251 
139. Arad, M., Seidman, C. E., and Seidman, J. G. (2007) AMP-activated 
protein kinase in the heart: role during health and disease. Circ Res 100, 
474-488 
140. Pederson, B. A., Cope, C. R., Schroeder, J. M., Smith, M. W., Irimia, J. M., 
Thurberg, B. L., DePaoli-Roach, A. A., and Roach, P. J. (2005) Exercise 
capacity of mice genetically lacking muscle glycogen synthase: in mice, 
 152 
muscle glycogen is not essential for exercise. J Biol Chem 280, 17260-
17265 
141. Koeberl, D. D., Kishnani, P. S., Bali, D., and Chen, Y. T. (2009) Emerging 
therapies for glycogen storage disease type I. Trends in endocrinology 
and metabolism: TEM 20, 252-258 
142. Chou, J. Y., Matern, D., Mansfield, B. C., and Chen, Y. T. (2002) Type I 
glycogen storage diseases: disorders of the glucose-6-phosphatase 
complex. Current molecular medicine 2, 121-143 
143. Koster, J. F., Busch, H. F., Slee, R. G., and Van Weerden, T. W. (1978) 
Glycogenosis type II: the infantile- and late-onset acid maltase deficiency 
observed in one family. Clinica chimica acta; international journal of 
clinical chemistry 87, 451-453 
144. Raben, N., Plotz, P., and Byrne, B. J. (2002) Acid alpha-glucosidase 
deficiency (glycogenosis type II, Pompe disease). Current molecular 
medicine 2, 145-166 
145. Raben, N., Danon, M., Lu, N., Lee, E., Shliselfeld, L., Skurat, A. V., Roach, 
P. J., Lawrence, J. C., Jr., Musumeci, O., Shanske, S., DiMauro, S., and 
Plotz, P. (2001) Surprises of genetic engineering: a possible model of 
polyglucosan body disease. Neurology 56, 1739-1745 
146. Douillard-Guilloux, G., Raben, N., Takikita, S., Ferry, A., Vignaud, A., 
Guillet-Deniau, I., Favier, M., Thurberg, B. L., Roach, P. J., and Caillaud, 
C. (2009) Restoration of muscle functionality by genetic suppression of 
glycogen synthesis in a murine model of Pompe disease. Human 
molecular genetics, ddp535 
147. Shen, J. J., and Chen, Y. T. (2002) Molecular characterization of glycogen 
storage disease type III. Current molecular medicine 2, 167-175 
148. Wolfsdorf, J. I., and Weinstein, D. A. (2003) Glycogen storage diseases. 
Reviews in endocrine & metabolic disorders 4, 95-102 
149. Raju, G. P., Li, H. C., Bali, D. S., Chen, Y. T., Urion, D. K., Lidov, H. G., 
and Kang, P. B. (2008) A case of congenital glycogen storage disease 
type IV with a novel GBE1 mutation. Journal of child neurology 23, 349-
352 
150. Burrow, T. A., Hopkin, R. J., Bove, K. E., Miles, L., Wong, B. L., 
Choudhary, A., Bali, D., Li, S. C., and Chen, Y. T. (2006) Non-lethal 
congenital hypotonia due to glycogen storage disease type IV. American 
journal of medical genetics. Part A 140, 878-882 
151. Mommaerts, W. F., Illingworth, B., Pearson, C. M., Guillory, R. J., and 
Seraydarian, K. (1959) A functional disorder of muscle assoiated with the 
absensce of phosphorylase. Proc Natl Acad Sci U S A 45, 791-797 
152. Schmid, R., and Mahler, R. (1959) Chronic progressive myopathy with 
myoglobinuria: demonstration of a glycogenolytic defect in the muscle. J 
Clin Invest 38, 2044-2058 
153. Chen, Y., and Burchell, A. (2001) The metabolic and molecular bases of 
inherited disease. McGraw-Hill, New York, 1521-1553 
 153 
154. DiMauro, S., Andreu, A., Bruno, C., and Hadjigeorgiou, G. (2002) 
Myophosphorylase Deficiency (Glycogenosis Type V McArdle Disease). 
Current molecular medicine 2, 189-196 
155. Ozen, H. (2007) Glycogen storage diseases: new perspectives. World 
journal of gastroenterology 13, 2541 
156. Nakajima, H., Raben, N., Hamaguchi, T., and Yamasaki, T. (2002) 
Phosphofructokinase deficiency; past, present and future. Current 
Molecular Medicine. 2, 197-212 
157. Delgado-Escueta, A. V. (2007) Advances in lafora progressive myoclonus 
epilepsy. Current neurology and neuroscience reports 7, 428-433 
158. Chan, E. M., Omer, S., Ahmed, M., Bridges, L. R., Bennett, C., Scherer, S. 
W., and Minassian, B. A. (2004) Progressive myoclonus epilepsy with 
polyglucosans (Lafora disease): evidence for a third locus. Neurology 63, 
565-567 
159. Lafora, G. R., and Glueck, B. (1911) Beitrag zur Histopathologie der 
myoklonischen Epilepsie. Zeitschrift für die gesamte Neurologie und 
Psychiatrie 6, 1-14 
160. DiMauro, S., and Lamperti, C. (2001) Muscle glycogenoses. Muscle & 
nerve 24, 984-999 
161. Carpenter, S., and Karpati, G. (1981) Ultrastructural findings in Lafora 
disease. Annals of neurology 10, 63-64 
162. Nishimura, R., Ishak, K., Reddick, R., Porter, R., James, S., and 
Barranger, J. (1980) Lafora disease: diagnosis by liver biopsy. Annals of 
neurology 8, 409-415 
163. Berkovic, S. F., Andermann, F., Carpenter, S., and Wolfe, L. S. (1986) 
Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl 
J Med 315, 296-305 
164. Harriman, D. G., Millar, J. H., and Stevenson, A. C. (1955) Progressive 
familial myoclonic epilepsy in three families: its clinical features and 
pathological basis. Brain 78, 325-349 
165. Minassian, B. A., Andrade, D. M., Ianzano, L., Young, E. J., Chan, E., 
Ackerley, C. A., and Scherer, S. W. (2001) Laforin is a cell membrane and 
endoplasmic reticulum-associated protein tyrosine phosphatase. Annals of 
neurology 49, 271-275 
166. Minassian, B. A. (2001) Lafora's disease: towards a clinical, pathologic, 
and molecular synthesis. Pediatric neurology 25, 21-29 
167. Yokoi, S., Austin, J., Witmer, F., and Sakai, M. (1968) Studies in 
myoclonus epilepsy (Lafora body form). I. Isolation and preliminary 
characterization of Lafora bodies in two cases. Archives of neurology 19, 
15-33 
168. Singh, S., and Ganesh, S. (2009) Lafora progressive myoclonus epilepsy: 
a meta-analysis of reported mutations in the first decade following the 
discovery of the EPM2A and NHLRC1 genes. Hum Mutat 30, 715-723 
169. Minassian, B. A., Lee, J. R., Herbrick, J. A., Huizenga, J., Soder, S., 
Mungall, A. J., Dunham, I., Gardner, R., Fong, C. Y., Carpenter, S., Jardim, 
L., Satishchandra, P., Andermann, E., Snead, O. C., 3rd, Lopes-Cendes, 
 154 
I., Tsui, L. C., Delgado-Escueta, A. V., Rouleau, G. A., and Scherer, S. W. 
(1998) Mutations in a gene encoding a novel protein tyrosine phosphatase 
cause progressive myoclonus epilepsy. Nature Genetics 20, 171-174 
170. Gentry, M. S., Dowen, R. H., 3rd, Worby, C. A., Mattoo, S., Ecker, J. R., 
and Dixon, J. E. (2007) The phosphatase laforin crosses evolutionary 
boundaries and links carbohydrate metabolism to neuronal disease. J Cell 
Biol 178, 477-488 
171. Gentry, M. S., and Pace, R. M. (2009) Conservation of the glucan 
phosphatase laforin is linked to rates of molecular evolution and the 
glucan metabolism of the organism. BMC evolutionary biology 9, 138 
172. Ganesh, S., Amano, K., Delgado-Escueta, A. V., and Yamakawa, K. (1999) 
Isolation and characterization of mouse homologue for the human 
epilepsy gene, EPM2A. Biochem Biophys Res Commun 257, 24-28 
173. Ganesh, S., Agarwala, K. L., Amano, K., Suzuki, T., Delgado-Escueta, A. 
V., and Yamakawa, K. (2001) Regional and developmental expression of 
Epm2a gene and its evolutionary conservation. Biochem Biophys Res 
Commun 283, 1046-1053 
174. Wang, J., Stuckey, J. A., Wishart, M. J., and Dixon, J. E. (2002) A unique 
carbohydrate binding domain targets the lafora disease phosphatase to 
glycogen. J Biol Chem. 277, 2377-2380 
175. Chan, E. M., Ackerley, C. A., Lohi, H., Ianzano, L., Cortez, M. A., Shannon, 
P., Scherer, S. W., and Minassian, B. A. (2004) Laforin preferentially binds 
the neurotoxic starch-like polyglucosans, which form in its absence in 
progressive myoclonus epilepsy. Human molecular genetics 13, 1117-
1129 
176. Wang, H., Wang, L., Erdjument-Bromage, H., Vidal, M., Tempst, P., Jones, 
R. S., and Zhang, Y. (2004) Role of histone H2A ubiquitination in 
Polycomb silencing. Nature 431, 873-878 
177. Minassian, B. A., Ianzano, L., Meloche, M., Andermann, E., Rouleau, G. 
A., Delgado-Escueta, A. V., and Scherer, S. W. (2000) Mutation spectrum 
and predicted function of laforin in Lafora's progressive myoclonus 
epilepsy. Neurology 55, 341-346. 
178. Wang, W., and Roach, P. J. (2004) Glycogen and related polysaccharides 
inhibit the laforin dual-specificity protein phosphatase. Biochem Biophys 
Res Commun 325, 726-730 
179. Wang, W., Parker, G. E., Skurat, A. V., Raben, N., DePaoli-Roach, A. A., 
and Roach, P. J. (2006) Relationship between glycogen accumulation and 
the laforin dual specificity phosphatase. Biochem Biophys Res Commun 
350, 588-592 
180. Chen, Y.-T., and Burchell, A. (1995) Glycogen storage diseases. in The 
Metabolic and and Molecular Bases of Inherited Disease (Scriver, C. R., 
Beaudet, A. L., Sly, W. S., and Valle, D. eds.), 7 th Ed., McGraw-Hill, New 
York. pp 935-965 
181. Moses, S. W., and Parvari, R. (2002) The variable presentations of 
glycogen storage disease type IV: a review of clinical, enzymatic and 
molecular studies. Current molecular medicine 2, 177-188 
 155 
182. Puri, R., Suzuki, T., Yamakawa, K., and Ganesh, S. (2009) 
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an 
animal model for Lafora disease. J Biol Chem 284, 22657-22663 
183. Solaz-Fuster, M. C., Gimeno-Alcaniz, J. V., Ros, S., Fernandez-Sanchez, 
M. E., Garcia-Fojeda, B., Criado Garcia, O., Vilchez, D., Dominguez, J., 
Garcia-Rocha, M., Sanchez-Piris, M., Aguado, C., Knecht, E., Serratosa, 
J., Guinovart, J. J., Sanz, P., and Rodriguez de Cordoba, S. (2008) 
Regulation of glycogen synthesis by the laforin-malin complex is 
modulated by the AMP-activated protein kinase pathway. Human 
molecular genetics 17, 667-678 
184. Worby, C. A., Gentry, M. S., and Dixon, J. E. (2006) Laforin: A dual 
specificity phosphatase that dephosphorylates complex carbohydrates. J 
Biol Chem 281, 30412-30418 
185. Fernandez-Sanchez, M. E., Criado-Garcia, O., Heath, K. E., Garcia-
Fojeda, B., Medrano-Fernandez, I., Gomez-Garre, P., Sanz, P., Serratosa, 
J. M., and Rodriguez de Cordoba, S. (2003) Laforin, the dual-phosphatase 
responsible for Lafora disease, interacts with R5 (PTG), a regulatory 
subunit of protein phosphatase-1 that enhances glycogen accumulation. 
Human molecular genetics 12, 3161-3171 
186. Lohi, H., Ianzano, L., Zhao, X. C., Chan, E. M., Turnbull, J., Scherer, S. W., 
Ackerley, C. A., and Minassian, B. A. (2005) Novel glycogen synthase 
kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. 
Human molecular genetics 14, 2727-2736 
187. Gentry, M. S., Worby, C. A., and Dixon, J. E. (2005) Insights into Lafora 
disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes 
the degradation of laforin. Proc Natl Acad Sci U S A 102, 8501-8506 
188. Wang, Y., Liu, Y., Wu, C., Zhang, H., Zheng, X., Zheng, Z., Geiger, T. L., 
Nuovo, G. J., and Zheng, P. (2006) Epm2a suppresses tumor growth in an 
immunocompromised host by inhibiting Wnt signaling. Cancer Cell 10, 
179-190 
189. DePaoli-Roach, A. A., Tagliabracci, V. S., Segvich, D. M., Meyer, C. M., 
Irimia, J. M., and Roach, P. J. (2010) Genetic depletion of the malin E3 
ubiquitin ligase in mice leads to lafora bodies and the accumulation of 
insoluble laforin. J Biol Chem 285, 25372-25381 
190. Wang, W., Lohi, H., Skurat, A. V., DePaoli-Roach, A. A., Minassian, B. A., 
and Roach, P. J. (2007) Glycogen metabolism in tissues from a mouse 
model of Lafora disease. Arch Biochem Biophys 457, 264-269 
191. Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I., Ueno, 
T., Koike, M., Uchiyama, Y., Kominami, E., and Tanaka, K. (2006) Loss of 
autophagy in the central nervous system causes neurodegeneration in 
mice. Nature 441, 880-884 
192. Rubinsztein, D. C. (2006) The roles of intracellular protein-degradation 
pathways in neurodegeneration. Nature 443, 780-786 
193. Williams, A., Jahreiss, L., Sarkar, S., Saiki, S., Menzies, F. M., Ravikumar, 
B., and Rubinsztein, D. C. (2006) Aggregateprone proteins are cleared 
 156 
from the cytosol by autophagy: therapeutic implications. Current topics in 
developmental biology 76, 89-101 
194. Inoki, K., and Guan, K.-L. (2009) Tuberous sclerosis complex, implication 
from a rare genetic disease to common cancer treatment. Human 
molecular genetics 18, R94-R100 
195. Kim, W., Bennett, E. J., Huttlin, E. L., Guo, A., Li, J., Possemato, A., Sowa, 
M. E., Rad, R., Rush, J., Comb, M. J., Harper, J. W., and Gygi, S. P. 
(2011) Systematic and quantitative assessment of the ubiquitin-modified 
proteome. Mol Cell 44, 325-340 
196. Kim, J., and Guan, K.-L. (2011) Amino acid signaling in TOR activation. 
Annual review of biochemistry 80, 1001-1032 
197. Jain, N., Rai, A., Mishra, R., and Ganesh, S. (2017) Loss of malin, but not 
laforin, results in compromised autophagic flux and proteasomal 
dysfunction in cells exposed to heat shock. Cell Stress and Chaperones 
22, 307-315 
198. Duran, J., Gruart, A., Garcia-Rocha, M., Delgado-Garcia, J. M., and 
Guinovart, J. J. (2014) Glycogen accumulation underlies 
neurodegeneration and autophagy impairment in Lafora disease. Human 
molecular genetics  
199. Niittyla, T., Comparot-Moss, S., Lue, W. L., Messerli, G., Trevisan, M., 
Seymour, M. D., Gatehouse, J. A., Villadsen, D., Smith, S. M., Chen, J., 
Zeeman, S. C., and Smith, A. M. (2006) Similar protein phosphatases 
control starch metabolism in plants and glycogen metabolism in mammals. 
J Biol Chem 281, 11815-11818 
200. Kotting, O., Santelia, D., Edner, C., Eicke, S., Marthaler, T., Gentry, M. S., 
Comparot-Moss, S., Chen, J., Smith, A. M., Steup, M., Ritte, G., and 
Zeeman, S. C. (2009) STARCH-EXCESS4 is a laforin-like Phosphoglucan 
phosphatase required for starch degradation in Arabidopsis thaliana. The 
Plant cell 21, 334-346 
201. Raththagala, M., Brewer, M. K., Parker, M. W., Sherwood, A. R., Wong, B. 
K., Hsu, S., Bridges, T. M., Paasch, B. C., Hellman, L. M., and Husodo, S. 
(2015) Structural mechanism of laforin function in glycogen 
dephosphorylation and lafora disease. Molecular cell 57, 261-272 
202. Gessler, K., Uson, I., Takaha, T., Krauss, N., Smith, S. M., Okada, S., 
Sheldrick, G. M., and Saenger, W. (1999) V-Amylose at atomic resolution: 
X-ray structure of a cycloamylose with 26 glucose residues 
(cyclomaltohexaicosaose). Proc Natl Acad Sci U S A 96, 4246-4251 
203. Chan, E. M., Bulman, D. E., Paterson, A. D., Turnbull, J., Andermann, E., 
Andermann, F., Rouleau, G. A., Delgado-Escueta, A. V., Scherer, S. W., 
and Minassian, B. A. (2003) Genetic mapping of a new Lafora progressive 
myoclonus epilepsy locus (EPM2B) on 6p22. Journal of medical genetics 
40, 671-675 
204. Freemont, P. S. (2000) RING for destruction? Current biology : CB 10, 
R84-87 
 157 
205. Cheng, A., Zhang, M., Gentry, M. S., Worby, C. A., Dixon, J. E., and 
Saltiel, A. R. (2007) A role for AGL ubiquitination in the glycogen storage 
disorders of Lafora and Cori's disease. Genes Dev 21, 2399-2409 
206. Moreno, D., Towler, M. C., Hardie, D. G., Knecht, E., and Sanz, P. (2010) 
The laforin-malin complex, involved in Lafora disease, promotes the 
incorporation of K63-linked ubiquitin chains into AMP-activated protein 
kinase beta subunits. Mol Biol Cell 21, 2578-2588 
207. Vilchez, D., Ros, S., Cifuentes, D., Pujadas, L., Valles, J., Garcia-Fojeda, 
B., Criado-Garcia, O., Fernandez-Sanchez, E., Medrano-Fernandez, I., 
Dominguez, J., Garcia-Rocha, M., Soriano, E., Rodriguez de Cordoba, S., 
and Guinovart, J. J. (2007) Mechanism suppressing glycogen synthesis in 
neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 
10, 1407-1413 
208. Worby, C. A., Gentry, M. S., and Dixon, J. E. (2008) Malin decreases 
glycogen accumulation by promoting the degradation of protein targeting 
to glycogen (PTG). J Biol Chem 283, 4069-4076 
209. Ganesh, S., Puri, R., Singh, S., Mittal, S., and Dubey, D. (2006) Recent 
advances in the molecular basis of Lafora's progressive myoclonus 
epilepsy. J Hum Genet 51, 1-8 
210. Turnbull, J., Epp, J. R., Goldsmith, D., Zhao, X., Pencea, N., Wang, P., 
Frankland, P. W., Ackerley, C. A., and Minassian, B. A. (2014) PTG 
depletion rescues malin-deficient Lafora disease in mouse. Ann Neurol  
211. Turnbull, J., DePaoli-Roach, A. A., Zhao, X., Cortez, M. A., Pencea, N., 
Tiberia, E., Piliguian, M., Roach, P. J., Wang, P., Ackerley, C. A., and 
Minassian, B. A. (2011) PTG depletion removes Lafora bodies and 
rescues the fatal epilepsy of Lafora disease. PLoS Genet 7, e1002037 
212. Pederson, B. A., Turnbull, J., Epp, J. R., Weaver, S. A., Zhao, X., Pencea, 
N., Roach, P. J., Frankland, P., Ackerley, C. A., and Minassian, B. A. 
(2013) Inhibiting glycogen synthesis prevents lafora disease in a mouse 
model. Ann Neurol  
213. Duran, J., Tevy, M. F., Garcia-Rocha, M., Calbo, J., Milan, M., and 
Guinovart, J. J. (2012) Deleterious effects of neuronal accumulation of 
glycogen in flies and mice. EMBO Mol Med 4, 719-729 
214. Roach, P. J., and DePaoli-Roach, A. A. (2013) Glycogen Metabolism and 
Lafora Disease. in Protein Tyrosine Phosphatase Control of Metabolism 
(Bence, K. K. ed.), Springer New York, New York, NY. pp 239-262 
215. Hizukuri, S., Tabata, S., Kagoshima, and Nikuni, Z. (1970) Studies on 
Starch Phosphate Part 1. Estimation of glucose-6-phosphate residues in 
starch and the presence of other bound phosphate(s). Starch - Stärke 22, 
338-343 
216. Mordoh, J., Krisman, C. R., and Leloir, L. F. (1966) Further studies on high 
molecular weight liver glycogen. Arch Biochem Biophys 113, 265-272 
217. Northcote, D. H. (1954) Electrophoresis of some neutral polysaccharides. 
The Biochemical journal 58, 353-358 
218. Wanson, J. C., and Drochmans, P. (1968) Rabbit skeletal muscle 
glycogen. A morphological and biochemical study of glycogen beta-
 158 
particles isolated by the precipitation-centrifugation method. J Cell Biol 38, 
130-150 
219. Contreras, C. J., Segvich, D. M., Mahalingan, K., Chikwana, V. M., Kirley, 
T. L., Hurley, T. D., DePaoli-Roach, A. A., and Roach, P. J. (2016) 
Incorporation of phosphate into glycogen by glycogen synthase. Arch 
Biochem Biophys 597, 21-29 
220. Ritte, G., Lloyd, J. R., Eckermann, N., Rottmann, A., Kossmann, J., and 
Steup, M. (2002) The starch-related R1 protein is an alpha -glucan, water 
dikinase. Proc Natl Acad Sci U S A 99, 7166-7171 
221. Mikkelsen, R., Baunsgaard, L., and Blennow, A. (2004) Functional 
characterization of alpha-glucan,water dikinase, the starch 
phosphorylating enzyme. The Biochemical journal 377, 525-532 
222. Kotting, O., Pusch, K., Tiessen, A., Geigenberger, P., Steup, M., and Ritte, 
G. (2005) Identification of a novel enzyme required for starch metabolism 
in Arabidopsis leaves. The phosphoglucan, water dikinase. Plant Physiol 
137, 242-252 
223. Baunsgaard, L., Lutken, H., Mikkelsen, R., Glaring, M. A., Pham, T. T., 
and Blennow, A. (2005) A novel isoform of glucan, water dikinase 
phosphorylates pre-phosphorylated alpha-glucans and is involved in 
starch degradation in Arabidopsis. Plant J 41, 595-605 
224. DePaoli-Roach, A. A., Vilardo, P. G., Kim, J.-H., Mavila, N., Vemuri, B., 
and Roach, P. J. (2003) Determination of mammalian glycogen synthase 
phosphatase activity. Methods in enzymology 366, 17-34 
225. Khanna, M., Imasaki, T., Chikwana, V. M., Perez-Miller, S., Hunter, G. O., 
Mosley, A., Takagi, Y., and Hurley, T. D. (2013) Expression and 
purification of functional human glycogen synthase-1 (hGYS1) in insect 
cells. Protein expression and purification 90, 78-83 
226. Paladini, A. C., and Leloir, L. F. (1952) Studies on uridine-diphosphate-
glucose. The Biochemical journal 51, 426-430 
227. Zmudzka, B., Szer, W., and Shugar, D. (1962) Preparation and chemical 
and enzymic properties of phosphate esters of 1-(beta-D-
glucopyranosyl)uracil and -thymine. Acta Biochim Pol 9, 321-341 
228. Chikwana, V. M., Khanna, M., Baskaran, S., Tagliabracci, V. S., Contreras, 
C. J., DePaoli-Roach, A., Roach, P. J., and Hurley, T. D. (2013) Structural 
basis for 2'-phosphate incorporation into glycogen by glycogen synthase. 
Proc Natl Acad Sci U S A 110, 20976-20981 
229. MacDonald, D. L. (1972) Phosphates and other inorganic esters. The 
Carbohydrates E2, 253-278 
230. Patel, M. K., and Davis, B. G. (2013) Control of Phosphoryl Migratory 
Transesterifications Allows Regioselecive Access to Sugar Phosphates. 
Organic Letters 15, 346-349 
231. Teranishi, K., and Ueno, F. (2003) Mechanism of 2-O→3-O silyl migration 
in cyclomaltohexaose (α-cyclodextrin). Tetrahedron Letters 44, 4843-4848 
232. Collins, G. H., Cowden, R. R., and Nevis, A. H. (1968) Myoclonus epilepsy 
with Lafora bodies. An ultrastruc- tural and cytochemical study. Arch 
Pathol 86, 239-254 
 159 
233. Fettke, J., Hejazi, M., Smirnova, J., Hochel, E., Stage, M., and Steup, M. 
(2009) Eukaryotic starch degradation: integration of plastidial and cytosolic 
pathways. J Exp Bot 60, 2907-2922 
234. Stitt, M., and Zeeman, S. C. (2012) Starch turnover: pathways, regulation 
and role in growth. Curr Opin Plant Biol 15, 282-292 
235. Zeeman, S. C., Kossmann, J., and Smith, A. M. (2010) Starch: its 
metabolism, evolution, and biotechnological modification in plants. Annu 
Rev Plant Biol 61, 209-234 
236. Blennow, A., and Engelsen, S. B. (2010) Helix-breaking news: fighting 
crystalline starch energy deposits in the cell. Trends Plant Sci 15, 236-240 
237. Pérez, S., and Bertoft, E. (2010) The molecular structures of starch 
components and their contribution to the architecture of starch granules: A 
comprehensive review. Starch - Stärke 62, 389-420 
238. Irimia, J. M., Tagliabracci, V. S., Meyer, C. M., Segvich, D. M., DePaoli-
Roach, A. A., and Roach, P. J. (2015) Muscle glycogen remodeling and 
glycogen phosphate metabolism following exhaustive exercise of wild type 
and laforin knockout mice. J Biol Chem 290, 22686-22698 
239. Ganesh, S., Delgado-Escueta, A. V., Suzuki, T., Francheschetti, S., Riggio, 
C., Avanzini, G., Rabinowicz, A., Bohlega, S., Bailey, J., Alonso, M. E., 
Rasmussen, A., Thomson, A. E., Ochoa, A., Prado, A. J., Medina, M. T., 
and Yamakawa, K. (2002) Genotype-phenotype correlations for EPM2A 
mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations 
associate with an early-onset cognitive deficit subphenotype. Human 
molecular genetics 11, 1263-1271 
240. DePaoli-Roach, A. A., Segvich, D. M., Meyer, C. M., Rahimi, Y., Worby, C. 
A., Gentry, M. S., and Roach, P. J. (2012) Laforin and malin knockout 
mice have normal glucose disposal and insulin sensitivity. Human 
molecular genetics 21, 1604-1610 
241. Zhai, L., Choi, C. S., Irimia-Dominguez, J., McGuire, A. C., Kim, S., Bock, 
C. B., Roach, P. J., Shulman, G. I., and DePaoli-Roach, A. A. (2007) 
Enhanced insulin sensitivity and energy expenditure in PPP1R3C (PTG) 
deleted mice. Diabetes 56 Supplement 1, A62 
242. Bergmeyer, H. U. (1974) Methods of Enzymatic Analysis, 2nd English ed., 
Academic Press, New York 
243. Hess, H. H., and Derr, J. E. (1975) Assay of inorganic and organic 
phosphorus in the 0.1-5 nanomole range. Anal Biochem 63, 607-613 
244. Zhu, A., Romero, R., and Petty, H. R. (2009) An enzymatic fluorimetric 
assay for glucose-6-phosphate: application in an in vitro Warburg-like 
effect. Analytical biochemistry 388, 97-101 
245. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem 72, 248-254 
246. Heyen, C. A., Tagliabracci, V. S., Zhai, L., and Roach, P. J. (2009) 
Characterization of mouse UDP-glucose pyrophosphatase, a Nudix 
hydrolase encoded by the Nudt14 gene. Biochemical and biophysical 
research communications 390, 1414-1418 
 160 
247. Lamerz, A.-C., Haselhorst, T., Bergfeld, A. K., von Itzstein, M., and 
Gerardy-Schahn, R. (2006) Molecular cloning of the Leishmania major 
UDP-glucose pyrophosphorylase, functional characterization, and ligand 
binding analyses using NMR spectroscopy. J Biol Chem 281, 16314-
16322 
248. Murphy, D. M., Ivanenkov, V. V., and Kirley, T. L. (2003) Bacterial 
expression and characterization of a novel, soluble, calcium-binding, and 
calcium-activated human nucleotidase. Biochemistry 42, 2412-2421 
249. Smith, T. M., Hicks-Berger, C. A., Kim, S., and Kirley, T. L. (2002) Cloning, 
expression, and characterization of a soluble calcium-activated 
nucleotidase, a human enzyme belonging to a new family of extracellular 
nucleotidases. Archives of biochemistry and biophysics 406, 105-115 
250. Wishart, D. S., Bigam, C. G., Yao, J., Abildgaard, F., Dyson, H. J., Oldfield, 
E., Markley, J. L., and Sykes, B. D. (1995) 1H, 13C and 15N chemical shift 
referencing in biomolecular NMR. J Biomol NMR 6, 135-140 
251. Hawker, J., Ozbun, J., Ozaki, H., Greenberg, E., and Preiss, J. (1974) 
Interaction of spinach leaf adenosine diphosphate glucose α-1, 4-glucan 
α-4-glucosyl transferase and α-1, 4-glucan, α-1, 4-glucan-6-glycosyl 
transferase in synthesis of branched α-glucan. Archives of Biochemistry 
and Biophysics 160, 530-551 
252. Devillers, C. H., Piper, M. E., Ballicora, M. A., and Preiss, J. (2003) 
Characterization of the branching patterns of glycogen branching enzyme 
truncated on the N-terminus. Arch Biochem Biophys 418, 34-38 
253. Waffenschmidt, S., and Jaenicke, L. (1987) Assay of reducing sugars in 
the nanomole range with 2, 2′-bicinchoninate. Analytical biochemistry 165, 
337-340 
254. Zmudzka, B. S., D. (1964) Preparation and chemical and enzymic 
properties of cyclic phosphates of D-glucopyranose and synthesis of 
derivatives of N-(D-glucopyranosyl) pyridine. Acta Biochimica Polonica 11, 
509-525 
255. De Clercq, E., Zmudzka, B., and Shugar, D. (1972) Antiviral activity of 
polynucleotides: role of the 2'-hydroxyl and a pyrimidine 5-methyl. FEBS 
letters 24, 137-140 
256. Piras, R. (1963) Synthesis of Some Aldose 2-Phosphates. Arch Biochem 
Biophys 103, 291-292 
257. Nitschke, F., Sullivan, M. A., Wang, P., Zhao, X., Chown, E. E., Perri, A. 
M., Israelian, L., Juana‐López, L., Bovolenta, P., and de Córdoba, S. R. 
(2017) Abnormal glycogen chain length pattern, not hyperphosphorylation, 
is critical in Lafora disease. EMBO Molecular Medicine, e201707608 
258. Andrade, D. M., Turnbull, J., and Minassian, B. A. (2007) Lafora disease, 
seizures and sugars. Acta Myol 26, 83-86 
259. Gentry, M. S., Dixon, J. E., and Worby, C. A. (2009) Lafora disease: 
insights into neurodegeneration from plant metabolism. Trends Biochem 
Sci 34, 628-639 
 161 
260. Ritte, G., Heydenreich, M., Mahlow, S., Haebel, S., Kotting, O., and Steup, 
M. (2006) Phosphorylation of C6- and C3-positions of glucosyl residues in 
starch is catalysed by distinct dikinases. FEBS letters 580, 4872-4876 
261. Lomako, J., Lomako, W. M., Whelan, W. J., and Marchase, R. B. (1993) 
Glycogen contains phosphodiester groups that can be introduced by 
UDPglucose: glycogen glucose 1-phosphotransferase. FEBS letters 329, 
263-267 
262. Koro, L. A., and Marchase, R. B. (1982) A UDP-glucose: glycoprotein 
glucose-1-phosphotransferase in embryonic chicken neural retina. Cell 31, 
739-748 
263. Criado, O., Aguado, C., Gayarre, J., Duran-Trio, L., Garcia-Cabrero, A. M., 
Vernia, S., San Millan, B., Heredia, M., Roma-Mateo, C., Mouron, S., 
Juana-Lopez, L., Dominguez, M., Navarro, C., Serratosa, J. M., Sanchez, 
M., Sanz, P., Bovolenta, P., Knecht, E., and Rodriguez de Cordoba, S. 
(2012) Lafora bodies and neurological defects in malin-deficient mice 
correlate with impaired autophagy. Human molecular genetics 21, 1521-
1533 
264. Ganesh, S., Delgado-Escueta, A. V., Sakamoto, T., Avila, M. R., 
Machado-Salas, J., Hoshii, Y., Akagi, T., Gomi, H., Suzuki, T., Amano, K., 
Agarwala, K. L., Hasegawa, Y., Bai, D. S., Ishihara, T., Hashikawa, T., 
Itohara, S., Cornford, E. M., Niki, H., and Yamakawa, K. (2002) Targeted 
disruption of the Epm2a gene causes formation of Lafora inclusion bodies, 
neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral 
response in mice. Human Molecular Genetics. 11, 1251-1262 
265. Garcia-Cabrero, A. M., Marinas, A., Guerrero, R., de Cordoba, S. R., 
Serratosa, J. M., and Sanchez, M. P. (2012) Laforin and malin deletions in 
mice produce similar neurologic impairments. J Neuropathol Exp Neurol 
71, 413-421 
266. Valles-Ortega, J., Duran, J., Garcia-Rocha, M., Bosch, C., Saez, I., 
Pujadas, L., Serafin, A., Canas, X., Soriano, E., Delgado-Garcia, J. M., 
Gruart, A., and Guinovart, J. J. (2011) Neurodegeneration and functional 
impairments associated with glycogen synthase accumulation in a mouse 
model of Lafora disease. EMBO Mol Med 3, 667-681 
267. Jorgensen, S. B., and Rose, A. J. (2008) How is AMPK activity regulated 
in skeletal muscles during exercise? Frontiers in bioscience: a journal and 
virtual library 13, 5589-5604 
268. Egan, B., and Zierath, J. R. (2013) Exercise metabolism and the molecular 
regulation of skeletal muscle adaptation. Cell metabolism 17, 162-184 
269. Winder, W., and Hardie, D. (1996) Inactivation of acetyl-CoA carboxylase 
and activation of AMP-activated protein kinase in muscle during exercise. 
American Journal of Physiology-Endocrinology And Metabolism 270, 
E299-E304 
270. Aschenbach, W. G., Suzuki, Y., Breeden, K., Prats, C., Hirshman, M. F., 
Dufresne, S. D., Sakamoto, K., Vilardo, P. G., Steele, M., and Kim, J.-H. 
(2001) The muscle-specific protein phosphatase PP1G/RGL (GM) is 
 162 
essential for activation of glycogen synthase by exercise. J Biol Chem 276, 
39959-39967 
271. Tiberia, E., Turnbull, J., Wang, T., Ruggieri, A., Zhao, X. C., Pencea, N., 
Israelian, J., Wang, Y., Ackerley, C. A., Wang, P., Liu, Y., and Minassian, 
B. A. (2012) Increased laforin and laforin binding to glycogen underlie 
Lafora body formation in malin-deficient Lafora disease. J Biol Chem 287, 
25650-25659 
272. Gayarre, J., Duran-Trío, L., Criado Garcia, O., Aguado, C., Juana-López, 
L., Crespo, I., Knecht, E., Bovolenta, P., and Rodríguez de Córdoba, S. 
(2014) The phosphatase activity of laforin is dispensable to rescue 
Epm2a−/− mice from Lafora disease. Brain 137, 806-818 
273. Striano, P., Zara, F., Turnbull, J., Girard, J.-M., Ackerley, C. A., Cervasio, 
M., De Rosa, G., Del Basso-De Caro, M. L., Striano, S., and Minassian, B. 
A. (2008) Typical progression of myoclonic epilepsy of the Lafora type: a 
case report. Nature Reviews. Neurology 4, 106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CURRICULUM VITAE 
 
Christopher J. Contreras  
Education 
Indiana University, Indianapolis, IN 
PhD in Biochemistry & Molecular Biology 
Minor in Diabetes and Obesity Research 
 PhD Mentor: Dr. Peter J. Roach 
 Dissertation title: Abnormal Glycogen Metabolism in Lafora Disease 
August 2009 – January 2018  
 
University of New Mexico, Albuquerque, NM 
Bachelor of Arts and Science in Biochemistry and Molecular Biology 
Graduated: May 2008 
 
Research and Work Experience 
Graduate Research 
Indiana University School of Medicine 
Indianapolis, IN  
August 2009 – January 2018 
PhD Mentor: Dr. Peter J. Roach 
PhD Candidate  
Main Projects 
1. Designed and performed exercise experiments to investigate glycogen 
metabolism in mouse models of Lafora disease 
2. Investigate how phosphate is incorporated into glycogen and how 
phosphate can affect physical, morphological and structural changes 
within glycogen. 
Techniques 
Conducting mouse exercise experiments 
Glycogen purification from mouse and rabbit tissues 
Measuring trace amounts of phosphate in glycogen and amylopectin 
Synthesize radiolabeled substrates for glycogen synthase 
Analyzing carbohydrates using high performance anionic 
chromatography (Dionex ICS 3000) 
Immunoblotting 
Teaching and working with rotating graduate students 
 
Research Technician III 
University of New Mexico School of Medicine 
Albuquerque, NM  
Summer 2008 – Summer 2009 
Principal Investigator: Dr. Angela Wandinger-Ness 
Main Responsibilities 
1. Designing and creating expression vectors for Rab-7 and a potential 
effector protein (VPS39) 
 2. Develop and test flow cytometry based enzymatic assays for Rab-7 
GTPase activity 
3. Maintain common supplies and solution stocks used in the lab 
Techniques 
Immunoblotting 
Expression vector cloning 
Transfection, transduction and maintaining mammalian cell cultures 
FACS scan flow cytometry 
Immunoflourecent microscopy  
Training and teaching new students 
 
Undergraduate Research 
University of New Mexico –Initiative for Maximizing Student Development (IMSD) 
Albuquerque, NM  
August 2006 – May 2000 
Undergraduate mentor: Dr. Scott Ness   
Undergraduate Researcher 
Main Projects 
1. Investigating the role of the 3’ UTR in post-transcriptional regulation of 
the oncogene c-myb. 
2. Developing methods to knock down endogenous levels of c-Myb using 
siRNAs.   
Techniques 
Immunoblotting 
RT-PCR 
Expression vector cloning 
Transfection, transduction and maintaining mammalian cell cultures 
FACS scan flow cytometry 
Training and teaching new students 
 
Food and Drug Administration (FDA) Internship: Hispanic Association of 
Colleges & Universities (HACU)  
Food and Drug Administration: Center for Drug Evaluation and Research 
(CDER)  
Rockville, MD 
June 2004-August 2004 
Main Project: 
1. Comparison of bone mineral density in normal and osteoperotic patients 
that were taking Fosamax and present findings to FDA-CDER personal. 
 
Awards 
• 2015 Indiana University Center for Diabetes and Metabolic Diseases 
Symposium Graduate Student Research Poster Award 
• 2010 - 2013 NIH T32 Diabetes Training Grant (T32-DK064466) 
 • 2013 Society for Advancement of Chicanos and Native Americans in 
Science (SACNAS) National Conference Graduate Student Presentation 
Award in Biochemistry  
• 2006 - 2008 UNM Initiative for Maximizing Student Development (IMSD) 
undergraduate research program 
• 2007 SACNAS National Conference Travel Award  
• 2005 & 2006 NIH Sponsored Summer Research Internship Program 
(Grant number: 5T35HL076595)  
• 2004 Summer internship at Food & Drug Administration (FDA) as part of 
the Hispanic Association of Colleges & Universities (HACU) program  
 
Meetings & Presentations 
• 2016 June, Lafora Disease Workshop: UCSD 
• 2015 Indiana University Center for Diabetes and Metabolic Diseases 
Symposium Graduate Student Research Poster 
• Impaired Glycogen Metabolism in Mouse Models of Lafora Disease  
• 2014 November, Indiana University Center for Diabetes Research (CDR) 
oral presentation 
• Impaired Glycogen Metabolism in Mouse Models of Lafora Disease  
• 2013 SACNAS National Conference graduate student oral presentation 
• Impaired Metabolism of the Abnormal Glycogen in Laforin Knockout Mice 
• 2007 SACNAS National Conference undergraduate research poster 
presentation   
 
Publications 
 
Christopher J. Contreras, Dyann M. Segvich, Anna A. DePaoli-Roach and 
Peter J. Roach (2017) Abnormal Glycogen Metabolism During Exercise in Mouse 
Models of Lafora Disease. (In Preparation) 
 
Christopher J. Contreras, Dyann M. Segvich, Krishna Mahalingan, Vimbai M. 
Chikwana, Terry L. Kirley, Thomas D. Hurley, Anna A. DePaoli-Roach and Peter 
J. Roach (2016) Incorporation of phosphate into glycogen by glycogen synthase. 
Archives of Biochemistry and Biophysics 597, 21-19 
Anna A. DePaoli-Roach
* 
, Christopher J. Contreras
*
, Dyann M. Segvich, 
Christian Heiss, Mayumi Ishihara, Parastoo Azadi 
 
and Peter J. Roach (2014) 
Glycogen Phosphomonoester Distribution in Mouse Models of the Progressive 
Myoclonic Epilepsy, Lafora Disease. The J Biol Chem 290(2): 841-850 
 
Chikwana, V. M., Khanna, M., Baskaran, S., Tagliabracci, V. S., Contreras, C. 
J., DePaoli-Roach, A., Roach, P. J., and Hurley, T. D. (2013) Structural basis for 
2'-phosphate incorporation into glycogen by glycogen synthase. Proceedings of 
the National Academy of Sciences of the United States of America 110, 20976-
20981 
 
 Baskaran, S., Chikwana, V. M., Contreras, C. J., Davis, K. D., Wilson, W. A., 
DePaoli-Roach, A. A., Roach, P. J., and Hurley, T. D. (2011) Multiple glycogen-
binding sites in eukaryotic glycogen synthase are required for high catalytic 
efficiency toward glycogen. The J Biol Chem 286, 33999-34006 
 
Tagliabracci, V. S., Heiss, C., Karthik, C., Contreras, C. J., Glushka, J., Ishihara, 
M., Azadi, P., Hurley, T. D., DePaoli-Roach, A. A., and Roach, P. J. (2011) 
Phosphate incorporation during glycogen synthesis and Lafora disease. Cell 
Metab 13, 274-282 
 
* Co-First Author 
 
 
Service 
• 2014 October-Febuary 2015, Student representative on search committee 
for the new Program and Evaluation Director for Indiana University School 
of Medicine Office of Diversity Affairs 
• 2014 July - July 2017, SACNAS-IUPUI chapter member.  
 
Other 
• Analyzing and quantifying carbohydrate profiles from yeast fermentations 
for Xylogenics 
